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ABSTRACT
C. difficile is the major identifiable cause of antibiotic-associated diarrhoea in the
UK. The association of C. difficile with the use of antibiotics is well established. A
number of other host and bacterial factors are likely to play a role in the development
and the severity of C. difficile associated disease.
Three hundred and ninety patients between 62 and 101 years of age admitted to a
geriatric unit in The Royal Victoria Hospital (RVH), Edinburgh were investigated for
the presence of C. difficile. C. difficile was cultured from 100 (26%) patients, on pre-
reduced cycloserine-cefoxitin egg-yolk agar. Toxin(s) were detected in the faeces of
34 of these patients with the Techlab™ ELISA test kit for the detection of C. difficile
toxins A and/or B. Toxin(s) were detected in a further 18 patients from whom no C.
difficile was detected in culture.
A number of possible risk factors associated with C. difficile disease, and relating to
medication, antibiotic use and underlying disease were investigated by logistic
regression modelling. A two-step predictive model for C. difficile disease was
hypothesised. In this two-step disease model, patients made a transition from C.
difficile negative (Cdc-) to C. difficile culture positive (Cdc+) and in some cases a
further transition from Cdc+ to C. difficile culture and toxin positive (Cdt+) was
made. The logistic regression modelling found that the factors significantly
associated with the transition from Cdc- to Cdc+ were the origin of the admission
(another hospital, nursing home or the community) and the use of ceftriaxone (a third
generation cephalosporin). Amoxycillin and cephalosporins (other than ceftriaxone)
were significantly associated with the transition from Cdc+ to Cdt+. Statistical
analysis also showed that Cdt+ patients were significantly older than the Cdc+
patients. These findings support the proposed two step model for infection and
indicate that different risk factors are significant in each of the two steps.
The variation and immuno-reactivity of the surface (S-) layer proteins from 24
strains of C. difficile were investigated. The S-layer proteins extracted from C.
difficile by treatment with guanidine hydrochloride were visualised on SDS-PAGE
and analysed using PhoretixIM gel analysis software. The two S-layer proteins were
shown to be highly variable in molecular mass between isolates of different serotype
and ribotype. Western blot analysis showed that there was cross-reactivity of the
heavier protein between strains, however there was much less cross-reactivity with
the lighter protein which appeared to be strain specific. The variation in molecular
mass of the S-layer proteins was exploited as the basis of a novel typing method for
C. difficile. Isolates from patients in RVH were designated a four-digit "S-type"
number based on their S-layer protein profile. A total of eight S-types were
identified, and one type, toxigenic S-type 5236 accounted for 73% of all clinical
isolates. No statistical association was evident between the S-type(s) which colonised
patients and the number of episodes of diarrhoea or the duration of illness.
A selection of 50 clinical isolates were also typed using PCR ribotyping methods,
this revealed ten ribotypes and a good correlation between the two typing methods.
The endemic S-type "5236" correlated to PCR ribotype 1 which is the most
frequently isolated PCR ribotype in England and Wales.
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1.1. Clostridium difficile, a description of the organism
Clostridium difficile is a strictly anaerobic, motile, gram-positive bacillus of 3-5pm
in length with sub-terminal spores. On blood agar, typical C. difficile colonies are
opaque, greyish in colour and have a pitted appearance with an irregular edge (Hafiz
and Oakley, 1976). Most colonies are non-haemolytic, however some strains do
produce alpha-type haemolysis on blood agar and sporulation is distinct on agar
cultures that have reached stationary phase (Brazier and Borriello, 2000). C. difficile
can be distinguished from other Clostridium spp. by biochemical profile and the
toxins which are produced.
1.2. The history of C. difficile and associated disease
1.2.1. The history of C. difficile
In 1935 Hall and O'Toole identified a spore-forming, motile, obligately anaerobic
bacillus from the intestinal flora of new-born infants. Due to the difficulty associated
with the isolation and study of the organism, the bacterium was named Bacillus
difficilis; this organism is now known as Clostridium difficile.
Further investigations were carried out in 1937, when Snyder isolated 18 strains of C.
difficile from the faeces of babies under one year of age. Snyder's investigations
determined that despite similarities in the morphology and culture characteristics,
some strains of "Bacillus difficilis'" isolated from the faeces of babies were
pathogenic in guinea pigs and rabbits. Snyder (1937), raised rabbit antiserum to a
pathogenic strain of C. difficile and experiments demonstrated that all pathogenic and
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non-pathogenic strains agglutinated at varying degrees with the antiserum. This
suggested that there were antigenic similarities between strains allowing
agglutination, but also antigenic differences which affected the level of agglutination
between strains.
Following Snyder's work in the late 1930s, there was little interest in C. difficile.
However, in the late 1970s, C. difficile provoked intense interest, when it was
identified as the organism commonly associated with pseudomembranous colitis
(PMC) and antibiotic-associated diarrhoea (AAD), cases ofwhich had soared with
the use of clindamycin.
1.2.2. C. difficile-associated disease (CDAD)
Hall and O'Toole (1935), detected toxins from C. difficile and postulated that the
organism could be pathogenic. C. difficile is now well documented as the major
identifiable cause ofAAD and PMC (Bartlett, 1994; Kelly et al, 1994a).
Diarrhoea is well associated with antibiotic use and reports of PMC after treatment
with antibiotics were made in the 1950s. Reiner et al (1952), made an association
between diarrhoea and PMC, and the use of aureomycin and chloramphenicol. PMC
was also associated with the use of lincomycin, it was hypothesised that the gut flora
could be affected by lincomycin use, and anticipated that the closely related drug
clindamycin would also be associated with PMC (Scott et al, 1973).
Tedesco et al (1974), made a strong association between clindamycin use and the
development of PMC; a prospective study showed a 21% incidence ofAAD and a
10% incidence ofPMC in a group of 200 patients who had been administered
clindamycin. However, no microbiological cause for the disease was determined.
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Larson et al (1977), suggested that the aetiology ofPMC could be of bacterial origin
after a toxin was detected in the faecal suspension from a 12-year old girl who
developed PMC following treatment with penicillin. The faecal suspensions from the
patient demonstrated a toxic effect on several cell lines. Subsequently faecal
specimens from six patients with PMC were investigated for a similar effect. The
presence of a toxic factor in five of the six patients with PMC was demonstrated.
The study could detect no viral cause and the investigators suggested that the toxin
could be of bacterial origin.
Rifkin et al (1977), implicated Clostridium spp. as the aetiological cause of PMC,
when it was shown that the faecal filtrate from patients with PMC caused death in
hamsters, and that the pre-incubation of the faecal extracts with gas-gangrene
antitoxin prevented death in hamsters. Further studies showed that the faecal filtrates
were cytopathic to m vitro cell lines, but that the effect was neutralised by C.
sordellii antitoxin. Rifkin et al (1977), concluded that C. sordellii was the cause of
PMC.
In the late 1970s Bartlett et al (1978a), were investigating the aetiology of PMC.
They also showed that the faecal filtrates from patients with PMC and with
clindamycin -associated diarrhoea could produce a cytopathic effect in vitro and that
this could be neutralised with gas-gangrene antitoxin. Further work determined that
C. difficile could be recovered from patients with PMC and implicated C. difficile as
the cause ofPMC (Bartlett et al, 1978b).
Larson et al (1978), also continued the search for the aetiologic agent and
demonstrated that C. difficile could be isolated from patients with PMC, but not from
control patients. The study showed C. sordellii antitoxin to inactivate the toxin in
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faecal filtrates and pure culture. Similar studies by George and Symonds (1978),
recovered C. difficile from patients with PMC and showed that in vitro cytopathic
effects were neutralised by C. sordellii antitoxin. Many studies have since made the
association between the use ofantibiotics and C. difficile colonisation and infection.
1.3. The ecology of C. difficile
1.3.1. C. difficile in the general environment
C. difficile is thought to be very common in the environment, it has been isolated
from numerous sources and as a spore forming organism that is resistant to air, heat
and desiccation, it may exist indefinitely in the environment. As the frequency of C.
difficile in the environment is uncertain, various studies have sought to determine the
regularity with which C. difficile can be isolated in our general environment. Early
reports such as the isolation of C. difficile from the gut of a Weddel seal in the
Antarctic (McBee, 1960) suggested the presence of C. difficile in the environment.
However, Riley (1994) failed to isolate C. difficile from soil, sand and water samples
from rivers and lakes. Kim et al (1981), also failed to isolate C. difficile from random
soil samples. A large environmental study was carried out around Cardiff, Wales,
with the aim of demonstrating how individuals might be exposed to C. difficile in
everyday life (Al Saif and Brazier, 1996). The study sampled 2580 sites which
included water from rivers, lakes, the sea, swimming pools and domestic tap water.
Soil samples from parks, play areas, gardens and fields were also subject to
investigation. In contrast to the previous studies (Riley et al, 1994; Kim et al, 1981),
C. difficile was isolated from 36% ofwater samples and 21.4% soil samples. Al Saif
and Brazier (1996), isolated C. difficile from tap water as well as lakes, sea-water and
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swimming pools. C. difficile was also isolated from 2.4% of raw vegetables tested.
This comprehensive study by AI Saif and Brazier (1996), used the best culture and
enrichment methods available and the study suggests that C. difficile is very common
in our environment and that we may regularly encounter the organism through
normal daily activities.
1.3.2. C. difficile in the hospital environment
The presence of C. difficile in the hospital environment is well documented and it is
likely to have a role in facilitating the spread of the organism. Studies have shown
that levels of environmental contamination can vary significantly between wards and
within different areas of the same ward. Recently, Fawley and Wilcox (2001),
isolated C. difficile from 34% and 36% of sites sampled in two general medicine
wards for the elderly. Al Saif and Brazier (1996), investigated 380 samples from
hospital surfaces and reported 20% to be culture positive for C. difficile. Several
earlier studies reported isolation rates of 2.1% to 19.6% (Kim et al, 1981), and 7% to
14% from the hospital sites sampled (Fekety et al, 1981). The levels of
environmental contamination in hospitals have been shown to be associated with the
number of colonised and infected patients in the vicinity of the site sampled (Kim et
al, 1981; Fekety et al, 1981; McFarland et al, 1989). Another study investigated the
hospital environment of eight patients who were culture positive for C. difficile, and
control environments where there were no known cases of diarrhoea. C. difficile was
isolated from 32.5% of sites sampled where patients known to be carrying the
organism were situated, and only 1.3% of areas where there were no known cases of
diarrhoea (Mulligan et al, 1980).
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It is significant to note for comparison that A1 Saif and Brazier (1996), isolated C.
difficile from only 2.6% and 2.2% of surfaces in nursing homes and private
residences respectively. These studies indicate a high prevalence of C. difficile in the
hospital environment which may act as an important reservoir of the organism for
cross-infection.
1.3.3. Colonisation and infection of animals with C. difficile
Borriello et al (1983), isolated C. difficile from 23% of household pets investigated,
including dogs, cats, a duck and a goose. Al Saif and Brazier (1996), studied the
faeces of fann and domesticated animals, they obtained C. difficile from the faeces of
a small number (<1%) of farm animals, and from 10.5% of domesticated cats and
dogs. A previous study investigated the faeces of animals in two veterinary clinics,
C. difficile was isolated from 61% in one clinic and 17.5% in the other clinic (Riley
et al, 1991). These studies indicate colonisation with C. difficile in healthy
domesticated animals. However, it has been demonstrated that animals can also
suffer from C. difficile related diseases, and as with human infection the disease
usually results after intestinal disruption with antibiotic therapy. Diarrhoea and fatal
colitis linked to lincomycin contaminated grain feed was reported in horses and the
likely cause of this disease was thought to be C. difficile (Raisbeck, 1991). C.
difficile has also been reported as the cause of chronic recurrent diarrhoea in dogs
(Berry and Levett, 1986), and the association with fatal colits in hamsters after
administration with clindamycin is well documented (Bartlett and Gorbach, 1977).
Although colonisation and infection with C. difficile in animals is common there is
no evidence for C. difficile as a zoonotic pathogen. The organism is very common in
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the environment and it is likely that animals acquire the organism from the
environment in a similar way to humans.
These studies indicate that C. difficile is an organism which is ubiquitous in the
environment and it is encountered by man and other animals on a regular basis. It is
therefore hardly surprising that it has found a niche in the hospital environment.
1.4. Epidemiology of C. difficile
As discussed, C. difficile is common in both general and hospital environments. It is
likely that individuals can acquire the organism from numerous environmental
sources. The organism is probably carried from time to time by healthy individuals
"in transit" as part of their healthy gut flora, and in most cases causes no adverse
effects. C. difficile is associated with asymptomatic colonisation in healthy adults,
individuals in both hospital and the community with a history of antimicrobial
therapy and a particularly high number of neonates are asymptomatically colonised
with C. difficile. Hospitalised adults and babies probably acquire C. difficile from the
hospital environment.
1.4.1. Asymptomatic colonisation with C. difficile
Healthy adults
The isolation rate of C. difficile from healthy adults has been shown to vary
considerably. The findings from several studies are presented in table 1.1, and show
isolation rates to vary from 0-12% in similar patient populations Nakamura et al
(1981), Wilson et al (1982a) and Sharp (1985), reported considerably higher rates of
isolation of C. difficile than the other studies. The discrepancy of these findings is
unclear, Wilson et al (1982a), did not state the source of the nonnal adults in the
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study, and whether or not they had recently received any antimicrobial therapy. A
small number ofpatients investigated by Sharp (1985), had undergone recent
exposure to antibiotics. Nakamura et al (1981), investigated a Japanese population
and it was thought that the high colonisation rates may reflect ethnic origin and
dietary differences. However, Kato et al (2001), recently reported average
colonisation rates of 7.6% from several populations of healthy Japanese adults. Kato
et al (2001), showed that the colonisation rate could vary between 4.2% and 15.3% in
healthy populations of adults indicating that factors other than culture methods and
ethnic origin could influence colonisation rates in healthy adults. Despite this, the
culture methods, processing and the storage of specimens did vary considerably
between the studies presented in table 1.1. For example, Ambrose et al (1985), used a
non-specified selective medium and Viscidi et al (1981), used an agar with cefoxitin
and cycloserine, the selective agents recommended by George et al (1979). Small
variations in selective agents can dramatically affect the sensitivity of the media, and
the enrichment of cultures used by Phillips and Rogers (1981), may have
significantly enhanced the recovery of the organism. Processing and storage of the
faecal specimens may also have affected the isolation rate. Viscidi et al (1981) and
Ambrose et al (1985), processed samples and froze them at -40°C before analysis,
this perhaps reflects their failure to detect any colonised individuals. When tested for,
free cytotoxin was not detected in the faeces of the healthy adult carriers. However, it
was shown that C. difficile isolates collected from healthy adults had the ability to
produce toxin in vitro (Aronnson et al, 1985).
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Table 1.1. The isolation rates of C. difficile the healthy adult population
NUMBER (%j OF INDIVIDUALS POSITIVE FOR
POPULATION C. DIFFICILE BY TOXIN(S) IN REFERENCE
SAMPLED CULTURE FAECES
Healthy adults 0/84 (0) 0/84 (0) Ambrose et al (1985).
General population 11/594 (1.9) 0/594 (0) Aronnson et al (1985).
Healthy adults 4/200 (2) NOT TESTED Phillips & Rogers (1981).
Normal adults 5/39 (12) 0/39 (0) Wilson et al (1982a).
Healthy adults 0/60 (0) 0/60 (0) Viscidi et al (1981).
Healthy adults 49/431 (11.4) 0/431 (0) Nakamura et al (1981).
Healthy adults 8/72 (11.1) NOT TESTED Sharp (1985).
Healthy adults 94/1234 (7.6) NOT TESTED Kato et al (2001).
Neonates
The high rate of asymptomatic colonisation of healthy neonates with C. difficile is
well documented but poorly understood. Many studies have investigated the
colonisation rates amongst neonates in hospital nurseries. The results from several
studies are shown in table 1.2, and these colonisation rates vary from 10.6%-66.7%.
This variation is likely to reflect both culture methodology and genuine variation in
the populations investigated. Taffinder et al (1997), investigated the colonisation
rates in neonates in a nursery over four different time periods and found that the
isolation rate varied from 10% to 57%, indicating that within an individual nursery
there can be considerable variation.
The source of neonatal colonisation with C. difficile is likely to be environmental.
Al-Jumaili et al (1984), isolated C. difficile from 71% of infants in a special care
baby unit, and related levels of colonisation to the duration of time spent in hospital.
9
This indicated that the acquisition of C. difficile from the environment and from
health personnel was a likely possibility. Larson et al (1982), also made an
association between environmental contamination and clusters of colonised infants.
Other possible sources of C. difficile have been implicated. Acquisition from both the
gastrointestinal tract and the vagina have been suggested. Hafiz et al (1975),
published a study which suggested that a high percentage ofwomen carried C.
difficile in the vagina. (Larson et al, 1982); Bolton et al (1984), failed to isolate C.
difficile in such high numbers from the vagina, however they did not use enrichment
culture methods. Both Bolton et al (1984) and Larson et al (1982), reported no
relationship between vaginal or gastrointestinal colonisation by the mother and
neonatal colonisation.
As discussed in section 1.3.2, the hospital environment is often contaminated with C.
difficile spores. As the environment is thought to be a major reservoir of C. difficile
for patients who develop AAD in adults, it is likely also to be a reservoir for the
colonisation of neonates.
A number of factors have been suggested to be influential in the colonisation of
neonates. Infants lack the complex flora of older children and adults; this may
explain how the organism can proliferate in the neonatal and infant gut. The
incidence of colonisation with C. difficile in children has been shown to decrease
with age. Viscidi et al (1981), showed that colonisation with C. difficile dropped
from 29% of neonates to 9% of infants aged between 3-24 months old Work carried
out by Cooperstock et al (1983), suggested that breast fed babies were less likely to
be colonised with C. difficile than formula fed babies, suggesting that the infant is
protected by maternal antibody in the breast milk. However, Donta and Myers
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(1982), showed that colonisation with C. difficile was more frequent in breast fed
babies.
Table 1.2. Isolation rates of C. difficile from neonates
NUMBER (%) OF INDIVIDUALS POSITIVE FOR
C. DIFFICILE BY CULTURE TOXIN(S) IN FAECES REFERENCE
46/150 (30.7) 22/150 (14.7) Bolton et al (1984).
8/75 (10.6) NOT TESTED Brettle and Wallace (1984).
76/114 (66.7) NOT TESTED Delmee et al (1988).
NOT TESTED 11/105 (10.5) Donta and Myers (1982).
4/10 (40) NOT TESTED Hall and O'Toole (1935).
32/61 (52.5) NOT TESTED Larson et al (1982).
28/182 (15.4) NOT TESTED Snyder (1940).
31/50 (62) NOT TESTED Tabaqchali et al (1984a).
28/99 (28) NOT TESTED Taffinder et al (1997).
6/22 (27.3) 1/22 (4.5) Torres et al (1984).
13/45 (28.9) 12/45 (26.7) Viscidi et al (1981).
As the summary of studies in table 1.2 shows, C. difficile toxins were detected in a
large number of asymptomatically colonised infants. The presence of toxin in the
adult gut usually indicates infection and is rarely detected in the faeces of
asymptomatic colonised adults. However, toxin is often detected in the faeces of
asymptomatic infants, the reason for this remains to be determined. Several
suggestions for the presence of toxin in the faeces of asymptomatically colonised
infants are lack of receptors for toxin or masked receptors in the infant gut. However,
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this does not explain why the organism produces toxin in detectable quantities in the
infant gut.
Adults with a history of antimicrobial therapy
Studies have shown an increase in the rate ofasymptomatic colonisation with C.
difficile in patients with a history of antibiotic use. Viscidi et al (1981), showed that
21% of patients carried C. difficile after antibiotic therapy. Another study
demonstrated the acquisition of C. difficile during or after treatment with cefoxitin by
5 of 6 patients (Mulligan et al, 1984). It was shown that 15 of 78 volunteers acquired
C. difficile after only one parenteral dose of cephalosporin (Ambrose et al, 1985).
Bartlett (1992), reported that 10-25% of patients receiving antibiotics were colonised
with C. difficile.
Individuals with cystic fibrosis are colonised with C. difficile at a higher rate than the
general population, this is likely to reflect the increased exposure to antibiotics in
these groups of individuals. Cystic fibrosis patients are almost always receiving an
antibiotic regime for prophylactic purposes, however, symptoms ofAAD are rarely
reported in cystic fibrosis patients (Wu et al, 1983). In a study of cystic fibrosis
patients receiving antibiotics, 50% were shown to carry C. difficile, compared to
none of the cystic fibrosis patients not receiving antibiotics. (Wu et al, 1983). In a
study by Peach et al (1986), 32% of cystic fibrosis patients carried C. difficile
asymptomatically compared to 17% of control patients on antibiotics. The relatively
high colonisation rate of C. difficile in cystic fibrosis patients is likely to be a result
of continual antibiotic therapy and is therefore not surprising.
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1.4.2. Infection with C. difficile
Hospital-acquired CDAD
AAD and PMC related to C. difficile is a significant hospital-acquired infection that
predominately affects elderly patients who have undergone antibiotic therapy. The
rates of infection vary from hospital to hospital and between wards within hospitals.
Rates ofconfirmed C. difficile infection varied between 0.76 and 6% in a report that
investigated nine different health authorities in the UK (Djuretic et al, 1999).
Karlstrom et al (1998), reported an overall rate of C. difficile infection at 17 in
10,000 patients in a survey of 21 Swedish hospitals. The study also demonstrated the
varying incidence of infection in different types ofward. The highest rate at 95 in
10,000 cases occurred in geriatric and rehabilitation wards, 16 in 10,000 cases
occurred in oncology wards and the lowest rates, 2 in 10,000 occurred in
ear/nose/throat, dennatology, gynaecology and neurology combined.
Any hospitalised patient undergoing antibiotic therapy is at risk of developing
CDAD, however it is generally accepted that elderly patients are most at risk of
acquiring the infection. Other immunocompromised and debilitated groups including
cancer patients undergoing chemotherapy and steroid treatment, and Human
Immunodeficiency Virus (HIV) positive patients are also at increased risk. A number
of risk factors relating to age, underlying illness and medications, including the use
of specific antimicrobial agents are thought to influence the development of disease.
The importance of these factors will be discussed in detail in section 1.5.
C. difficile associated illness has become an increasing problem since the 1980s. The
Public Health Laboratory Service for England and Wales reported a steep increase in
the number of laboratory identifications of C. difficile over the last decade. The
13
number of laboratory identifications of C. difficile in England and Wales has risen
from 682 in 1998 to 4375 in 2000; this increase is illustrated in figure 1.1
(www.phls.co.uk). Similar increases have also been shown in Scotland (data
obtained from The Scottish Centre for Infection and Environmental Health); this is
illustrated in figure 1.2. It should be noted that C. difficile associated disease is a
reportable infection in Scotland, but not in England and Wales.
Figure 1.1. Laboratory reports of C. difficile in England and Wales
1988-2000
Year




organism and its virulence factors. It is the events of these interactions that
determine the pathology and outcome of the disease.
Infection with C. difficile requires the initial disruption of the gut flora, usually with
antibiotics, followed by exposure to C. difficile. The bacterium, C. difficile colonises
the gut and expresses a number of virulence factors which may contribute to the
pathology of disease. C. difficile toxins A and B are the major virulence factors and
they are responsible for the principal pathological effects of C. difficile disease.
Other putative virulence factors such as capsules, flagella, hydrolytic enzymes, other
toxic factors and the S-layer proteins (SLPs) may be involved in the colonisation
process, and the virulence associated with C. difficile.
1.7.1. The C. difficile toxins- toxin A and toxin B
The major pathology ofCDAD is a result of the actions the two potent cytotoxins, C.
difficile toxins A and B. These toxins belong to the family of Large Clostridial
cytoToxins (LCTs).
The structure of toxin A and toxin B
Both toxins are large, single-chained peptides, toxin A has a molecular mass of 308
kilo Daltons (kDa), and toxin B has a mass of 250 kDa. The toxins have an average
of 49% amino acid sequence homology (von Eichel-Streiber, 1995), and each toxin
has three functional domains, as shown in figure 1.3.
Figure 1.3. The general structure of the toxin A and toxin B peptide











were frequently associated with community acquired cases ofCDAD.
Cephalosporins are frequently used to treat community-acquired pneumonia, and as
the elderly often suffer from such illnesses they are likely to be at an increased risk
of acquiring community acquired C. difficile, and should be closely monitored by
their GP.
1.5. Risk factors associated with CDAD
A large number of potential risk factors for CDAD relating to medication, medical
diagnoses, medical procedures, underlying diseases and host factors have been
suggested. Epidemiological investigations of possible risk have produced conflicting
results. However approaches to studies have varied, different statistical methods have
been used and many early reports did not account for confounding factors.
The multifactorial nature ofCDAD makes analysis for influential risk factors more
difficult as many factors and many combinations of factors may induce patient
susceptibility, it is important that analysis accounts for any confounding interactions
of risk factors. Accurate identification of the most significant and most frequently
associated risk factors would be beneficial in the development of control and
treatment strategies.
Age and antibiotic use are well-established risk factors for C. difficile colonisation
and disease. The significance of other factors such as medications other than




The association of C. difficile infection with increasing age is well documented. A
number of epidemiological studies have determined age as a significant risk factor
for the disease (McFarland et al, 1990; Buchner & Sonnenberg, 2001). Aronnson et
al (1985), reported that the incidence ofCDAD was significantly higher in patients
over 60 years of age.
Elderly patients are also more likely to have been exposed to the hospital
environment, and other possible risk factors, as a result of underlying diseases and
poor general health. Their poor health may affect the efficiency of their immune
system and their ability to deal with infection.
1.5.2. Antibiotic use
Most antibiotic agents have been associated with the CDAD. The disease was
initially associated with clindamycin use, however broad-spectrum agents such as
cephalosporins and ampicillin most frequently provoke the disease (Bartlett, 1981;
Aronnson et al, 1985)
The normal gut flora offers protection from colonisation by pathogenic bacteria. This
protective effect is referred to as "colonisation resistance." The effect of the gut flora
against C. difficile growth and toxin production has been shown in vitro (Borriello
and Barclay, 1986). Treatment with antibiotics diminishes the gut flora and therefore
decreases the effect of colonisation resistance, this exposes a patient to colonisation
by pathogenic bacteria including C. difficile.
Cephalosporins have been implicated as the cause ofCDAD in many studies, and
evidence suggests that they are potent inducers of C. difficile colonisation and
disease. Aronnson et al (1985), found that cephalosporins were implicated 40 times
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more often than narrow spectrum penicillins, and Silva et al (1984), reported that
cephalosporin use was implicated in 71 of 130 cases ofCDAD. Impallonemi et al
(1995), reported a sudden increase in the number of cases ofCDAD in geriatric
patients following a 20-fold increase in the use ofcefotaxime, the number of cases
dropped when cefotaxime use was terminated. Several studies have indicated that
antibiotic policies restricting the use of cephalosporins can significantly reduce the
incidence of infection. Cartmill et al (1994), reduced the use of cephalosporins
during an outbreak, the number of cases ofCDAD were reduced and a decreased rate
of disease was maintained. McNulty et al (1997), showed that controlled use of
cefuroxime in an elderly care unit reduced and maintained a low level ofCDAD.
Ampicillin and amoxycillin have long been associated with CDAD (Freeman and
Wilcox, 1999). Silva et al (1984), showed ampicillin use in 38 of 130 cases of
CDAD, and Bartlett (1981), demonstrated that 109 of 329 patients with C. difficile
disease had been exposed to ampicillin.
Other antimicrobial agents including erythromycin, tetracycline, other penicillins
(Bartlett, 1981), clarythromycin ( Braeggar and Nadal, 1994) and co-trimoxazole
(Gordin et al, 1994) have been implicated. Almost all antibiotics have been
implicated at some time, and due to the multiple antibiotic regimes it can be difficult
to determine the inciting agent. The association with the 4-fluoroquinolones is rare
despite their wide-spread use following their introduction in the 1980s (Freeman and
Wilcox, 1999). Golledge et al (1992), failed to isolate C. difficile from 117 patients
who had received ciprofloxacin treatment. Studies have shown that ciprofloxacin is
non-bactericidal in anaerobic conditions, and may therefore not affect the protective
anaerobic components of the gut flora (Smith et al, 1988).
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However, it is the cephalosporins, clindamycin, ampicillin and amoxycillin which
most frequently induce disease.
CDAD is usually associated with antibiotic treatments, however the use of single
dose surgical prophylaxis has also been implicated. Privitera et al (1991), showed
that of 108 volunteers undergoing elective surgery, 23% of those who received a
single dose of cephalosporin acquired C. difficile, however only 3.3% of those who
received mezlocillin acquired C. difficile, none of the patients developed diarrhoea.
Ambrose et al (1985), also showed a higher acquisition rate of C. difficile in patients
who received a single dose of a cephalosporin compared to those who received a
single dose of penicillin.
Antibiotics are clearly a predisposing factor for the development ofCDAD. In
addition to the diminishing effect on the gut flora allowing colonisation, the
antibiotics may also induce stress responses which can upregulate toxin production,
increase adherence and expression of virulence factors (Freeman and Wilcox, 1999).
1.5.3. Medical procedures and medication
Medical procedures
A number ofmedical procedures which may allow entry of C. difficile to the
intestinal tract and/or reduce the "colonisation resistance" in the gut allowing C.
difficile to colonise and proliferate have been suggested to increase the risk of
developing C. difficile infection.
Nasogastric feeding tubes have been associated with C. difficile infection, Simor et al
(1993), investigated patients in a long tenn care facility and logistic regression
modelling showed nasogastric feeding to be significant in those patients with CDAD
when compared to those without. Pierce et al (1982), investigated ten cases of C.
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difficile, three patients had received nasogastric feeding for two or more days, and it
was suggested that this may be an influencing factor. However, MacFarland et al
(1990), investigated patients in a general medicine ward over an 11-month period
and found that the use of nasogastric feeding tubes was not significant in colonised
patients or patients with CDAD.
One study reported a significant reduction in the number of cases of C. difficile
infection following the replacement of reusable rectal thermometers with single use
disposable thermometers (Brooks et al, 1992). This indicates that C. difficile may be
allowed to enter the gastrointestinal tract via contaminated instruments, thus
sigmoidoscopy and endoscopy procedures may carry a risk for C. difficile infection.
Both McFarland et al (1990) and Pierce et al (1982), reported that the use of enemas
was significant in patients with CDAD. Pierce et al (1982), also reported that
gastrointestinal surgery could predispose patients to C. difficile disease. However,
Gerding et al (1986), did not find gastrointestinal surgery to be significantly
associated with C. difficile infection, and in a one year prospective study of 241
patients who had undergone gastrointestinal surgery only nine developed CDAD. A
number of case reports have linked gastrointestinal surgery with CDAD, however
other factors such as antibiotic use were not taken into account.
Medication (other than antibiotics)
Antacids and anti-ulcer H2 antagonists have been implicated in C. difficile disease. It
is thought that as these medications increase the pH in the stomach that this could
facilitate the entry of C. difficile to the gastrointestinal tract. McFarland et al (1990),
found that the use of gastric acid suppressants was a significant factor in the
colonisation of patients, but was not significant in those patients with CDAD.
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Simor et al (1993), investigated patients in a long term care facility and found that
the use of anti-ulcer drugs did not influence infection in these patients. Shah et al
(1998), investigated the records of patients who had been investigated for C. difficile.
The study revealed that usage of gastric acid suppressants was similar in patients
who tested positive and patients who tested negative for C. difficile. It is likely that
the low pH of the gastric secretions have no effect on C. difficile spores.
MacFarland et al (1990), reported that the use of stool softeners was significant for
colonisation and CDAD, however laxatives were not. Simor et al (1993), also
reported that laxatives were not significant in CDAD. Cancer chemotherapy drugs
and steroids have also been associated with CDAD.
1.5.4. Underlying diseases and immune status
Gastrointestinal disease
Harbarth et al (2001), studied patients in a cardiac surgery ward who developed C.
difficile and found that gastrointestinal disease was an associated risk factor.
Greenfield et al (1983), reported that C. difficile could be isolated in significantly
more patients with inflammatory bowel diseases than in healthy individuals with
normal bowel habits. Patients with inflammatory bowel diseases are more frequently
exposed to antibiotics and this may reflect the high isolation rate from these patients.
Keighley et al (1982), reported that patients with inflammatory bowel disease did not
develop CDAD unless they were exposed to antibiotics and Gerding et al (1986),
also found no association with colonic diseases and the development ofCDAD.
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Cancer
Milligan and Kelly (1979), reported fatal PMC in five patients with leukaemia
undergoing chemotherapy and antibiotic treatment, and suggested strict control of
antibiotic regime in patients with serious underlying illness. Several later reports
linked the possible suppression of the gut flora by anti-cancer chemotherapy and
histopathological changes in the gut mucosa with PMC (Fainstein et al 1981;
Cudmore et al 1982). A number of studies have since made the association with
cancer chemotherapy and CDAD.
As well as the effects of anti-cancer chemotherapy, cancer patients often have
reduced immune status as a result of steroid therapy. Steroids have been implicated
in CDAD, as these drugs are often combined with chemotherapy and can diminish
the effects of the immune system.
The importance of immune status is reflected in the relatively high incidence of C.
difficile infection reported in immunocompromised patients including HIV positive
and acquired immune deficiency syndrome (AIDS) patients. Hutin et al (1993),
reported CDAD in 4.1% ofHIV infected patients, the incidence of C. difficile
diarrhoea in HIV infected patients was reported by Tacconelli et al (1999), to be
3.1%, almost double that ofnon-HIV infected patients in a large university hospital.
However, the high frequency of hospitalisation, cancer therapy and antibiotic use in
HIV patients are also important influential factors.
Immune status
A reduced immune status is a common factor in the groups of patients who most
frequently suffer from C. difficile infection. Elderly and debilitated patients often
have impaired immune function, the immune systems of elderly patients become less
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efficient and various functions of the immune system become defective with the
progression of age (Haeney, 1994). Elderly, HIV-positive and cancer patients with
underlying health problems are more likely to be hospitalised and are more
frequently exposed to a variety of the potential risk factors.
However, as discussed, one of the first lines of defence against any gastrointestinal
pathogen is "colonisation resistance." It is the reduction in colonisation resistance by
antibiotics and other drugs that allow the colonisation of the gut with C. difficile.
Barclay and Borriello (1986), showed that the colonisation resistance in elderly
patients was diminished suggesting that they require less compromise before
developing the disease.
Following colonisation with C. difficile the role of the immune system in eliminating
the infection is undetermined. Several investigators have studied antibody responses
to C. difficile toxins (Johnson et al, 1992; Warny et al, 1994) and to cell surface
proteins (Pantosti et al, 1989). Johnson et al (1992), showed that immunoglobulin G
(IgG) and immunoglobulin A (IgA) responses to C. difficile toxin A vary greatly
between patients and controls. Warny et al (1994), showed that IgG and IgA levels to
toxin A were higher in those patients that suffered only from a single episode of
diarrhoea compared to those who suffered from relapses. Kyne et al (2001), also
showed higher antibody levels to toxin in patients who did not suffer from relapses.
Many factors have been shown to significantly influence the development ofCDAD
in specific populations. Factors such as the level of environmental contamination and
proximity to infected patients are thought to be important in the spread of infection,
however this is difficult to investigate. Evidence would also suggest that host factors,
including age, play a major role in determining patient susceptibility. Host factors
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cannot be controlled, however, by the identification of the influential host factors and
other risk factors effective control strategies may be developed.
Starr et al (1997), proposed a "herd immunity" model for C. difficile infection. The
model suggests that within a ward ("herd") there is an overall state of resistance to C.
difficile. However, if the number of resistant patients in the ward drops below a
critical level then cases of C. difficile will occur. By identifying the factors which
shift the equilibrium of resistant patients below the critical level, and careful
attention to case-mix to account for uncontrollable host factors, effective control of
C. difficile infection may be achieved.
1.6. The spectrum and clinical presentations of C. difficile disease
The clinical manifestations associated with C. difficile colonisation range from
asymptomatic colonisation (discussed in section 1.4), mild diarrhoea and non-
pseudomembranous colitis to fulminant colitis which can result in death. Most
patients suffer only from the mildest forms of the disease and fortunately the more
serious outcomes are relatively rare (Kelly and LaMont, 1991). The reasons for the
variation in the severity of C. difficile infection are unclear, however host factors are
likely to be of paramount importance.
Antibiotic-associated diarrhoea (AAD)
It is common for patients using antibiotics to develop mild symptoms of diarrhoea
due to the disturbance of the normal bacterial flora. The normal fermentation process
in the gut is altered during antibiotic treatment resulting in unabsorbed carbohydrate
in the gut. This carbohydrate in the gut binds water and causes diarrhoea which is
relieved on the termination of antibiotic therapy and the return of the nonnal gut
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flora (Rao et al, 1988). AAD can also be a result of colonisation with C. difficile. The
diarrhoea is usually mild to moderate and can be accompanied by abdominal
cramping, and usually ceases upon termination of the offending antibiotic therapy
requiring no further treatment (Kelly et al, 1994a).
C. difficile colitis (without the formation of pseudomembranes)
C. difficile colitis without the production of pseudomembranes is more serious than
the mildest form ofAAD. Patients suffer from abdominal pain, cramping and much
more profuse and debilitating diarrhoea. Other symptoms may also include malaise,
anorexia, nausea, dehydration and fever. Colonic bleeding is rare and sigmoidoscopy
reveals patchy colitis (Kelly et al, 1994a).
Pseudomembranous Colitis (PMC)
Symptoms ofPMC are similar to, but more severe than the symptoms associated
with the milder form of colitis. Sigmoidoscopy reveals the yellow plaques associated
with PMC on the colon and rectum mucosa. In severe cases the pseudomembrane
may cover large areas of the colorectal mucosa (Kelly et al, 1994a).
Fulminant colitis
This only occurs in about three percent of patients but can result in gut perforation
and megacolon requiring the need for surgical intervention, in the most severe cases
death may occur. Patients suffer from abdominal pain, cramping, severe diarrhoea
and gut distension, high temperatures and leukocytosis (Kelly et al, 1998).
1.7. The virulence factors associated with C. difficile.
Any infectious disease is a complex set of interactions between host and pathogen.
The host immune system triggers a series of events in response to the infecting
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organism and its virulence factors. It is the events of these interactions that
determine the pathology and outcome of the disease.
Infection with C. difficile requires the initial disruption of the gut flora, usually with
antibiotics, followed by exposure to C. difficile. The bacterium, C. difficile colonises
the gut and expresses a number of virulence factors which may contribute to the
pathology of disease. C. difficile toxins A and B are the major virulence factors and
they are responsible for the principal pathological effects of C. difficile disease.
Other putative virulence factors such as capsules, flagella, hydrolytic enzymes, other
toxic factors and the S-layer proteins (SLPs) may be involved in the colonisation
process, and the virulence associated with C. difficile.
1.7.1. The C. difficile toxins- toxin A and toxin B
The major pathology ofCDAD is a result of the actions the two potent cytotoxins, C.
difficile toxins A and B. These toxins belong to the family of Large Clostridial
cytoToxins (LCTs).
The structure of toxin A and toxin B
Both toxins are large, single-chained peptides, toxin A has a molecular mass of 308
kilo Daltons (kDa), and toxin B has a mass of 250 kDa. The toxins have an average
of 49% amino acid sequence homology (von Eichel-Streiber, 1995), and each toxin
has three functional domains, as shown in figure 1.3.
Figure 1.3. The general structure of the toxin A and toxin B peptide











The three functional domains of C. difficile toxins A and B:
(i) The enzymatic domain: This is located at the N-terminus and catalyses the
glucosylation of guanosine 5'-triphosphate (GTP)-binding proteins (Hofmann
et al, 1997).
(ii) The transmembrane domain: Centrally located, this domain is likely to
mediate the translocation of the toxin to the cytosol, however this has not
been proven (Just et al, 2000).
(iii) The receptor binding domain: Located at the C-terminus, this domain is
constructed of repeat motifs and mediates binding to specific carbohydrate
structures (Pothoulakis et al, 1991; Pothoulakis et al, 1996; Krivan et al,
1986; Clark et al, 1987).
The pathogenicity locus (PaLoc)
Toxins A and B are coded on a 19.6 kb pathogenicity locus (PaLoc). The PaLoc
encompasses the two toxin genes (tedA and tcdB) and three accessory genes, txel,
txe2 and txe3, this is shown in figure 1.4.
Figure 1.4. The pathogenicity locus of C. difficile
Adapted from Moncreiff and Wilkins (2000).
+> ► -► ► <
txel tcdB txe2 tedA txe3
(Arrows indicate the direction of transcription)
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The possible functions of the accessory genes:
txel and txe2 both reach peak transcription in stationary phase, txel may positively
regulate the toxin gene promoters.
txe 2 is structurally and functionally similar to holin proteins which may facilitate the
release of toxin A and B, via cell lysis (Soo Tan et al, 2001).
txe3 - transcript levels peak in exponential phase, it may be a negative regulator
(Moncrief and Wilkins, 2000).
A number of toxin variant strains have been identified (Lyerly et al, 1992, Borriello
et al, 1992a; Deptire et al, 1993). These toxin variant strains possess the PaLoc.
However, it is different when compared to the pathogenicity locus from the reference
strain (VPI 10463). These differences result from deletions in the genes and the
outcome can be the production of toxin B only (tox A-B+), or failure to produce
either toxin (tox A-B-). However, some variant strains can still produce both toxins
A and B (Rupnik et al, 2001).
Cellular intoxication with toxin A and toxin B
As previously mentioned both toxin A and toxin B are potent cytotoxic GTP-ase
glucosylating proteins. The cytotoxic activity of toxin A and toxin B results from the
glucosylation of small GTP-binding proteins such as Rho, Ras and Cdc42, which
leads to disruption of the cellular cytoskeleton (Just et al, 1995 a & b).
The toxins bind to the cell surface via a specific receptor, Toxin A has been shown to
bind to carbohydrate domains on rabbit sucrase-isomaltase, rabbit erythrocytes and
to specific carbohydrate domains on human red blood cells (Pothoulakis et al, 1991;
Krivan et al, 1986; Clark et al, 1987). However, the specific carbohydrate receptor
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for toxin A on human colonic cells has yet to be determined, and the receptor for
toxin B is not known. The toxin enters the cells by receptor mediated endocytosis
(von Eichel Streiber et al, 1991). Once in the cytosol the toxins glucosylate small
GTP-binding proteins such as Rho and Rac (Just et al, 1995 a & b). The small
GTPases are modified and inactivated, thus affecting the signalling pathways within
the cell and ultimately leading to the collapse of the actin cytoskeleton. This
sequence of events is summarised in Figure 1.5.
Figure 1.5. Cellular intoxication by C. difficile toxins A and B




Action of toxins A and B on the intestine
Toxin A exhibits both enterotoxic and cytotoxic activity, and toxin B has cytotoxic
activity 1000 times more potent than toxin A (Lyerly and Wilkins, 1995). Toxin B
alone is not active in rabbit intestinal loops assays, however when injected with sub-
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lethal amounts of toxin A, death occurs. This indicates that the two toxins act
synergistically (Lyerly and Wilkins, 1985).
The C. difficile toxins induce a strong inflammatory reaction and it has been shown
that both toxins directly and indirectly affect immune cells. It is thought that the
binding of toxin A and toxin B to the receptors on the intestinal epithelial cells elicits
a signal, which activates fluid secretion and inflammation by both the activation of
the enteric neuronal system and the immune response.
Activation of the immune response
Toxin mediated monocyte and macrophage infiltration
Toxin A has been shown to elicit a dose dependent stimulation of neutrophil
migration and recruitment (Kelly et al, 1994b). It has been shown that cultured
monocytes release tumour necrosis factor-a (TNF- a) upon stimulation with toxins A
and B, and that toxin B is 1000 times more potent than toxin A in the same system
(Souza et al, 1997). Human monocytes produce IL-8, a neutrophil chemotactic factor
upon exposure to C. difficile toxins A and B (Linevesky et al, 1997). Mast cells have
also been shown to play a role in the neutrophil recruitment. Calderon et al (1998),
showed that mast cells produce TNF- a upon stimulation with toxin A, but that
prolonged exposure of the mast cells to toxin A impaired their function, affecting the
release of inflammatory mediators. This could potentially diminish the effects of the
immune response and facilitate disease progression.
Neuronal activation
An early study by Castagliuolo et al (1994), indicated that the neuronal system may
be involved in the inflammation resulting from C. difficile toxins. Pothoulakis et al
(1994), demonstrated that inflammation decreased when rats were pre-treated with a
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substance P (SP) antagonist before ileal loops were exposed to toxin A. SP is a major
neurotransmitter, the activation ofwhich results in secretion, inflammation and tissue
damage. Castagliuolo et al (1997), subsequently showed that in rats, toxin A caused
an increase in SP response in mucosal scrapings and lumbar dorsal root ganglia.
Recently, Keates et al (1998), showed that another neurotransmitter, calcitonin gene-
related peptide (CGRP) was involved in the inflammation response induced by toxin
A. Castagliuolo et al (1998), showed that intestinal epithelial cells release
macrophage inflammatory protein (MIP-2) after exposure to toxin A. MIP-2 then
activated sensory nerves to release SP and CGRP which stimulates neutrophils.
These studies provide good evidence for the neuronal involvement in the
inflammation and fluid secretion induced by process of C. difficile toxins.
The pathology of C. difficile
The actions of the C. difficile toxins are summarised in figure 1.6. The current
understanding of the pathogenesis of C. difficile resulting from the action of the
toxins indicates that following intestinal colonisation with C. difficile, toxin A binds
to specific carbohydrate receptors on the intestinal epithelium. As a result of the
toxin effects on the cellular cytoskeleton, the tight junctions open. This process
allows toxin B to pass through the tight junctions where it is taken up by enterocytes,
and as well as causing the death of cells, the toxins upregulate the recruitment of
neutrophils by both the upregulation of neutrophil chemotactic factors and neuronal
activation. The neutrophils can pass through the tight junctions to the gut mucosa
where they release inflammatory mediators resulting in mucosal inflammation.
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Figure 1.6. Action of the C. difficile toxins on the intestinal epithelium
Adapted from Thelestam and Chaves-Olartes (2000).
O
/o o
C. difficile O O
> o oo




Toxin A binding to
O specific receptors
Neuronal activation
Cell rounding and death
As cells round and are shed into the lumen of the gut, an ulcer forms on the mucosal
surface, and mucus and inflammatory cells flow out through the ulcer forming the
pseudomembrane. The pseudomembrane contains cellular debris, fibrin and mucin.
They appear on the colonic or rectal mucosa as yellow-white plaques of 0.2-2cm in
diameter. These plaques are usually interspersed with normal tissue, however in
severe cases a confluent pseudomembrane can cover the entire mucosal surface of
the affected area. Usually it is only the epithelium and lamina propria which are
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affected, although deeper tissue damage can occur in severe cases (Price and Davies,
1977)
The normal patchy distribution of the pseudomembrane can be described by differing
local concentrations of toxin. Reigler et al (1995), showed that mucosal strips
exposed to toxin in vitro under low concentrations of toxin produced patchy lesions,
and as the concentration of toxin increased that patches became almost confluent
1.7.2. Capsules
Polysaccharide capsules are well-defined bacterial virulence determinants. They can
offer protection against immune recognition and phagocytosis by preventing
opsonisation, by antigenic variation and by mimicking host molecules.
Davies and Borriello (1990), were the first to demonstrate the production of a
capsule by C. difficile in vitro. They showed all 15 strains of C. difficile tested to
produce capsular material. Another investigation has shown C. difficile to be very
resistant to phagocytosis. Both toxigenic and non-toxigenic strains were resistant to
phagocytosis and the removal of cell-surface carbohydrates had no effect on
phagocytosis. It was therefore suggested that the capsule might act as an
antiphagocytic factor (Dailey et al, 1987), thus contributing to the virulence of C.
difficile. However, phagocytosis is unlikely to play an important role in the gut
mucosa.
1.7.3. Hydrolytic enzymes
The presence of hyaluronidase, chrondroitin sulphatase, gelatinase and collagenase
was detected a clinical isolate of C. difficile (Steffen, 1981). Popoff and Dodin
(1985), investigated 25 C. difficile strains for neuraminidase production and failed to
detect it in any of the strains tested. Seddon et al (1990), investigated hyaluronidase,
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chondroitin-4-sulphatase, heparinase, collagenase and protease production from 30
strains of C. difficile with different degrees ofvirulence in the hamster model. Not all
enzymes were detected in all strains, but the study showed that some strains of C.
difficile produced some of these hydrolytic enzymes and an association between
enzyme production and virulence was evident (Seddon et al, 1990). It is likely that
these hydrolytic enzymes contribute to tissue damage, thus releasing nutrients and
potentially revealing receptors which could facilitate adhesion and/or toxin binding.
1.7.4. Flagella
Flagella are often associated with motility and, together with chemotaxis, can
increase the efficiency with which bacteria can contact the host mucosal surface and
penetrate the mucous layer. Little research into the role of the flagella of C. difficile
has been carried out. However, Tasteyre et al (2001a), showed that non-flagellated
strains ofC. difficile associate with mouse caecum to an extent ten-fold less than
flagellated strains. The study also showed that the two flagella proteins adhered in
vitro to mouse caecal mucus, thus suggesting a role in adherence. It was also shown
that the FliD (the flagellar cap protein) is very well conserved between many
different serotypes of C. difficile, suggesting that it has a very specific function
Tasteyre et al (2001b).
1.7.5. Other toxic factors
C. difficile has also been shown to produce toxic factors other than toxins A and B.
Justus et al (1982), described a toxic substance distinct from C. difficile toxins A and
B which altered motility and caused changes in the electrical potential of the ligated
rabbit intestine.
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C. difficile also produces an ADP-ribosyltransferase (binary toxin) which acts in the
same way as C. botulinum C2 toxin and C. perfringens E iota toxin (Popoff et al,
1988). Perelle et al (1997), identified the two genes which transcribed the two
components of the toxin, the sequence of which was highly homologous to C.
perfringens iota toxin. Stubbs et al (2000), investigated the production of the binary
toxin in 170 C. difficile strains and determined that only toxin variant strains
possessed the binary toxin genes. The role of the binary toxin is unclear. It is possible
that this toxin can enhance the virulence potential of the organism. The predominant
ribotypes isolated from cases in the UK do not possess the binary toxin, although
strains producing this toxin have been isolated from patients in the UK and the US.
1.7.6. S-layer proteins
C. difficile possesses two S-layer proteins (SLPs) of different molecular mass
(Kawata et al, 1984). The S-layer is a common feature on many Gram-positive and
Gram negative bacteria and is composed of protein or glycoprotein sub-units which
make up a regularly ordered crystalline array (Sleytr and Messner, 1988). All S-
layers share general features; the proteins are relatively large, have a crystalline
structure and they self-assemble. There is however a lot of variation in the lattice
formats and the molecular weight of the proteins forming these S-layers between
species as well as within species (Sleytr and Messner, 1988).
It is presumed that because the SLPs are one of the most abundant bacterial proteins
that they must have a role, otherwise the energy expense required for their
production would be wasteful. Many functions have been suggested such as cell
shape determinants, protective coats and sieves which might protect from antibodies,
complement and lytic enzymes. It has also been suggested that they could be
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involved in cell adhesion and recognition (Sleytr and Messner, 1988). The location
of the proteins on the cell surface makes them ideal candidates for host-pathogen
interactions and as potential virulence factors.
The function of the S-layer ofC. difficile is undetermined, it is thought that it may
play a role in adhesion or immune system evasion. A number of other pathogenic
organisms including Campylobacterfetus subsp. fetus and Bacillus cereus possess
SLPs which have been shown to play a role in the pathogenesis of infection.
C. fetus subsp. fetus causes ovine abortion and the SLPs have been shown to be
essential for colonisation and/or translocation to the placenta, but do not play a role
in foetal injury (Grongono-Thomas et al, 2000). The SLPs from Bacillus cereus
were shown to play a role in adhesion to the cell matrix (Kotiranta et al, 1998).
Lactobacillus acidophilus is part of the normal gut flora and it has been shown that
cell-surface proteins including the SLPs bind to collagen and fibronectin and may
play a role in the mediation of adhesion of the bacteria to the extracellular matrix
proteins (Lorca et al, 2002).
The S-layer of C. difficile consists of two SLPs of varying molecular mass. Early
work carried out on C. difficile by Taekoa et al (1991), showed that there was no
immunological relationship between the two SLPs, and immunoblot analysis showed
the lower of the two proteins appeared to be strain specific. Earlier, Sharp and
Poxton (1988), had shown that the treatment of C. difficile with urea released one to
three cell surface proteins that reacted only with homologous antiserum. It is likely
that these urea extracts included the S-layer proteins from C. difficile. More recently,
Cerquetti et al (2000), determined that the S-layer of C. difficile was in fact two
structurally distinct protein lattices superimposed upon one another. The outer layer
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formed the square lattice, and the inner layer formed a hexagonal lattice. The study
also reported that the C. difficile SLPs are glycoproteins. More recently, Calabi et al
(2001), identified the gene coding for the C. difficile SLPs and showed that both
proteins were derived from a single gene product through post translational
processing. They showed that the amino acid sequence of the high molecular weight
SLP showed some conserved regions between strains, whereas the protein of lower
molecular weight showed more sequence diversity which would account for the
strain specificity reported by Taekoa et al (1991) and Cerquetti et al (2000). The high
molecular weight SLP from C. difficile showed some sequence homology to Bacillus
subtilis amidase. One of the open reading frames identified by Calabi et al (2001),
was shown to be homologous to the open reading frame of the Cw66 protein which
was shown to function as an adhesin (Waligora et al, 2001) suggesting a possible role
in adhesion for the SLPs. The function of the SLPs from C. difficile remains to be
determined. Recent evidence suggests that these surface proteins play a role in the
pathogenesis of C. difficile.
1.7.7. Fimbriae
In general, fimbriae are associated with bacterial attachment and can undergo phase
and antigenic variation. However, a role for virulence has not been shown in C.
difficile. Borriello et al (1986), showed that some strains of C. difficile possess
fimbriae but that no correlation with toxin production, the disease state of
experimental animals or adherence to the gut could be made. This may reflect the in
vitro situation where fimbriae may not be expressed.
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1.8. Laboratory diagnosis of CDAD
Laboratory diagnosis of C. difficile requires detection of toxin from patients with
diarrhoea. Only liquid stools should be investigated to confirm a clinical diagnosis of
CDAD. Formed stool samples should only be investigated for epidemiological
purposes (Delmee, 2001).
1.8.1. Detection of C. difficile by culture methods
Early efforts to isolate C. difficile used selective media with agents including
clindamycin hydrochloride and p-cresol (Bartlett et al 1977a; Hafiz and Oakley
1976). In 1979, George et al developed a selective medium; cycloserine, cefoxitin-
fructose agar (CCFA). The medium was successful and it is the basis of this formula
that is still used in many laboratories. The original formula used cycloserine at
500mg/L and cefoxitin at 16 mg/L. Flowever, several studies indicated that the
concentration of the selective antibiotics were too high and the growth of some
strains were inhibited, as a consequence the concentrations were halved (Willey and
Bartlett, 1979; Levett, 1985). Various methods for improving selectivity and
recovery have been suggested. Delmee, (2001) states that for the majority of cases,
direct plating of stools to CCFA and incubation under anaerobic conditions for 24-48
hours is a satisfactory method of recovering C. difficile.
Treatment of faecal samples with alcohol shock prior to plating was shown to
improve recovery and enhance selectivity (Borriello and Honour, 1981). Wilson et al
(1982b), showed that bile salts such as sodium chlolate and taurochlolate enhance
spore recovery, by enhancing germination. Cholic acid sodium salt is much cheaper
and is an as effective alternative to sodium taurocholate in selective media (Brazier,
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1993). Enrichment of specimens has also been shown to enhance recovery
significantly. However, the clinical significance of the small numbers of bacteria
recovered by enrichment is unclear. Enrichment studies are more useful for recovery
of small numbers in epidemiological studies (Riley et al, 1987).
The UK Anaerobe Reference Unit (ARU) in Cardiff currently recommends the use
of cycloserine cefoxitin egg-yolk agar (CCEY) agar for the detection of C. difficile
(Brazier, 1990). The medium contains cholic acid sodium salt, p-
hydroxyphenylacetic acid to enhance the colony odour, lysed blood to facilitate
fluorescence under ultra-violet (UV) light and egg-yolk to screen out lecithinase and
lipase producers. C. difficile colonies are relatively easy to identify by their
characteristic odour, colonial morphology and fluorescence under UV light. The
fluorescence exhibited by C. difficile is not unique, several other Clostridium spp.
present this characteristic (Brazier, 1993).
Gas liquid chromatography can be used if necessary to confirm the identity of
cultures thought to be C. difficile. However, this facility is not available in most
diagnostic laboratories (Levett, 1984). Biochemical test and commercial latex kits
can also confirm identity, however cross-reactions with C. sordellii and C.
bifermentans have been reported with latex kit tests (Bowman and Riley, 1986a).
1.8.2. Detection of C. difficile toxin(s)
The cytotoxic activity of C. difficile can be detected in faecal filtrates by challenging
many different cell lines such as Vero, HeLa and HEp2 with the faecal filtrate. The
cytopathic effect is a result of the activity of toxin B, which is about 1000 times more
potent than toxin A (Lyerly and Wilkins, 1995). The specific cytotoxic effect is
confirmed by neutralisation with C. difficile or C. sordellii antiserum. The tissue
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culture assay can take between 24-48 hours and requires the upkeep of tissue culture
cell lines in the appropriate facilities. However, reliable results can be obtained in
around five hours if large amounts of toxin are present (Delmee, 2001).
A large number of commercial kits are available for the detection of the C. difficile
toxins in faecal specimens. Enzyme immunoassay (EIA) kits such as Clearview™ C.
difficile A and Triage® C. difficile Panel detect toxin A in faecal samples via a
colour change and are designed for single use. A large number ofEnzyme- linked
immunosorbent assay (ELISA) kits, most of which detect toxin A only, are also
available. More recently however, a number of kits such as Techlab1M C. difficile A
and B which can detect both toxins in faecal specimens have been introduced as a
result of reported outbreaks due to toxin A-B+ strains of C. difficile (Alfa et al,
2000).
Most of these kits have been evaluated and in general they offer good sensitivity and
specificity. ELISA kits are almost as specific as tissue culture, but tend to be slightly
less sensitive. The major advantage of these kits over tissue culture is their rapidity
and the ease of use. The ELISA based assays are costly per test and as a result many
laboratories test specimens in batches. This is however also the case with tissue
culture. Single use tests are more economical for only one or two tests, but may not
offer the sensitivity and specificity required.
The clinical diagnosis of C. difficile is difficult, as patients do not always test
positive for both toxin and culture, and this, together with symptoms, are required for
a confirmed diagnosis. Occasionally patients test positive for toxin only and rather
more frequently patients test positive for culture only and it can be difficult to make
an accurate interpretation of the results. Toxin can become inactivated in samples
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that are stored at ambient temperature (Bowman and Riley, 1986b; Borriello et al,
1992b) thus, the need for careful transport and storage of samples to ensure that
accurate results can be obtained needs to be emphasised. The accurate diagnosis of
CDAD requires good communication between clinician and microbiologist and
regular monitoring of patients. Repeat samples should be collected if necessary, and
should be processed rapidly.
1.9. Typing of C. difficile
1.9.1. Phenotypic typing methods
Early phenotypic typing methods for C. difficile included the combined
bacteriophage and bacteriocin method used by Sell et al (1983), and the plasmid
analysis, soluble protein polyacrylamide gel electrophoresis (PAGE),
immunoelectrophoresis of extracellular antigens and antibiograms methods
compared by Wust et al (1982).
Since these early studies a number of phenotypic methods have been investigated.
Poxton et al (1984), investigated 28 C. difficile isolates from an outbreak of disease
in Sweden by an immunochemical method that involved PAGE analysis of
ethylendiaminetetraacetic acid (EDTA) extracted surface proteins and
immunoblotting. Tabaqchali et al (1984b), took a different approach and
•7 C
incorporated [ Sjmethionine into cellular proteins, separated them by sodium
dodecyl sulphate-PAGE (SDS-PAGE) and visualised the proteins by
autoradiography.
Delmee et al (1985), developed the familiar method of serotyping, which is still used
to assess and compare novel typing methods. An investigation of 315 C. difficile
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isolates from various origins formed the basis of the serological typing scheme. Of
the 315 isolates under investigation, 99% agglutinated with one of the 6 different
antisera raised against C. difficile in rabbits, and each serogroup was designated a
letter A, B, C, D F and G (Delmee et al 1985). A later comparison of serogrouping
and PAGE methods showed that each of ten designated serotypes was represented by
a different PAGE protein pattern and that within serotype A, 12 different protein
profiles were identified (Delmee, 1986a). Delmee et al (1990a), showed that cross
reactivity between the SDS-PAGE subtypes of serotype A was due to flagella and
that the cross-reactivity could be suppressed by the shearing off of flagella before
agglutination with the antiserum. Delmee et al (1990b), later demonstrated that the
serogroup specific detenninant was a strain specific surface antigen responsible for
agglutination. Heard et al (1986) and Sharp (1988), showed that surface proteins
were strain specific and reacted only with homologous antiserum.
Pyrolysis mass spectrometry (PMS) was used by Cartmill et al (1992) and Magee et
al (1993), to investigate several outbreaks of C. difficile infection. PMS is rapid, it
offers high through-put technique and excellent discrimination, however the
equipment required for PMS analysis is extremely expensive, the results are not
reproducible and cannot assign permanent designations. This method is only useful
for within-batch comparisons of isolates.
The preliminary findings from the international typing study on C. difficile showed
excellent correlation between serotyping, PAGE and immunoblot typing methods
which are based on cell surface proteins (Brazier et al, 1997a).
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1.9.2. Genotypic typing methods
In general, genotypic typing methods are considered to be more reproducible and to
offer better discrimination. Phenotypic characteristics can vary in growth conditions
and growth phase making them less reliable. For these reasons phenotypic methods
are often considered inferior to genotypic methods.
The first available genotypic typing methods for C. difficile were restriction enzyme
analysis (REA) and restriction fragment polymorphism (RFLP) both of which
analyse total cellular DNA. Kuijper et al (1987), used REA to analyse only six
isolates from patients with CDAD and their environment, and reported that the
method warranted further investigation. Devlin et al (1987), also used REA and
reported the method to offer stability, good discrimination and the REA grouping
agreed with cytotoxicity status. REA and RFLP have been replaced by pulsed-field
gel electrophoresis (PFGE) and more recently polymerase chain reaction (PCR)
based methods which are less labour intensive and easier to perform.
Kato et al (1994), used PFGE to investigate 91 unrelated isolates, and compared the
method to immunoblotting. PFGE was more discriminative than immunoblotting,
however problems associated with DNA degradation and untypeability were
reported. In a later study, Hyett et al (1997), used PFGE to type clinical isolates from
patients with diarrhoea. Fifty-six isolates produced 18 patterns, however 19 isolates
could not be typed. The untypeable isolates belonged to PCR ribotype 1 and suffered
from DNA degradation. PCR ribotype 1, is the type most frequently isolated from
patients in England and Wales (Brazier et al, 1997b), thus most UK isolates would
not be typeable by PFGE.
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PFGE is highly discriminatory, however the procedure is labour intensive,
technically demanding, and the major problem associated with the technique is that a
large number of C. difficile strains have been reported to be untypeable by PFGE.
This untypeability is due to difficulties with DNA degradation and this compromises
the overall value of the technique. Corkhill et al (2000), reported that the problems
with the DNA degradation of some strains could be alleviated by the addition of
thiourea in the electrophoresis buffer. It is thought that thiourea neutralises a
derivative of Tris which is formed at the anode during electrophoresis and causes the
degradation ofDNA, although Klaassen et al (2002), reported that even with this
modification the PFGE profiles were far from satisfactory.
McMillin and Muldrow (1992), reported that C. difficile could be typed by arbitrarily
primed PCR (AP-PCR). The method was used to investigate 41 C. difficile isolates.
This typing method identified nine groups, with 66% of all isolates falling into one
group. AP-PCR was compared to immunobotting and it offered more discrimination
Killgore et al (1994). Tang et al (1995), compared AP-PCR with immunoblotting and
REA, good correlation between all methods was reported. It was reported that AP-
PCR was a rapid and sensitive method that was useful for typing C. difficile.
Random amplified polymorphic DNA (RAPD) is a similar method to AP-PCR and
was used to type ten different serotypes, a further 11 outbreak related strains and 11
unrelated strains (Barbut et al, 1993). The method distinguished each of the
serotypes, and demonstrated different patterns from all the unrelated strains and
identified a predominant pattern within the related strains. Barbut et al (1994), used
RAPD to type 30 C. difficile isolates from 15 HIV positive patients in an infectious
disease unit. Twenty-five isolates produced the same pattern, and the other five
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produced five different patterns. AP-PCR was a rapid, effective, simple and
discriminatory method for typing C. difficile.
A novel PCR-ribotyping method was applied to C. difficile by Gurtler (1993). The
method involved the amplification of the spacer region between the 16S and 23S
ribosomal ribonucleic acid (rRNA) genes by PCR using specific primers. The region
is very heterogeneous, C. difficile possesses 10 copies of the rRNA genes and the
intergenic space is highly variable both between strains, and within the same
chromosome. O'Neill et al (1996), adapted and simplified the method described by
Gurtler (1993), and it is currently the method used by the ARU in Cardiff. PCR
ribotyping of 2030 isolates from a variety of sources has created a library of 116
distinct ribotypes (Stubbs et al, 1999).
Several studies have compared the genotypic methods described. Bidet et al (2000),
reported that PFGE offered the best discrimination, however PCR ribotyping was
superior to AP-PCR and PFGE, as it offered good levels of reproducibility, easy
interpretation and it was easy to perform. A similar comparison ofAP-PCR, PCR
ribotyping and PFGE stated that PCR ribotyping was the method of choice (Collier et
al, 1996), The major advantages of this method are rapidity, reproducibility and ease
of performance.
Recently, a toxinotyping scheme has been developed by Rupnik et al (1998). This
method is based on variations in the PaLoc which codes the toxin genes. The method
correlated well with both serotyping and PFGE, and more recently good correlation
was observed with PCR ribotyping (Rupnik et al, 2001).
The International Typing Study of C. difficile investigated a large number of isolates
of diverse origin from the UK, Belgium, USA and Australia. More types than
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previously thought were identified by many different typing methods and the study
emphasised the need for a common typing scheme and a common nomenclature
(Brazier et al, 1997a). The major problem with the typing of C. difficile is the lack of
inter-laboratory reproducibility due to variation which can occur when reagents and
equipment differ; variations in results can occur when different thermocyclers are
used, or the procedure is performed by different personnel within the same
laboratory.
1.10. Prevention and treatment of CDAD
1.10.1. Antibiotic and infection control policies
Good antibiotic and infection control policies that are regularly reviewed and
adhered to are of paramount importance in any hospital. The combination of these
policies is imperative to the control and prevention of hospital-acquired infections
including C. difficile infection.
Aspects of the antibiotic policy that have implications on C. difficile disease include
the avoidance of unnecessary antibiotic use, the reduction in use of antibiotics
commonly associated with C. difficile and the use of narrow spectrum antibiotics
whenever possible. Health care professionals should also be encouraged to
communicate with microbiologists to ensure the use of the most appropriate
antibiotic (Worsley, 1998).
Changes in antibiotic policies can significantly affect the number of cases of C.
difficile disease. Impallomeoni et al (1995), reported an increase in the number of
cases of C. difficile in geriatric wards following the recommendations by the British
Thoracic Society to use cefotaxime for the treatment of community-acquired
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pneumonia (British Thoracic Society, 1993). As a result the British Thoracic Society
published new guidelines in 2001. A study by Ludlam et al (1999), reported a
decrease in the number of cases of CDAD in a geriatric unit following the
implementation of a policy restricting the use of intravenous third generation
cephalosporins. A similar study also showed the reduction in cases ofCDAD
following the restrictive use of cefuroxime, and reported no increase in the morbidity
and mortality of patients following the changes in the antibiotic policy (McNulty et
al, 1997). Cartmill et al (1994), saw a reduction in cases ofCDAD when they
restricted the use of all antibiotics and encouraged the use of 4-quinolones instead of
broad spectrum (3-lactams and the use ofnarrow spectrum antibiotics.
At the forefront of an effective infection control policy is hand washing. Compliance
with hand washing and hand disinfecting policies is generally thought to be low, and
therefore hand contamination with pathogenic organisms is thought to be important
in the transmission of infection. A study that monitored compliance with hand
washing in Switzerland during a programme of hand hygiene promotion showed
compliance with hand washing recommendations to rise from 48% to 66%. The
improvements were due to increased compliance by nursing staff, but not by doctors.
During this period nosocomial infections dropped from 16.9% to 9.9% (Pittet et al,
2000). In another study that surveyed the incidence of C. difficile six months before
and six months after an education programme promoting the use of gloves when
handling all body substances, the rate of C. difficile dropped from 7.7 in 1000
patients to 1.5 in 1000 patients. This indirectly provides evidence for transmission of
C. difficile by hand colonisation (Johnson et al, 1990a). Mathematical modelling of
Staphylococcus aureus transmission showed that relatively small increments in hand
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washing compliance can be significant in controlling infections (Cooper et al, 1999).
As well as fulfilling the need for compliance with hand washing there is a need for
improvements in the efficacy of soaps and hand washes used in hospitals (Worsley,
1998).
Contamination of the hospital environment with C. difficile spores is well
documented (and was discussed in section 1.3). C. difficile spores survive well in the
environment and as there are few effective sporicidal agents available it is difficult
to remove C. difficile from environmental surfaces, and it is plausible that cleaning
may facilitate the movement of spores around the hospital ward. Often equipment
such as commodes and lifting equipment are not subject to regular cleaning and may
be a source of transmission of C. difficile (Worsely, 1998). The Department of
Health guidelines state that commodes and hoists should be cleaned immediately
after each use and that disposable equipment and instruments should be used where
possible (Pratt et al, 2001). The need for regular cleaning of all hospital equipment
after every use cannot be over-emphasised.
Wilcox and Fawley (2000), have shown sub-inhibitory concentrations of a number of
commonly used hospital disinfectants and detergents to enhance sporulation. The
effects of cleaning on the removal of C. difficile are unclear due to lack of efficient
sporicides. However, regular cleaning of all areas and deep cleansing procedures in
areas subjected to contamination should be encouraged. It is of great importance that
all healthcare personnel are well informed about the epidemiology and modes of
transmission of C. difficile. Awareness of the high rates of asymptomatic
colonisation with C. difficile particularly in elderly patients and other high risk
groups needs to be increased. Precautionary measures should be taken with all
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patients and not only those with symptomatic infections. When cases of infection do
develop, further spread can be prevented by isolating symptomatic patients and
implementing enteric precautions including gloves, aprons and the immediate
disinfecting of equipment and soiled surfaces or linen (Worsley, 1998).
It is unclear which of the many infection control strategies can help to reduce the
incidence ofC. difficile, therefore it is important that all aspects of infection control
policies are implemented to prevent and control infection with C. difficile. Cartmill et
al (1994), showed that strict infection control including staff education, increased
vigilance, strict enteric precautions, cohort nursing, deep cleaning and restricted staff
and patient movement together with a restriction on antibiotic use led to a significant
decrease in the number of cases of C. difficile. Until the risk factors for C.. difficile
infection are well defined and effective control strategies are developed, education
programmes, infection control and antibiotic policies should be developed, reviewed
and complied with stringently.
1.10.2. Treatment of C. difficile infection
Since the emergence ofCDAD, treatment of the condition with vancomycin or
metronidazole has become well established and has remained relatively unchanged
(Gerding et al, 1995). In a large number (23%) of cases ofCDAD, discontinuation of
the inciting antibiotic can resolve symptoms within several days and further
intervention is not required (Teasely et al, 1983).
Current treatment strategies for C. difficile largely depends on the removal of the
inciting antibiotic and where required the administration of a course of vancomycin
or metronidazole. Vancomycin use is currently discouraged due to recent problems
with vancomycin resistant enterococci in hospitals. Vancomycin is also considerably
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more expensive than metronidazole and both offer equivalent efficacy in the removal
of C. difficile (Department of Health/PHLS joint working group report, 1995).
Guidelines for the treatment of CDAD recommend discontinuation of antibiotics
with supportive therapy including fluids and electrolytes. Metronidazole should be
prescribed upon microbiological confirmation of C. difficile if necessary.
Vancomycin should be used only ifmetronidazole is ineffective, the patient is
intolerant to metronidazole or critically ill (Fekety et al, 1997).
The major problem associated with CDAD is the high relapse and re-infection rate
following treatment (Gerding et al, 1995). Relapse rates of 5-23% have been
reported (Wilcox and Spencer, 1992). The only recognised treatment available is the
further use of antibiotics (metronidazole and vancomycin), and this may perpetuate
the condition by further diminishing the gut flora.
As the diarrhoea resolves the faecal levels of vancomycin and metronidazole fall,
this could permit the germination of surviving spores and survival of vegetative cells
leading to the proliferation of the organism and a subsequent relapse (Gerding et al,
1995). It has also been shown in vitro that the high faecal concentrations of
metronidazole and vancomycin achieved during therapy have a bacteriostatic effect
rather than a bacteriocidal effect on C. difficile, thus C. difficile may remain viable
even after the completion of treatment (Levett, 1991).
Treatment regimes for recurrent problems include supportive therapy combined with
re-treatment with prolonged and tapering courses of vancomycin or metronidazole.
Recently biotherapeutic approaches to treatment of recurrent CDAD have been
investigated in an attempt to reconstitute the "colonisation resistance" in the gut.
Therapies have included the administration ofSaccharomyces boulardii,
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Lactobacillus spp. and "faecal transplants". Trials of such treatments have been small
and have in most cases been used in combination with vancomycin and
metronidazole.
A number of investigations have sought to determine the merits of treatment with
Saccharomyces boulardii. S. boulardii has been shown to offer hamsters protection
from cecitis if administered before treatment with clindamycin (Toothacher et al,
1984). Elmer et al (1987), showed that the administration of S. boulardii to hamsters,
following exposure to clindamycin and treatment with vancomycin resulted in a
lower count of C. difficile, lower toxin B titres and fewer animals tested positive in
agglutination assays. The study suggested that S. boulardii may maintain
colonisation resistance, could be antagonistic to C. difficile, and may be a useful
treatment to prevent the relapses commonly associated with vancomycin therapy. A
number of combined therapies including vancomycin and S. boulardii have been
investigated. MacFarland et al (1994), reported a significantly lower risk of recurring
CDAD following combination treatment with vancomycin or metronidazole with S.
boulardii. Surawicz et al (2000), investigated patients with a history of recurrent
CDAD, and determined that a high dose vancomycin therapy combined with S.
boulardii decreased the frequency of recurring CDAD, when compared to high dose
vancomycin therapy only.
However, there are concerns regarding the efficacy of treatment with 5. boulardii.
Lewis et al (1998), reported that S. boulardii did not prevent AAD in a study of
elderly patients receiving antibiotics and highlighted the need for such therapies to be
evaluated properly. The safety of S. boulardii in immunocompromised and
debilitated patients has also raised concerns as it can result in invasive fungal
infection (Bassetti et al, 1998).
Other more radical treatments have included "faecal transplants" from healthy
individuals, usually a close relative. Bowden et al (1981), treated 16 patients with
PMC using faecal enemas to restore faecal flora and reported no ill effects and good
convalescence. This approach offered good rates of success, however, there are
concerns regarding the safety of such procedures. Tvede and Rask-Madsen (1989),
treated six patients with a synthetic faecal enema following treatment with
vancomycin, the enema consisted of a mixture of ten facultative aerobes and
anaerobes and led to a rapid loss of C. difficile and patient recovery. Such findings
warrant further research for treatment of patients with chronic recurrent infection.
These treatments show varied success rates but have practical limitations and safety
concerns. The success of novel treatments may depend on the individual, as factors
such as the immune status of the patient are likely to be important when using
biotherapeutic treatments. A novel soluble anionic polymer for the treatment of C.
difficile is currently under development and a published study shows promising
results. The polymer neutralises the effects of toxins and it has been used
successfully in hamster experiments and has produced no ill effects in healthy human
volunteers (Kurtz et al, 2001).
Successful treatment of C. difficile remains a challenge, due to the high rate of
recurrences associated with current therapies and the difficulties associated with the
treatment of complications such as perforations, toxic megacolon and ileus.
Improved treatments that neutralise toxins, promote the re-establishment of
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colonisation resistance and do not rely on traditional antimicrobial action are
required.
THE AIMS OF THIS THESIS
1. To determine the level of asymptomatic and symptomatic colonisation with C.
difficile in wards 5 and 6 of The Royal Victoria Hospital (RVH), Edinburgh.
2. To determine the level of isolation of C. difficile from the environment of the
geriatric patients in wards 5 and 6, RVH, and to determine if there was any
association with the level of patient colonisation.
3. To determine the significance of risk factors relating to age, gender, underlying
disease, medication and medical procedures in patients colonised with C.
difficile, with and without detectable levels of toxin in the faeces.
4. To determine the variation in the molecular masses, antigenic nature and
immuno-reactivity of the S-layer proteins from C. difficile.
5. To assess a novel typing method based on the variation of the molecular masses
of the SLPs from C. difficile, to compare it with PCR ribotyping and to determine
which S-types and PCR ribotypes colonised patients in wards 5 and 6, RVH.
6. To relate the development of symptoms and the severity of symptoms to the S-




2.1. Collection of patient information and clinical specimens
2.1.1. Subjects
Faecal specimens and patient information were collected from admissions to wards 5
and 6 of the Royal Victoria Hospital (RVH) in Edinburgh during the period July
1999 and December 2000, with the exception of the period 29/04/00 to 17/06/00 due
to the illness of the research nurse. The research nurse designated to this research
project obtained informed consent from all patients and with the help of the nursing
staff collected all faecal and environmental samples.
2.1.2. Patient information
The research nurse collected information from patients relating to the following:
1. Patient hospital number
2. Patient age
3. Patient gender
4. The origin of the patient (from the community, a nursing home or another
hospital/ward)
5. Ward and location within ward 5 or 6.
6. Diagnoses including colonic disease, leukaemia, neoplasia and episodes of
diarrhoea.
7. The use ofmedications including antibiotic therapy, antacids, laxatives, steroids




The aim of the study was to collect at least one faecal specimen from as many
patients as possible who were admitted to wards 5 and 6, RVH at some point during
their hospital stay. Specimens were collected and investigated for the presence of C.
difficile irrespective of whether the patient was suffering from symptoms associated
with C. difficile disease. Fresh faecal specimens were collected and transported to the
laboratory as quickly as possible.
2.1.4. Environmental samples
During the period of the study, the environment of patients in wards 5 & 6, RVH was
sampled using contact plates and swabs, details of which are given in section 2.3.1.
These samples were investigated for the presence of C. difficile.
2.2. Isolation and identification of C. difficile from faecal specimens
2.2.1. Isolation of C. difficile from faecal specimens
A standard loopful (ca. 0.2g, or 6-10 x 20pl loopfuls of liquid specimen, depending
on the consistency) of faecal material was plated directly to pre-reduced CCEY agar
-details given in appendix 1, (Brazier, 1993). The pre-poured agar was supplied by
Oxoid, Basingstoke, Hampshire and the cultures were incubated under anaerobic
conditions at 37°C for 24-48 h. The CCEY agar plates were examined for growth
after 24-48 h as required. A preliminary identification of C. difficile was made by
characteristic smell, colonial morphology and chartreuse fluorescence under ultra¬
violet light (X=365 nm). Several suspect colonies were sub-cultured to Columbia
blood agar (Oxoid). The sub-cultures were incubated under anaerobic conditions at
37°C for 24-48 h as required.
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2.2.2. Identification and storage of C. difficile clinical isolates
The suspect C. difficile sub-cultures were examined by wet and Gram's film, colony
morphology, chartreuse fluorescence (A,=365nm) and characteristic smell. Confirmed
isolates were inoculated to 4 ml cooked meat broth (CMB) medium (details are given
in appendix 1) and incubated under anaerobic conditions at 37°C conditions for 48 h.
The CMB cultures were checked for purity by wet and Gram's film and stored at
room temperature. A list of all clinical isolates is given in appendix 2.
(Several atypical isolates were confirmed as C. difficile by gas liquid
chromatography, this work was carried out by Mr R. Brown.)
2.2.3. Detection of toxins A and/or B directly in faecal specimens using
a commercial ELISA kit for the detection of C. difficile toxin(s)
Batches of faecal samples were tested retrospectively after storage at -20°C using the
Techlab1M C. difficile Tox A/B test kit, an ELISA for the detection of C. difficile
Toxins A and B. In accordance with the manufacturers instructions, the faecal
specimen was emulsified with 200pl of the supplied diluent and lOOpl of the diluted
faecal specimen was added to the supplied assay wells and the manufacturer's
instructions were followed. The principle of the test kit is given in section 2.2.4 on
the following page.
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2.2.4. The Techlab™ C. difficile toxin A/B test kit
Microtitre wells coated in purified polyclonal goat antibody against toxins
A and B
IConjugate = Detecting antibody:


















Incubation with sample and conjugate for 20 min




The colour was read in an Anthos 2001 plate reader at 450/620nm
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2.3. Isolation and identification of C. difficile from the environment of
wards 5 and 6, RVH, Edinburgh
2.3.1. Environmental sampling using contact plates
Environmental surfaces were sampled using 55 mm contact plates (Bibby Sterilin
Ltd, Stone, Staffordshire) with pre-reduced CCEY agar (Brazier, 1993). The contact
plates were placed on an inanimate surface and the agar was allowed to make contact
with the surface for 5 seconds. After sampling the plates were stored in an anaerobic
gas jar with an anaerobic gas generating system (Oxoid) for transport to the
laboratory. The contact plates were transferred to the anaerobic cabinet and
incubated at 37°C for up to 5 days. The plates were examined after 2 and 5 days as
required. Suspect C. difficile colonies were sub-cultured to blood agar, identified and
stored as described in section 2.2.2.
2.3.2. Environmental sampling using swabs
Environmental surfaces were also sampled using sterile plain cotton wool swabs
(Greiner Labortechnik Ltd, Germany). The swabs were moistened in sterile distilled
water before the area was sampled. The swabs were transported to the laboratory
where they were inoculated to 4 ml fastidious anaerobe broth (Lab M, Bury,
England) supplemented with cholic acid sodium salt (Sigma Chemicals, USA) and
Modified C. difficile Selective Supplement (Oxoid) [further details are given in
appendix 1], The broth cultures were incubated at 37°C for 5 days under anaerobic
conditions and examined for turbidity after 2 and 5 days as required. Turbid broth
cultures were sub-cultured to CCEY agar for 24-48h, suspect C. difficile colonies
were sub-cultured to blood agar, identified and stored as described in section 2.2.2.
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2.4. Detection of toxin(s) from C. difficile isolates.
2.4.1. Growth of C. difficile isolates for the production of toxins
Isolates of C. difficile were inoculated from stored CMB cultures to 4 ml brain heart
infusion/proteose peptone medium (Brettle et al, 1982) [details are given in appendix
1] for the detection of toxin, the cultures were incubated at 37°C under anaerobic
conditions for 5 days.
2.4.2. Determination of the toxin-producing potential of C. difficile
isolates from patients in wards 5 and 6, RVH
The Techlab™ C. difficile toxin A/B test kit, an ELISA for the detection of C.
difficile Toxins A and B was used to detect toxin from pure C. difficile cultures. The
5-day cultures were centrifuged at 1500g for 15 min to remove bacteria. The culture
supernatants were collected and tested for the presence of C. difficile toxin(s). The
supernatant was diluted 1 in 5 in the supplied toxin assay diluent. Toxins A and/or B
were detected by adding lOOpl of the diluted supernate to the assay wells and the kit
was used in accordance with the manufacturer's instructions.
2.5. Extraction of the SLPs from C. difficile
2.5.1. Growth of C. difficile cultures for extraction of SLPs
Cultures of C. difficile were grown in proteose peptone yeast extract (PPY) medium
(Holbrook et al, 1977) pH 7.1, supplemented with sodium carbonate 0.04% w/v and
cysteine hydrochloride 0.075% w/v (Poxton and Cartmill, 1982) [details are given in
appendix 1], The cultures were incubated overnight under anaerobic conditions at
37°C.
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2.5.2. Treatment of C. difficile whole cells with guanidine hydrochloride
Bacteria were harvested from overnight cultures and washed twice in 4 ml phosphate
buffered saline (PBS), pH 7.3 (Oxoid BR14-Dulbecco A tablets), by centrifugation at
1500g for 20 min. The harvested cells were re-suspended in 0.3 ml of 5M-guanidine
hydrochloride and shaken for 2 h at room temperature. The bacteria were removed
from the protein extract by centrifugation twice for 2 min at 16,000g. Previous work
in the laboratory had determined these to be the optimal conditions for the extraction
of the SLPs.
2.5.3. Dialysis of protein extracts for the removal of guanidine
hydrochloride
Guanidine hydrochloride was removed from the S-layer protein extracts by dialysis
against 6.25 mM Tris/HCl buffer, pH 6.8 using a Spectra/Por® Microdialyzer
(Spectrum®, USA) with a membrane of 10,000 molecular weight cut off. The
dialysed extracts were stored at -20°C.
2.6. Visualisation of the C. difficile S-layer proteins (SLPs)
2.6.1. SDS-PAGE
The surface protein extracts (ca.l mgmf1) were mixed with an equal amount of
double strength SDS-PAGE buffer and heated in a 100°C boiling bath for 3 min.
Protein extracts were run on 10% slab gels using the buffer system of Laemmli
(1970), as described by Hancock and Poxton (1988). Details of all SDS-PAGE
buffers are given in appendix 1.
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2.6.2 Coomassie Blue Staining
The proteins separated on SDS-PAGE gels were stained with Coommasie blue stain
R250 (Fisher Scientific, UK) as described by Hancock and Poxton, 1988, (details are
given in appendix 1).
2.7 Analysis of the SLPs
2.7.1. Calculation of the molecular masses of the SLPs
The molecular masses of the SLPs from the C. difficile strains listed in appendix 2
and section 2.11.1, were calculated using Phoretix1M gel analysis 1 -D software.
Mark 12™ molecular weight standards (Invitrogen, USA) were used as calibrations
for the calculation of molecular masses. Each isolate was designated a four-digit
number based on the molecular mass in kDa of the two SLPs.
2.7.2 Immunoblotting
The Tris-glycine transfer method as described by Towbin el al (1979), was followed,
(details of all immunoblotting buffers are given in appendix 1). The guanidine
hydrochloride extracts, which were separated on SDS-PAGE, were transferred to a
nitro-cellulose membrane (0.2p,m pore size, Schleicher & Schuell, Germany) in Tris
(0.025M), glycine (0.192M), methanol (20% v:v) buffer, pH 8.3 at 5 V and 40 mA
for 18hat4°C.
The following procedure was carried out with gentle agitation. After washing the
nitro-cellulose in Tris buffered saline (TBS: 0.02M Tris, 0.5M sodium chloride, pH
7.5) for 10 min the unbound sites on the membrane were blocked with 10 ml of 3%
(w/v) gelatin in TBS for 45 min. The nitro-cellulose membrane was incubated with
C. difficile rabbit antiserum diluted 1 in 200 in 1% (w/v) gelatin in TBS. This was
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incubated at room temperature for 3 h. After washing twice for 10 min in Tween
TBS (0.02M Tris, 0.5M sodium chloride, 0.025% Tween 20, pH 7.5) the membrane
was incubated in anti-rabbit IgG-horseradish peroxidase (HRP) diluted 1 in 2000 at
room temperature for 1 h. After two further washes in Tween TBS as above, the
nitro-cellulose membrane was washed three times in distilled water. The nitro¬
cellulose was placed into HRP developer (details given in appendix 1) and the colour
developed within 5-30 min. The development was stopped by several washes in
distilled water.
2.7.3. Rabbit antiserum
Rabbit anti-sera from laboratory stocks were used. Antiserum to the following four
strains of C. difficile were used in the study:
mprl 683 (antiserum 117)
mprl 1128 (antiserum 119)
mprl 604 (antiserum 123)
mprl 2520 [NCTC 11223] (antiserum 642).
Antisera were raised against ultra-violet killed bacteria as described by Poxton
(1979). New Zealand White rabbits were injected intravenously over a five week
period.
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2.8. C. difficile S-typing based on the molecular masses of SLPs
The C. difficile clinical isolates collected from patients in wards 5 and 6, RVH were
typed on the basis of the molecular masses of their two S-layer proteins. The S-layer
proteins were extracted as described in section 2.5.1 and 2.5.2. The protein extracts
were run on SDS-PAGE and Coomassie stained as described in section 2.6.2.
2.8.1. Designation of an "S-type" number to clinical isolates
The molecular masses of the SLPs were calculated as described above in section
2.7.1. Each isolate was designated a strain number (S-type) based on the four digit
number assigned to each isolate.
2. 9. PCR Ribotyping of C. difficile
(Adapted from the method described by O'Neill et al 1996.)
2.9.1. Extraction of C. difficile DNA
C. difficile were sub-cultured on to fastidious anaerobe agar (Lab M, Bury, UK)
supplemented with 6% horse blood (Oxoid) and incubated at 37°C in anaerobic
conditions, overnight. Ten colonies of C. difficile were emulsified in lOOpl of a 5%
solution of Chelex® 100 Resin, biotechnology grade 100-2000 mesh sodium form
(Biorad Laboratories, USA) and incubated in a boiling bath for 10 min. After
incubation the cell debris was removed by micro-centrifugation for 2 min at 16,000g.
The supernatant was retained and used as the DNA template for the PCR reaction.
2.9.2. Primers
The primers used were identical to those described by O'Neill et al (1996). The
oligonucleotide primers were designed to be complementary to the 3' end (bases
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1445-1446) of the 16S rRNA gene of C. difficile -CTGGGGTGAAGTAACAAGG
and the 5' end (bases 1-20) of the 23S rRNA gene of C. botulinum -
GCGCCCTTTGTAGCTTGACC.
2.9.3. PCR amplification mix
Amplifications were performed in 100pi reactions, containing:
10 pi template C. difficile DNA
1.5 units Taq DNA polymerase (Roche, Diagnostics, Mannheim, Germany).
10 pi PCR reaction buffer (WOmM Tris-HCl, 15mM MgCl2, 500mM KC1; pH 8.3),
supplied with Taq DNA polymerase.
8 pi of a 1.25 mM solution of each deoxyribo-nucleic-triphosphate (Amersham
Pharmacia Biotech inc. New Jersey, USA)
1 pi of a 50 pM solution of each primer (MWG, Germany)
The amplification program was as follows:
1 cycle: 95°C for 2 min
35 cycles: 92°C for 1.5 min
55°C for 1 min
72°C for 1 min
1 cycle: 72°C for 5 min.
A negative control including all reaction reagents, but excluding the DNA template
was prepared for each set of reactions.
2.9.4. Concentration of PCR products
After PCR amplification the products were concentrated by evaporation on a heating
block at 70°C for 90 min, or until concentrated to ca. 20pl.
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2.9.5. Visualisation of the PCR Products
The concentrated PCR products were electrophoresed in 3% high resolution agarose
gel (Sigma) containing 1.5% ethidium bromide at 80 volts for 2.5 h in a Scie-plas
mini gel tank.
2.10. Media and Buffers
Details of all media and buffers are given in appendix 1.
2.11. Bacterial strains
C. difficile strains from the laboratory culture collection
The strains with designated serotypes and ribotypes, mprl 4196-mprl 4219 were
kindly donated by Dr Jon Brazier, ARU, Cardiff, Wales. The other laboratory strains
used in the S-layer protein analysis are given below,
mprl 2520 NCTC 11223
mprl 604
Clinical isolates from patients with antibiotic
mprl 683 associated diarrhoea.
mprl 1128 A poorly virulent C. difficile clinical isolate from
an infected patient-donated to the laboratory
culture collection by Prof. P Borriello
Details of MPRL 4196-4219 and a list of all clinical isolates collected during the
study of patients in RVH is given in appendix 2.
2.12. Statistical analysis of data
All statistical analyses (Chi-squared tests, Mann Whitney U tests and the logistic
regression modelling) were carried out using SPSS software.
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CHAPTER THREE
Microbiological analysis of patients and the environment of a geriatric
unit in The Royal Victoria Hospital, Edinburgh.
AIMS
1. To determine the level of colonisation and symptomatic infection of patients
with Clostridium difficile in wards 5 and 6 of The Royal Victoria Hospital
(RVH), Edinburgh.
2. To determine the level of isolation of C. difficile from the environment of
wards 5 and 6, RVH, Edinburgh.
3. To determine an association between the level of patient colonisation and the
level of isolation of C. difficile in the environment of wards 5 and 6 RVH,
Edinburgh.
RESULTS
3.1. Detection of C. difficile from patients in RVH
3.1.1. The study plan
Eight hundred and sixty five patients were admitted to the geriatric unit, RVH over
the 17-month period (12/07/1999 to 11/12/2000). The geriatric unit consists of two
wards (wards 5 and 6) with 60 beds. The unit cares for elderly patients who are
debilitated and are often recovering from an illness. Many admissions are patients
who have had previous care in acute care wards in other hospitals. During the study
period, 500 patients aged 60 to 101 years of age were admitted to ward 5, and 365
patients aged between 56 and 100 years of age were admitted to ward 6.
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The patient "mix" in ward 5 and ward 6 were different as six beds in ward 5 were
used for 'respite' patients who were admitted from the community for short time
periods. It was usual that these patients had no acute illness but required 24 hour
nursing care.
The aim of the study was to investigate at least one faecal specimen from as many of
the patients as possible who were admitted to the geriatric unit between 12/07/1999
and 11/12/2000. Over this 17-month study period a total of 1003 faecal specimens
were collected from 390 (45%) of the patients admitted to the unit. Specimens from
43% (213) of patients admitted to ward 5 and 48% (177) of patients admitted to ward
6 were investigated for the presence of C. difficile. The specimens were investigated
by culture on CCEY agar and by the Techlab™ ELISA test kit for the detection of C.
difficile toxins A and/or B.
(NB. Unfortunately, due to the ill health of the research nurse no specimens were
collected between 29/04/00 to 17/06/00).
3.1.2. Detection of C. difficile by culture on cycloserine-cefoxitin egg-
yolk (CCEY) agar
C. difficile was isolated directly from faecal specimens using CCEY selective agar.
Of the 1003 specimens from 390 patients investigated, C. difficile was isolated from
206 specimens, from 100 (26%) patients.
3.1.3. Detection of C. difficile by Techlab™ ELISA test kit for the
detection of C. difficile toxins A and/or B
C. difficile toxin(s) A and/or B were detected directly from batches of faecal
specimens which had been stored at -20°C, using the Techlab™ ELISA test kit for
the detection of C. difficile toxins A and/or B. Of the 1003 specimens tested, C.
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difficile toxin(s) were detected in 124 specimens, which represented 52 (13%)
patients. Of these 52 patients, 18 patients tested positive for toxin(s) only and C.
difficile was cultured from the remaining 34 patients. The results of the culture and
toxin tests are summarised in table 3.1. The results in table 3.1 show the number of
patients who were assigned to the following three categories based on the results of
the culture and toxin tests for C. difficile.
1. Detection by culture test only.
2. Detection by culture and toxin test.
3. Detection by toxin test only.
Table 3.1. The culture/toxin status of patients investigated for C. difficile
by culture and toxin detection methods.
NUMBER (%) OF PATIENTS WITH A POSITIVE RESULT
POSITIVE RESULT IN
DETECTION TEST WARD 5 WARD 6 TOTAL
n;=213 n= 177 n=390
Culture only 36 (17) 30 (17) 66 (17)
Culture and toxin 12 (6) 22 (12) 34* (9)
Toxin only 10 (4.5) 8 (4.5) 18 (5)
Total 58 (27) 60 (34) 118 (30)
*Culture and toxin may not have been detected in the same specimen.
The results in table 3.1. show that C. difficile was detected in a total of 118 (30%) of
the 390 patients investigated for the presence of C. difficile during the study period.
Of the patients tested 17% were positive by culture only, 9% were positive by both
culture and toxin tests and toxin only was detected in 5% of patients.
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When the results for wards 5 and 6 were compared, the overall level of detection of
C. difficile by culture and/or toxin from patients in wards 5 and 6 was 27% and 34%
respectively. The level of detection of C. difficile was not a significantly different
between the two wards (Chi2 test, p=0.14). Seventeen percent of patients from both
wards tested positive for C. difficile by culture only. However, 12% of patients from
ward 6 were culture and toxin positive compared to only 6% of the patients in ward
5.
3.1.4. Incidence of diarrhoea in C. difficile positive patients from ward 5
and 6, RVH
The results of the culture and toxin tests from patients with diarrhoea are summarised
in table 3.2. Of the patients from whom C. difficile was detected, 49% had diarrhoea;
40% of patients from ward 5 and 58% from ward 6. Those from whom both culture
and toxin was detected had the highest levels of diarrhoea, 79% of patients in this
category had symptoms compared to less than a third of those patients who tested
culture-positive only.
Patients with CDAD are defined as symptomatic patients from whom both C.
difficile and its associated toxin(s) can be detected. From this definition 4% (8/213)
of patients from ward 5 and 11% (19/177) from ward 6 were determined as suffering
from CDAD. However, up to a further 7% (15 patients) from ward 5 and 9% (15
patients) from ward 6 may have been suffering from C. difficile related symptoms, as
they harboured the organism and had diarrhoea.
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Table 3.2 The number of symptomatic patients in each culture/toxin
category.
NUMBER (%) OF SYMPTOMATIC PATIENTS IN
POSITIVE RESULT


















Total 23/58 (40) 35/60 (57) 58/118 (49)
3.2. Detection of C. difficile in the local environment of patients in wards
5 and 6, RVH
The environment of wards 5 and 6, RVH was investigated for the presence of C.
difficile over the duration of the 17-month study period. Environmental sampling was
performed on at least monthly intervals, on 24 occasions and approximately 30 areas
in each ward were sampled on each occasion. A total of 1348 environmental samples
were taken during the study.
Large flat surfaces such floors, sinks and shower trays were investigated using
contact plates with CCEY agar. The contact plates were stored in anaerobic
conditions prior to sampling and after sampling the plates were returned to the
laboratory in an anaerobic environment for incubation. Small areas such as tap
handles and door handles were sampled using swabs moistened with sterile distilled
water. The swabs were returned to the laboratory and then inoculated to an anaerobic
enrichment medium for incubation.
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3.2.1. Isolation of C. difficile from the environment of wards 5 and 6,
RVH
Various inanimate objects from rooms within wards 5 and 6 were sampled for the
presence ofC. difficile. Surfaces and objects in the main patient bays, toilet areas,
bathrooms, shower-rooms, sluice rooms, side-rooms and kitchens were all sampled.
A total of672 samples were taken from ward 5, 331 areas were sampled with contact
plates and 341 with swabs. From ward 6, a total of 676 samples were taken, 344
areas were sampled with contact plates and 332 with swabs. C. difficile was isolated
from 23% of samples taken by contact plates and 4% of samples using swabs. Details
of objects, areas sampled, the method of sampling and the result are given in
appendix 3.
Each ward consists of four main bays with six beds in each, and each ward had five
side-rooms. Each bay had its own designated toilet area and the bathroom and
shower-room facilities were shared between bays. Each of the side-rooms had its
own designated toilet and bathroom facilities. In addition, each ward had a sluice-
room and kitchen.
The number of samples taken and the number of areas that tested positive from each
room in wards 5 and 6 is summarised in table 3.3. In ward 5, C. difficile was most
frequently isolated from the sluice room, followed by the toilet areas associated with
side-rooms. In ward 6, the most frequent isolations were from toilet areas associated
with side-rooms and the side-rooms themselves. The main toilet areas and sluice
room in ward 6 also had relatively high isolation levels, 17% and 15% of areas
respectively. The data in table 3.3. show an overall level of isolation of C. difficile
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from the environment of ward 5 at 7% and 20% from ward 6. Correspondingly, all
rooms ofward 6 showed higher levels of isolation of C. difficile than the equivalent
rooms in ward 5. Consistent with the overall results for wards 5 and 6, the level of
isolation ofC. difficile in the side-rooms of ward 6 was much higher than those
isolation levels from the side-rooms ofward 5.
Of the areas sampled C. difficile was most frequently isolated from floors; 29% of all
floors from which samples were taken throughout wards 5 and 6 yielded a positive
culture of C. difficile, including one positive sample from the kitchen floor ofward 6.
Of the floors sampled, the toilet floors and the sluice room floor yielded the highest
isolation levels, with 40% of samples taken from toilet floors and 60% of samples
from sluice room floors yielding a positive result. Other areas with relatively high
isolation levels included toilet seats (17%), commodes (11%), toilet handles (8%),
and three and of the five toilet cisterns tested from ward 6 gave culture positive
results for C. difficile.
Numerous other objects were sampled and gave positive results, amongst these, the
paper-towel dispenser from the ward 6 kitchen, side-room 8 in ward 6 and bay 3 in
ward 6 all tested positive for C. difficile. Two of six windowsills in ward 6 produced
culture positive results, as did 25% of the shelves and cupboard tops from the sluice
rooms and bathrooms of ward 6.
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Table 3.3. The number of samples taken and the number of samples
positive for the culture of C. difficile from each room in wards 5 and 6.
NUMBER (%) OF SAMPLES IN
WARD 5 WARD 6
NUMBER (%) OF NUMBER (%) OF AREAS





Main patient room 160 9 (6%) 138 12 (9%)
Main toilet areas 235 16 (7%) 174 30 (17%)
Bathrooms 78 3 (4%) 64 6 (9%)
Shower-rooms 41 3 (7%) 40 3 (7.5%)
Sluice rooms 60 8 (13%) 71 11 (15%)
Side-rooms: main area 53 4 (7.5%) 80 32 (40%)
Side-rooms: toilet area 43 4 (9%) 98 41 (42%)
Kitchen 2 0 11 2 (18%)
Total 672 48 (7.1%) 676 137(20%)
3.2.2. Association between environmental contamination and patient
colonisation levels
There was considerable variation in the level of isolation of C. difficile from the
environment of the different bays within the same ward. In ward 5, the level of
isolation ofC. difficile varied between 3% and 12% of the total environmental
samples taken for each of the four main patient bays. The percentage of colonised
patients in each of the four bays ofward 5 varied between 9% and 10%, and the
percentage of colonised symptomatic patients varied between 1% and 5% over the
duration of the project. In ward 6, the levels of isolation of C. difficile in each of the
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four main patient bays varied between 0% and 16% of the total environmental
samples taken. The percentage of colonised patients in the four bays ofward 6 varied
between 11% and 15%, and the percentage of colonised symptomatic patients varied
between 7% and 12% over the duration of the project. The percentage of colonised
patients and colonised symptomatic patients in ward 6 bays is higher than in ward 5.
This is consistent with a higher level of isolation of C. difficile from the environment
of ward 6. There is however no correlation between the number colonised patients
and the level of isolation of C. difficile from environment within the individual bays
of either ward 5 or 6. It is also difficult to make any solid deductions as a significant
number of patients and areas of the enviromnent were not sampled.
Figures 3.1 and 3.2 below show the level of colonisation of patients and the
percentage of environmental samples from which C. difficile was isolated from ward
5 and 6 over the duration of the study. The levels of patient colonisation are
calculated as the percentage of positive specimens investigated during that month,
and as the data show there is considerable fluctuation in the colonisation level from
month to month. The levels of environmental contamination are calculated as the
percentage of positive environmental samples investigated during that month.
Data from ward 5 shown in figure 3.1 does not indicate much correlation between the
levels of isolation of C. difficile from environmental samples and the level of patient
colonisation in ward 5. However, a high environmental level in November 1999 is
followed by a high percentage of colonised patients in December 1999. The data
from ward 6 shown in figure 3.2 are more suggestive of an association between the
level of environmental contamination and patient colonisation. Between October
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1999 and January 2000 there is evidence of a similar general trend in patient
colonisation and environmental contamination.
Figure 3.1. The percentage of colonised patients and the percentage of
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Figure 3.2. The percentage of colonised patients and the percentage of
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Data from several side-rooms from both wards 5 and 6 were examined. The
results in figures 3.3-3.4 show the percentage of C. difficile positive environmental
samples against the date on which the samples were taken.
Data from side-room 8 in ward 5 revealed that C. difficile was not isolated from this
ward between 7/10/99 and 26/10/99 and that the patients resident in the side-room
during this time were not colonised (data not shown). C. difficile was isolated from
60% of sites tested on 20/03/00 when a colonised patient occupied the side-room
(data not shown). Subsequent environmental samples were negative for C. difficile
and the patients occupying the room at these times were not colonised, thus
suggesting that the presence of a C. difficile colonised patient leads to environmental
contamination. In support of this, side-room 10, ward 5 was sampled on four
occasions and on all four occasions the patient occupying the side-room was
uncolonised and no C. difficile was isolated from the environment, this data is not
shown.
Figures 3.3 and 3.4 show data from side-rooms 6 and 10 in ward 6. The data from the
environment suggest high levels of environmental contamination of these side-rooms
with C. difficile. All patients occupying these rooms at the times of sampling were
colonised with C. difficile and the levels of isolation of C. difficile from the
environment of side-room 6 range from 25% to 80% and side-room 10 from 0-100%.
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Figure 3.3. Percentage of C. difficile culture positive environmental
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Figure 3.4. Percentage of C. difficile culture positive environmental

































Date of sample collection
The data illustrated in figures 3.3 and 3.4 suggest an association between
environmental contamination with C. difficile and the presence of a colonised
individual in a particular room.
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3.3. Discussion
This study of a geriatric unit in RVH, Edinburgh investigated patients for
colonisation and symptomatic infection with C. difficile, the study revealed a 30%
incidence of colonisation with C. difficile in the patients investigated. The presence
of C. difficile was detected in 27% of the patients tested in ward 5 and 34% of
patients tested in ward 6.
In general, the published reported levels of isolation of C. difficile from different
groups of hospitalised patients are highly variable. McFarland et al (1989), reported
the isolation of C. difficile from 26% of patients in a general medical ward. Brettle et
al (1982), demonstrated the isolation of C. difficile from 12% of patients in an
Infectious Disease unit and an isolation level of 21% was shown in a combined study
of patients from surgical, medical and orthopaedic wards (Johnson et al, 1990b).
Gerding et al (1986), reported that 30% of a group of geriatric patients with diarrhoea
harboured the organism, and in an investigation of six different Welsh hospitals, C.
difficile was isolated from 16.5% elderly patients. Two of the Welsh hospitals
investigated, reported that C. difficile was not isolated and that the range of
acquisition from the other four hospitals was 4-24% (Brazier et al, 1999).
Approximately 30% of patients in a chronic care facility for the elderly were found
to harbour C. difficile. Of the patients studied, 28% were toxin positive and 33%
were culture positive (Bender et al, 1986). This compares well with the 27% of
culture positive and 14% of toxin positive patients in RVH, it also correlates with the
overall detection levels of 30% from RVH.
In contrast to the studies mentioned above, Cefai et al (1988), described levels of
isolation of C. difficile at 7.7% and 1.9% in two separate investigations of patients in
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an elderly, chronic care hospital. A similarly low isolation level was noted by
Corrado et al (1990), who determined that only 4% of patients from a mixed-function
ward for the elderly were positive for C. difficile, thus suggesting that the organism is
not always endemic in elderly care wards. It should be noted that during the last
decade the reported incidence of CDAD has increased exponentially, therefore the
levels of C. difficile reported by early studies are likely to be lower than those of
more recent studies.
Findings from RVH are comparable with other studies which have established
colonisation levels of up to 30% in patients in elderly care units such as RVH. The
published studies discussed indicate a substantial amount of variation from hospital
to hospital, and as the results of the RVH study indicate, the levels of isolation of C.
difficile also vary from ward to ward and from time to time. Differences in study
methodology may also have an influence on the variation in findings between
studies.
The study of patients in RVH demonstrated the variation in the level of isolation of
C. difficile from patients over time. Levels of isolation from patients in ward 5 varied
from 7-67%, and levels from patients in ward 6 varied from 0-50% per month during
the study. Bender et al (1986), also noted variation in colonisation levels over time
and Gerding et al (1986), also showed the identification of cases of CDAD to vary
between 7 and 21 patients per month over a given time period.
Attention is drawn to the bias on sample collection from patients in RVH. Not all of
the admissions to wards 5 and 6 were sampled and it is likely that specimens were
easier to collect from patients with diarrhoea. As the symptomatic patients are more
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likely to harbour C. difficile this study may overestimate the reported incidence of C.
difficile in this geriatric unit.
From the study described 4% of patients from ward 5 and 11% from ward 6 were
determined as suffering from CDAD. There were however a significant number of
symptomatic patients from whom C. difficile was detected by culture or toxin tests,
and although they did not fulfil the criteria for CDAD, their symptoms may possibly
be related to infection with C. difficile.
The study of patients in RVH used CCEY agar to investigate the faecal samples from
patients for C. difficile. This medium is currently recognised as the best available
selective medium for the isolation of C. difficile and consequently it was chosen for
this study. It is the medium recommended by the ARU, Cardiff, Wales and studies in
our laboratory have shown it to be superior to CCFA. The medium contains cholic
acid sodium salt, a more economical, but as effective alternative to sodium
taurocholate (Brazier, 1993). Studies in the early 1980s showed enhanced recovery
of spores from faecal samples with the use of sodium taurocholate (Wilson et al,
1982b).
The methods used in the study offered optimal recovery of C. difficile. The use of the
best available medium and the storage of all agar plates in an anaerobic environment
for a minimum of 18 hours before plating faecal material to them facilitated
maximum recovery of C. difficile. Alcohol shock or enrichment may have recovered
small numbers of bacteria that could have gone undetected by direct plating to
CCEY, however any small numbers that were missed were not thought be significant
and due to the highly selective nature of the CCEY agar.
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Toxin was not detected in the faecal samples of 54% of patients who were colonised
with C. difficile. It is well documented that toxin is often not present in the faeces of
asymptomatic, colonised patients. This may be because the toxin it is not produced in
these patients in detectable quantities, or that patients are colonised by non-toxigenic
strains. It is undoubtedly the case that most of these patients did not have detectable
levels of toxin in their faeces. The Techlab™ A/B kit was used as described in the
manufacturer's instructions. The positive and negative controls provided with the kit
were used and the results interpreted in accordance with the manufacturer's
instructions. Aldeen et al (2000) and O'Conner et al (2001), carried out comparisons
of the Techlab™ A/B kit with the "gold standard" tissue culture method. Both
showed that the kit is highly sensitive and specific. The results from the study of
patients in RVH can therefore be interpreted with confidence.
However, there are several other possible explanations, which may account for the
failure to detect toxin in some of the specimens. Degradation of C. difficile toxins
occurs rapidly. It is therefore possible that some toxin-positive specimens may have
failed to give a positive result if there was only a very small amount of toxin present,
which degraded during transport or storage at -20°C.
It is interesting to note that patients from whom both culture and toxin(s) were
detected did not always produce both toxin and culture positive results in the same
faecal specimen. This could be due to variation in the amount of toxin produced or
the bacterial load in the gut over the time course of colonisation and/or infection with
C. difficile. However, most patients who produced specimens from which only toxin
was detected had prior to, or subsequently produced specimens from which culture
was detected. Toxin only was detected from only 5% of all patients investigated, this
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finding of patients from whom only toxin only could be detected is not unique, both
Gerding et al (1986) and Cefai et al (1988), also reported small numbers of patients
from who toxin only was detected. It is likely to reflect failure of the culture
detection method as the presence of toxin also indicates the presence ofbacteria.
Environmental sampling of the study area utilised both contact plates and swabs.
Samples taken by contact plates yielded a much higher isolation level of C. difficile
than the samples taken with swabs. In a study comparing the relative merits of
contact plates and swab methods, it was stated that contact plates were the preferred
method of sampling and that they were better than swabs (Buggy et al, 1983). It is
therefore probably the case that the lower yields from the swabs were a result of the
sampling method rather that the areas sampled.
Sampling of the environment of the wards RVH indicated that ward 6 was much
more heavily contaminated that ward 5. C. difficile was isolated from 7% of
environmental surfaces sampled in ward 5, and 20% of those surfaces sampled in
ward 6. These findings compare with a study which isolated C. difficile from 15% of
environmental surfaces in a chronic care ward for the elderly (Bender et al, 1986)
and an investigation by Al Saif and Brazier (1999), which isolated C. difficile from
20% of inanimate objects from various hospital environments.
The areas with the highest isolation levels of C. difficile were toilet areas, sluice-
rooms and side-rooms. As toilet areas and sluice rooms are most likely to become
contaminated by faecal material infected with C. difficile, this finding is not
surprising. Patients who were symptomatic carriers of the organism often occupied
the side-rooms and therefore contamination of such an environment is inevitable.
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The environmental study showed a correlation between the overall level of detection
of C. difficile from wards 5 and 6 and the levels of colonisation in wards 5 and 6. In
ward 6, 19% of patients were symptomatically colonised, compared to only 10% in
ward 5, suggesting a relationship between symptomatic colonisation and
environmental contamination.
The level of isolation in specific rooms was associated with the colonisation status of
the patient occupying the room at that time. This outcome is supported by other
studies which have shown that isolation of C. difficile is greater from the
environment of colonised patients, and greater still from colonised symptomatic
patients. McFarland et al (1989), demonstrated an isolation level of 29% from the
environment of asymptomatic colonised patients, and 49% from the environment of
symptomatic colonised patients. Fekety et al (1981), reported isolation levels of 2.5-
2.8% from the environment were there were no known disease cases and 10% from
the environment of known cases of C. difficile associated infection.
These studies also demonstrated frequent isolation of C. difficile from floors,
commodes and toilets. McFarland et al (1989), isolated C. difficile from 36% of
floors, 18% of toilets and 38% of commodes and Samore et al (1986), also isolated
the organism from 48% of floors, 41% of commodes and 33% of toilets. C. difficile
was most frequently isolated from the floor ofRVH, and toilets and commodes were
also frequently contaminated. The high levels of contamination of floors may be due
to the initial contamination and subsequent movement of spores from place to place
on the feet of staff, patients and visitors. Interestingly, McFarland et al (1986), and
Samore et al 1986, isolated C. difficile from windowsills at levels of 30% and 38%
respectively. C. difficile was isolated from 20% of windowsills sampled in RVH. The
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organism was also isolated from shelves and cupboard tops. Areas such as these
collect dust and may not be subject to cleaning as frequently as other areas, and
hence the spores collect and provide a reservoir of the organism. Fekety et al (1981),
reported the recovery of C. difficile from an intentionally contaminated surface for up
to five months, demonstrating the ability of the organism to survive in the
environment.
The data from RVH and other previous investigations demonstrate the widespread
contamination of the environment with C. difficile and hence the opportunity for
cross-infection. The need for regular cleaning and effective disinfectants is essential
for the removal of the organism. Wilcox and Fawley (2000), published a study which
found that some common hospital cleaning chemicals enhance spore production at
sub-inhibitory concentrations, as a spore former, the difficulties in eliminating the C.
difficile spores are challenging.
The findings from this study illustrate the endemic nature of C. difficile in a geriatric
population and the degree to which their environment is contaminated. It emphasises
the need for good infection control policies, the need for thorough, regular cleaning
and the requirement for an effective agent against C. difficile spores.
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CHAPTER FOUR
Risk Factors for colonisation and infection with C. difficile.
AIM
To determine by univariate and multivariate analysis, the statistical significance of
exposure to a number of potential risk factors associated with C. difficile colonisation
and disease.
As discussed in chapter three, faecal specimens from 390 patients admitted to wards
5 and 6, RVH, Edinburgh were investigated for the presence of C. difficile. Of the
390 patients investigated, C. difficile was detected in 118 patients by culture and
or/toxin detection methods. A total of 66 patients tested positive by culture detection
methods only (Cdc+), 34 by both culture and toxin detection methods (Cdt+), 18
patients by toxin methods only and the remaining 272 patients were C. difficile
culture and toxin negative (Cdc-). For the purpose of this analysis the 18 patients
who tested positive by toxin detection methods only will be disregarded due to the
difficulties associated with categorising them. These toxin positive only results may
have been a result of false positive ELISA result, or the failure to detect C. difficile in
culture, this was discussed in detail in chapter three.
RESULTS
4.1. Risk factors for C. difficile colonisation and disease
Information relating to a number of factors that could potentially influence C.
difficile colonisation and infection was collected from patients in wards 5 and 6,
RVH. Data relating to medication used, diagnoses and several underlying diseases
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were collected from patients in wards 5 and 6, RVH. This investigation focused on
risk factors which may have the capacity to alter the normal gut flora, thus affecting
the colonisation resistance. Previous studies have also implicated these risk factors
investigated as influential on colonisation with C. difficile and the development of












d) Nasogastric or percutaneous endoscope gastrostomy (NG/PEG) tube
feeding.
5. Origin of the patient admitted to wards 5 and 6 (community, other hospital/ward
or nursing home).
6. Antibiotic therapy1




d) "Other" penicillins (e.g. flucloxacillin)
e) Ceftriaxone (a third generation cephalosporin)
f) "Other" cephalosporins1
g) All cephalosporins (ceftriaxone and "other" cephalosporins)
h) Macro)ides (erythromycin, clarithromycin)
i) Quinolones (e.g. ciprofloxacin)
j) Other parenteral [intravenous (IV)/ intramuscular (IM)] antibiotics
k) Trimethoprim
'All analyses was based on the use of antibiotics within the two-week period prior to the
collection of a faecal specimen.
2Any antibiotic use- this group includes all antibiotics.
'"Other" cephalosporins- this group includes all cephalosporins except ceftriaxone.
NB. The number ofpatients exposed to each of the risk factors listed above and their C.
difficile status in given in appendix 4.
The influence of these factors on C. difficile colonisation was investigated using both
univariate and multivariate statistical analysis of the data. The data from all patients
who tested negative for C. difficile (Cdc-) and from all those patients who tested
positive (Cdc+ and Cdt+) for C. difficile was analysed to determine a one-step
predictive model for colonisation and infection with C. difficile. The data were then
analysed to determine a two-step predictive model (Starr et al, 1997), for
colonisation and infection with C. difficile. It was hypothesised that the risk factors
which influence conversion from Cdc- to Cdc+, may be different from those factors
which influence conversion from the Cdc+ to Cdt+, which can induce diarrhoea.
Evidence has shown that many patients become asymptomatically colonised with C.
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difficile, and that exposure to certain risk factors facilitate this colonisation. It is also
thought that asymptomatic colonised patients can become susceptible to CDAD as
the result of further exposure to the same and/or different risk factors which allow
production of large amounts ofC. difficile toxin(s) in the gut.
Increasing age and antibiotic use have been implicated in both colonisation and
infection with C. difficile. However, it is probable that a number of other factors may
be influential in colonisation and CDAD. Logistic regression analysis was used to
determine which specific factors influence the transition from Cdc- to Cdc+ and from
Cdc+ to Cdt+.
4.2. Risk factors influencing the transition from a C. difficile
uncolonised state (Cdc-) to a C. difficile colonised (with or without toxin
in faeces) state (Cdc+ and Cdt+)
Data from the 272 patients who tested negative for C. difficile (Cdc-) and from the
100 patients who tested positive for C. difficile by culture and toxin detection
methods (Cdc+ and Cdt+) were analysed. The data were investigated with univariate
and subsequently multivariate logistic regression models.
4.2.1. Univariate analysis
Univariate analysis was used to investigate the exposure of the Cdc- patient group
and the Cdc+ and Cdt+ patients to each of the potential risk factors under
examination. Age and gender were forced into the model a priori. Increasing age is
recognised as a significant factor in C. difficile disease, and the influence of age may
be confounded by gender, as there is a higher proportion of females in the very
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elderly population. Each of the factors under investigation was added to the logistic
regression model on a univariate basis to determine which factors reached
significance, the output from the univariate analysis is shown in table 4.1. This
analysis indicated that age, laxative use, admission from another hospital and any
antibiotic use were significant factors in the transition from Cdc- to Cdc+ and Cdt+.
Individual antibiotics reaching significance were co-amoxiclav, macrolides and all
cephalosporins. Univariate analysis showed that exposure to a number of factors may
be significant in the transition from Cdc- to Cdc+ and Cdt+. Laxatives and macrolides
were used in a higher proportion of the Cdc- patients, thus they are not thought to be
significantly influential in the development of colonisation and disease. Many
patients were exposed to a number of potential risk factors, for example many
patients received more than one antibiotic, therefore, when investigating a multi¬
factorial disease such as C. difficile disease, it is necessary to consider individual
factors simultaneously to adjust for confounding interactions amongst the factors
under investigation. Multivariate analysis, was used in this study to adjust for
confounding interactions.
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Table 4.1. Results from univariate analysis of risk factors influencing
the transition from Cdc- to Cdc+ and Cdt+.
risk factor odds ratio 95% Confidence intervals p-value








Neoplasia 0.63 0.27-1.51 0.30
Colonic disease 0.54 0.23-1.28 0.16
Leukaemia 2.69 0.36-19.84 0.33
Laxative use 0.58 0.37-0.93 0.03*
NG/PEG use 5.01 0.81-28.44 0.07
Steroid use 1.10 0.44-2.73 0.84
Antacid use 1.50 0.89-2.50 0.13
Source




Nursing home 0.21 0.03-1.66 0.14
Any antibiotic use 2.52 1.60-4.16 <0.01*




Other penicillins 1.46 0.52-4.07 0.47
Ceftriaxone 13.88 2.88-67.02 <0.01*
"Other" cephalosporins 7.84 1.99-30.96 <0.01*
Macrolide 3.06 1.43-6.65 <0.01*




Trimethoprim 0.56 0.32-1.87 0.56
Cephalosporins 7.59 2.55-22.59 <0.01*
*
- A significant statistical result
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4.2.2. Multivariate analysis
Those factors that reached significance by univariate analysis were added one by one
in a stepwise logistic regression model to adjust for any confounding interactions
between these factors, the results are shown in table 4.2 with age and gender forced
into the model a priori.
The reduced stepwise logistic regression analysis showed that increasing age,
admission from another hospital or ward, exposure to any antibiotics, and
cephalosporins, especially ceftriaxone were significant factors in the transition from
Cdc- to Cdc+ and Cdt+. The final model of best fit determined age (O.R. 1.04, 95%
C.I. 1.01-1.06), hospital admission (O.R. 1.99, 95% C.I. 1.21-3.29) and any
antibiotic use (O.R. 2.20, 95% C.I. 1.32-3.64), especially the use of ceftriaxone (O.R.
11.53, 95% C.I. 1.2.03-65.46) as the significant factors influencing the transition
from Cdc- to Cdc+ and Cdt+.
Forward conditional logistic regression was also applied to all of the factors under
investigation. All factors were added simultaneously to the forward conditional
logistic regression analysis and the results from this analysis are shown in table 4.3.
This analysis indicated that increasing age, admission from another hospital and any
antibiotic use, especially ceftriaxone were significant risk factors for the transition
from Cdc- to Cdc+ and Cdt+. This model also identified the use of trimethoprim as
being a borderline significant factor in the transition from Cdc- to Cdc+ and Cdt+. It
is unlikely to be a significant factor in C. difficile colonisation or disease, as a larger
proportion ofCdc- patients than Cdc+ and Cdt+ patients used trimethoprim.
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Table 4.2. Results of stepwise logistic regression of risk factors
influencing the transition from Cdc- to Cdc+ and Cdt+.
FACTOR ODDS RATIO 95% CONFIDENCE INTERVALS P-VALUE
Age (increasing per year) 1.04 1.01-1.08 0.02*
Gender 0.62 0.38-1.02 0.62
Source <0.01*
(Hospital and nursing home admissions compared to community)
Hospital 2.35 1.45-3.80 <0.01*
Nursing home 0.21 0.03-1.66 0.14
Laxative use 0.63 0.39-1.03 0.06
Any antibiotic use 2.51 1.52-4.11 <0.01*
Co-amoxiclav 1.02 0.55-1.88 0.96
(augmentin)
Cephalosporins 6.02 1.87-19.40 <0.01*
ceftriaxone 11.53 2.03-65.46 <0.01*
"Other" cephalosporins 3.24 0.66-15.9 0.15
Macrolides 1.41 0.59-3.38 0.44
*
- A significant statistical result
Table 4.3. Results of forward logistic regression of factors influencing
the transition from Cdc- to Cdc+ and Cdt+.
FACTOR ODDS RATIO 95% CONFIDENCE INTERVALS P-VALUE
Age (increasing per year) 1.04 1.00-1.08 0.03*
Hospital source 1.95 1.18-3.23 <0.00*
Any antibiotic use 2.51 1.49-4.22 <0.00*
Ceftriaxone 12.51 2.21-70.69 <0.00*
Trimethoprim 0.37 0.14-1.00 0.05*
*
- A significant statistical result
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As described, logistic regression modelling was used to determine a one-step
predictive model for factors which could significantly influence the transition from
Cdc- to Cdc+ and Cdt+. The proposed predictive model is illustrated in figure 4.1.
Figure 4.1. The proposed one-step predictive model for Cdc- transition
to Cdc+ and Cdt+.
Age
Admission from another hospital
C. difficile uncolonised ^ C. difficile colonised
(Cdc-) (Cdc+ and Cdt+)
Any antibiotic use
Cephalosporin use- especially ceftriaxone
As discussed in section 4.1, it has been suggested that C. difficile colonisation and
infection may occur as a two-step process. The data were analysed using the logistic
regression modelling methods described above, to determine significant factors
which influence each transition in the hypothesised two-step disease process.
4.3. Risk factors influencing the transition from a C. difficile
uncolonised (Cdc-) to C. difficile colonised (Cdc+) state
Data from the 272 patients who tested negative for colonisation with C. difficile and
from the 66 culture positive only patients was analysed. The data were investigated
by univariate and subsequently logistic regression modelling.
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4.3.1. Univariate analysis.
Univariate logistic regression was used to analyse the exposure ofCdc- and Cdc+
patients to each of the risk factors under investigation. As before age and gender
were forced into the model apriori. Each of the factors under investigation was
added to the logistic regression model on a univariate basis to determine which risk
factors reached significance and the results of the univariate analysis are shown in
table 4.4. This analysis indicated that gender, admission from another hospital, any
antibiotic use, macrolides and cephalosporins, especially ceftriaxone may be
important in the transition from Cdc- to Cdc+.
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Table 4.4. Results from univariate analysis of risk factors influencing
Cdc- transition to Cdc+.
FACTOR ODDS RATIO 95% CONFIDENCE INTERVALS P-VALUE
Age (increasing per year) 1.03 0.99-1.07 0.19
Gender 0.56 0.31-0.97 0.05*
Neoplasia 0.81 0.32-2.05 0.65
Colonic disease 0.74 0.29-1.86 0.52
Leukaemia 0.16 0.58-31.87 4.29
Laxative use 0.63 0.36-1.10 0.11
NG/PEG 3.36 0.45-24.99 0.24
Steroid use 0.69 0.20-2.42 0.56
Antacid use 0.39 0.71-2.41 1.31
Source <0.01*
(Hospital and nursing home admissions compared to community)
Hospital 2.40 1.37-4.19 <0.01*
Any antibiotic use 1.87 1.08-3.23 0.03*




Other penicillins 1.76 0.59-5.29 0.31
Ceftriaxone 11.84 2.21-63.50 <0.01*
"Other" cephalosporins 2.89 0.45-18.03 0.26
Macrolides 3.17 1.34-7.56 <0.01*




Trimethoprim 0.72 0.24-2.17 0.56
Cephalosporins 5.69 1.66-19.57 <0.01*
*
- A significant statistical result.
NB. Odds ratios were omitted for patients admitted from a nursing home as they
were non-significant and there were very small numbers in the group.
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4.3.2. Multivariate analysis
Those factors, which showed significance in the univariate analysis, were applied
one by one in a stepwise logistic regression model, and age and gender were forced
into the model apriori. The results from this reduced logistic regression model are
shown in table 4.5. The analysis showed that admission from another hospital, any
antibiotic use, especially cephalosporins and in particular ceftriaxone use were
significant factors influencing the transition from Cdc- to Cdc+.
The final model with the best fit showed that factors reaching significance were
admission from another hospital (O.R. 2.15, 95% C.I. 1.20-3.85), the use of
ceftriaxone (O.R. 16.57, 95% C.I. 1.80-151.86).
Table 4.5. Results of reduced stepwise logistic regression of risk
factors influencing the transition from Cdc- to Cdc+.
FACTOR ODDS RATIO 95% CONFIDENCE
INTERVALS
P-VALUE
Age (increasing per year) 1.03 0.99-1.07 0.19
Gender 0.56 0.32-1.00 0.05
Source (hospital admissions compared to community) <0.00*
Hospital 2.40 1.37-4.19 <0.00*
Any antibiotic use 1.80 1.02-3.17 0.04*
Cephalosporins 6.03 1.52-23.94 0.01*
Ceftriaxone 16.57 1.81-151.86 0.01*
Macrolide 2.40 0.77-5.42 0.15
*- A significant statistical result.
NB. Odds ratios were omitted for patients admitted from a nursing home as they
were non-significant and there were very small numbers in the group.
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Forward conditional logistic regression modelling was also applied to the data. All
factors under investigation were added to the model simultaneously and the resulting
analysis showed that the factors reaching significance were admission from another
hospital (O.R. 2.30, 95% C.I. 1.31-4.41) and the use ofceftriaxone (O.R. 18.95, 95%
C.I. 2.12-169.31).
The analysis described above determined factors which are important for the first
step of the proposed two-step predictive model. The model is illustrated in figure 4.2.
Figure 4.2. Factors influencing the first step of the proposed two-step
predictive model.
Cdc- ► Cdc+
Admission from another hospital
Cephalosporins (especially
ceftriaxone)
4.4. Factors influencing the transition from a C. difficile colonised
(Cdc+) to C. difficile colonised with detectable toxin in faecal samples
state (Cdt+).
The data from the 66 culture positive only patients (Cdc+) and the 34 culture and
toxin positive patients (Cdt+) was investigated using the univariate and multivariate
analysis.
4.4.1. Univariate analysis
Each of the factors under investigation was added to a logistic regression model on a
univariate basis to determine which factors reached significance in the transition
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from Cdc+ to Cdt+. Age and gender were forced into the model a priori. The results
are shown in table 4.6. Factors reaching significance were any antibiotic use,
amoxycillin, other parenteral (IV/IM) antibiotics and "other" cephalosporins.
Table 4.6. Results from univariate analysis of risk factors influencing
Cdc+ transition to Cdt+.
FACTOR ODDS RATIO 95% CONFIDENCE INTERVALS P-VALUE
Age 1.04 0.98-1.10 0.23
Gender 1.42 0.58-3.50 0.45
Neoplasia 0.37 0.04-3.31 0.37
Colonic disease 0.23 0.03-2.09 0.19
Laxative use 0.78 0.32-0.19 0.57
NG/PEG 2.76 0.36-21.50 0.33
Steroid use 3.06 0.60-15.55 0.18
Antacid use 1.32 0.53-3.31 0.57
Source
(hospital and nursing home
Hospital




Any antibiotic use 3.05 1.15-8.12 0.03*




Other penicillins 0.42 0.05-3.82 0.44
Ceftriaxone 1.83 0.44-7.61 0.40
"Other" cephalosporins 7.36 1.35-40.35 0.02*
Macrolide 0.91 0.28-2.97 0.87




Trimethoprim 1.30 0.26-6.52 0.75
Cephalosporins 2.29 0.66-8.01 0.19
*- A significant statistical result
NB. Odds ratios were omitted for patients admitted from a nursing home and
patients with leukaemia as they were non-significant and there were very small
numbers in the group.
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4.4.2. Multivariate analysis
The factors that were significant by univariate analysis were added one by one to a
stepwise logistic regression model. Age and gender were forced into the model a
priori, the results from the reduced logistic regression analysis is shown in table 4.7.
Table 4.7. The results of stepwise logistic regression of factors
influencing the transition from Cdc+ to Cdt+.
FACTOR ODDS RATIO 95% CONFIDENCE INTERVALS P-VALUE
Any antibiotic use 3.02 1.15-7.92 0.02*
Amoxycillin 6.13 1.16-32.37 0.03*





- A significant statistical result.
The final model of best fit determined amoxycillin (O.R. 8.72, 95% C.I. 1.66-45.86)
and "other" cephalosporin use (O.R. 7.27, 95% C.I. 1.34-39.65) as significant factors
influencing the transition from Cdc+ to Cdt+.
Forward conditional logistic regression was applied, all factors were added
simultaneously to the model. This model also determined amoxycillin (O.R. 0.12,
95% C.I. 0.02-0.60) and "other" cephalosporin use (O.R. 0.14, 95% C.I. 0.03-0.75)
as significant factors in the transition from Cdc+ to Cdt+.
The analysis described above has determined a two-step predictive model for the
colonisation and infection with C. difficile. The proposed model is shown in figure
4.3.
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Figure 4.3. A two-step predictive model for C. difficile colonisation and
infection.
Cdc- ^ Cdc+ ^ Cdct+
Admission from another hospital Amoxycillin
Any antibiotics (especially "Other" cephalosporins
ceftriaxone)
This logistic regression analysis provides good evidence that colonisation and
infection with C. difficile is a two-step process and that each of the two-steps is
influenced by different factors. The initial one-step predictive model showed that
increasing age was a significant risk factor. Cdt+ patients were shown to be
significantly older than the Cdc+ patients (p=0.01, Mann Whitney U test), the mean
age ofCdt+ patients was 85.26 compared to 82.23 for Cdc+ patients. Age did not
appear as a significant factor in the logistic regression modelling of either of the two
individual steps, however it was important in the overall disease process.
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4.5. Discussion
CDAD in hospitalised patients is well recognised as a multi-factorial disease which
has been associated with a number of predisposing risk factors. In 1978, Bartlett et
al, identified C. difficile as a major cause ofAAD, thus the association ofCDAD
with exposure to antibiotics is well established. However, not all patients who
undergo antibiotic therapy develop CDAD, or even become colonised with C.
difficile. This can be explained partly by the varying degrees to which different
antibiotics influence colonisation with C. difficile and CDAD. It is also is well
established that other factors relating to underlying diseases, medication, medical
procedures and the general health of the patient are likely to be influential in the
development of C. difficile disease.
C. difficile colonisation and disease is predominately associated with elderly patients.
A number of studies have provided statistical evidence that increasing age is a
significant risk factor for CDAD. Aronnson et al (1985), surveyed the incidence of
C. difficile as the cause of antibiotic associated diarrhoea in Swedish patients aged
from <1 year to 101 years of age. The study determined a higher incidence ofCDAD
in patients over 70 years old. In another study, records from all C. difficile positive
patients in Sweden in 1995 were investigated. The study determined that there was a
ten-fold higher incidence of C. difficile in the group aged 60 to 93, and that more
cases occurred in the geriatric wards than in the other types of ward (Karlstrom et al,
1998). Increasing age was also a significant factor in C. difficile carriage and
diarrhoea in a study of 399 patients aged 18 to >75 in a general medicine ward over
an 11-month period (McFarland et al, 1990).
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Age and the use of antibiotics are well-established risk factors for C. difficile
colonisation and disease. However, it is clear there must be other predisposing
factors for the disease, as many hospitalised elderly patients receive antibiotics and
do not become colonised with, or develop C. difficile disease.
The major risk factors which predispose patients to colonisation and infection with
C. difficile have been the subject of numerous investigations. Studies have
investigated the possible influence of a range of diagnoses, medical procedures and
underlying diseases, of which many have been significantly associated with CDAD
(McFarland et al, 1990; Bignardi, 1998; Buchner and Sonnenberg, 2001).
Comparison of these studies is difficult as the patient groups, the methods of data
collection and analysis is variable between studies.
This study of patients in RVH, Edinburgh investigated an endemic setting where all
patients subject to analysis were investigated for the presence of C. difficile.
Comparisons were made between C. difficile negative patients (Cdc-), C. difficile
culture positive only patients (Cdc+) and C. difficile culture and toxin positive
patients (Cdt+). Initial analysis considered CDAD as a one step process. Subsequent
analysis considered CDAD as a two-step disease process. It was hypothesised that C.
difficile disease occurs as a two-step disease process (Starr et al, 1997). The proposed
two-step model suggests that patients undergo the transition from a C. difficile
culture negative state (Cdc-) to an often asymptomatic C. difficile culture positive
state (Cdc+), with no detectable toxin in the faeces. The patient may remain in this
asymptomatic state, or the patient may undergo the transition from Cdc+ to C.
difficile culture and toxin positive (Cdt+).
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The aim of this study was to determine which of the risk factors investigated
significantly influenced the overall disease process and each of the two-steps in the
model. The study investigated risk factors that had been implicated by other workers
and that focused on medications, medical procedures and underlying diseases which
might affect the endogenous gut flora therefore reducing colonisation resistance and
making the patient susceptible to C. difficile colonisation and disease. It was
anticipated that the study would provide useful information regarding the risk factors
which allow colonisation with C. difficile, followed by the factors that allow or
enhance toxin production in high levels in the gut.
When the disease was considered as a one-step process and the transition from Cdc-
to Cdc+ and Cdt+ was investigated, the analysis determined that age, admission from
another hospital, any antibiotic use, especially cephalosporins, and in particular
ceftriaxone, were significant factors in the transition. These findings correlated well
with other studies. Univariate analysis also implicated co-amoxiclav. However,
multivariate analysis failed to find this significant, and as co-amoxiclav has been
reported as having a low association with C. difficile, it is likely that it is not a
significant factor.
When the two-step model was investigated, the analysis determined admission from
another hospital, any antibiotic use, and the use of ceftriaxone (a third generation
cephalosporin) as the factors which significantly influenced that transition from Cdc-
to Cdc+. When the second transition from Cdc+ to Cdt+ was investigated the factors
which significantly influenced the transition were amoxycillin and the "other"
cephalosporins (first and second-generation cephalosporins). These findings indicate
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that different risk factors are significant in each of the two-steps in the proposed
model, thus the findings support the proposed model.
Almost all antibiotics have been associated with C. difficile, however the evidence
suggests that certain antimicrobial agents are more frequently associated with the
disease than others. Much of the evidence implicates cephalosporin use as the most
potent inducer of CDAD, in a study of 130 patients diagnosed with C. difficile
diarrhoea cephalosporins were shown to be the most frequently implicated antibiotic
(Silva et al, 1984). Cephalosporins were also shown to be 40 times more likely to
induce C. difficile than narrow spectrum penicillins (Arronson et al, 1985). In 1993
the British Thoracic Society recommended the used of cephalosporins to treat
community acquired pneumonia. As a result of the implementation of this practice
Impallomeni et al (1995), showed a direct correlation between the use of cefotaxime
and the number of cases of C. difficile diarrhoea in a geriatric unit. The study
indicated that up to one in every five users of cefotaxime would develop C. difficile
associated diarrhoea. This study suggested that cefotaxime should be used as a last
resort in geriatric patients.
It is interesting that the investigation from patients in RVH shows that a third
generation cephalosporin, ceftriaxone is associated with C. difficile colonisation and
that the "other" (first and second generation) cephalosporins are associated with
toxin production. The model also implicates amoxycillin in the transition from Cdc+
to Cdt+. This is not surprising, as amoxycillin and ampicillin have been strongly
associated with CDAD in previous investigations. Silva et al (1984), found that 41 of
130 cases ofCDAD had been exposed to ampicillin. Bartlett et al (1981), also
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showed that of 329 cases of CDAD reviewed that 109 had been exposed to
ampicillin and amoxycillin.
It can be hypothesised that different antibiotic agents have different effects on both
C. difficile and the normal gut flora and may therefore explain the finding from the
study in RVH. Both the cephalosporins and some penicillins (such as ampicillin and
amoxycillin) are broad spectrum agents and therefore their deleterious effect on the
colonic flora would be considerable, thus reducing the colonisation resistance in the
gut and increasing susceptibility to C. difficile.
Borriello and Barclay (1986), have shown that the colonic flora is inhibitory to C.
difficile growth and toxin production. It has also been shown that Bacteroides spp.,
Bifidobacterium spp., Lactobacillus spp., Pseudomonas spp., Staphylococcus spp.
and Streptococcus spp. inhibit C. difficile (Rolfe et al, 1981).
A study by Canawati, (1992) showed that cefotaxime acted in synergy with its
metabolite desacetylcefotaxime to increase activity against Bacteroides fragilis. This
illustrates the intricate nature of antibiotic activity in the complex environment of the
gut, suggesting that there is much to be understood about the actions of antibiotics on
the gut flora.
Less is known about the effect of antibiotics on C. difficile itself. It is reasonable to
suggest that certain antibiotics could up-regulate virulence factors and growth.
Relatively little research has focused on this area, however several studies have
investigated the effect ofantibiotics on toxin production. Increases in the production
of enterotoxin when C. difficile is grown in sub minimum inhibitory concentrations
of antibiotics including clindamycin and cephaloridine have been shown (Honda et
al, 1983). Freeman and Wilcox (1999), stated that in their study that cefotaxime,
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ciprofloxacin and piperacillan-tazobactam did not have any effect on the growth or
toxin production by C. difficile. As relatively little is known about the virulence
factors of C. difficile and the mechanisms of disease it is difficult to speculate how
factors such as antibiotics could affect C. difficile in vivo.
The significance of admission from another hospital is likely to be explained in the
same way as the association of the length of stay with C. difficile. Length of stay has
been implicated as a risk factor for C. difficile by several workers (MacGowan et al,
1995 and Rudensky et al, 1993) However, Shek et al (2000) and Bignardi (1998),
showed that length of stay was not a significant risk factor in C. difficile disease.
Bignardi (1998), suggests that most studies have failed to address this factor
correctly, and that length of stay is confounded by other factors such as antibiotic
use. It is also suggested that extended length of stay is a result of C. difficile infection
rather than the cause. Although length of stay was not investigated in patients in
RVH, the significantly higher incidence of colonisation in patients admitted from
another hospital/ward would indicate that exposure to the hospital environment is a
risk factor for colonisation. In agreement with Bignardi (1998), McFarland et al
(1990), showed that length of stay was significantly longer both in asymptomatically
colonised patients and in patients with diarrhoea. McFarland et al (1990), suggested
that the significant association with the length of stay was by virtue of the fact that
increased length of stay provides more opportunity for a patient to be exposed to
potential risk factor such as antibiotics, the hospital environment and health care
workers. Thus, the patients who had been hospitalised elsewhere before admission to
RVH would have had more opportunity for exposure to risk factors, and were thus
more likely to be colonised than those admitted from the community.
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As discussed, age is a well-established risk factor for C. difficile disease. The study
of patients in RVH showed that Cdt+ were significantly older that Cdc+ (however
Cdc+ were not significantly older than Cdc-) suggesting that even within the geriatric
population older patients are more likely to develop the CDAD. The risks associated
with age are likely to be a result of numerous intrinsic host factors such as general
debilitation and a less efficient immune system. Borriello and Barclay (1986),
showed that faecal emulsions from elderly patients were less inhibitory against C.
difficile, suggesting a decrease in colonisation resistance, thus requiring less
compromise before becoming susceptible to C. difficile.
Age is obviously a factor which cannot be controlled, however the antibiotic and
medical procedures to which the patients are exposed can be controlled. An increased
knowledge of the disease process, significant risk factors and the effects of these
factors on the mechanisms which cause C. difficile disease are needed in order to
develop effective control and prevention strategies.
Starr et al (1997), proposed a "herd immunity" model. The model suggests that
within a ward ("herd") there is an overall state of resistance to C. difficile. However,
as the number of resistant patients in the ward drops below a critical level, then cases
of C. difficile will occur. It is thought that the use of antibiotics (and other factors)
can reduce the number of resistant patients, thus shifting the equilibrium, and with
more susceptible patients an outbreak may occur. This model reinforces the need for
control over significant influential factors, and it suggests that careful case-mix could
reduce the incidence of C. difficile by maintaining a resistant "herd".
The study of patients in RVH provides evidence for the two-step predictive model
and it indicates that different risk factors are significant for each of the two-steps to
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occur. CDAD is clearly a complex disease in which a number of risk factors play a
role. However, until more is understood in relation to how C. difficile causes disease
then results from epidemiological studies such as this are difficult to interpret and
exploit to develop effective prevention and control strategies.
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CHAPTER FIVE
An investigation of the variation and antigenic nature of the surface
layer proteins of C. difficile.
AIMS
1. To extract the surface layer proteins (SLPs) from C. difficile isolates and to
determine the variability of the molecular masses of the SLPs amongst isolates of
C. difficile.
2. To determine the antigenic nature and immuno-reactivity of the SLPs of C.
difficile.
RESULTS
5.1. Extraction of SLPs from C. difficile by treatment of whole cells with
5M guanidine hydrochloride
The SLPs of twenty-eight C. difficile isolates from the laboratory culture collection
were investigated. Twenty-four of the isolates investigated (mprl 4196 to 4219)
represented a different serotype or ribotype of C. difficile. The remaining four
isolates (2520 [nctc 11223], 1128, 604, 683) were those isolates to which antisera
was raised in four different rabbits. (Details relating to the 28 laboratory isolates are
given in chapter 2.11 and appendix 2). The C. difficile isolates were cultured and the
SLPs were extracted by treatment with 5m guanidine hydrochloride. Treatment of
whole C. difficile cells with guanidine hydrochloride was shown to produce two
major and several minor protein bands on SDS-PAGE. This characteristic banding
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pattern is indicated in figure 5.1(a). The two major protein bands indicated on Figure
5.1(a) and (b) are characteristic of the SLPs described by Kawata et al, (1988).
5.2. Variation of the molecular mass of the SLPs among C. difficile
isolates of different serotypes and ribotypes.
Figures 5.1(a) and (b) show the high degree of variation in the molecular mass of
both of the SLPs amongst the C. difficile isolates investigated. The larger of the two
major proteins varies in molecular mass from 50-57 kilo Daltons (kDa) and the
smaller protein from 35-48 kDa. Several minor proteins are visible in most of the
extracts from the isolates tested. One of the minor proteins appears to be conserved,
is common to most isolates and has a molecular mass of 70 kDa, it is not thought to
be one of the SLPs.
Each of the twenty four isolates of different serotype or ribotype (mprl 4196-4219)
was designated a 4-digit "S-type" number based on the molecular masses of the two
SLPs; e.g. 5336, where 53 is the molecular mass of the heavier protein and 36 is the
molecular mass of the lighter protein, in kDa.
The isolates were grouped on the basis of this "S-type" number, and this is shown in
table 2. The twenty-four isolates investigated were assigned to a total of 16 groups.
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Figure 5.1(a) and (b). SDS-PAGE of S-layer proteins from C. difficile
isolates of different serotypes, ribotypes (mprl strains 4196-4219; 4217
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Table 5.1. Twenty-four C. difficile isolates of different serotype and
ribotype grouped on the basis of their "S-type" number.
S-type number Serotype Ribotype
(Laboratory number)
51 48 A (4196) 23 (4216)
50 41 A3 (4207) 26 (4217)
50 45 D (4199) 10 (4215)
51 37 A6 (4210)
51 40 A5 (4209)
51 42 A4 (4208)
52 39 A2 (4206)
53 35 A9 (4213)
53 36 C (4198) G (4201) K (4204)
53 37 I (4203)
54 37 F (4200)
53 42 H (4202) 106 (4218)
56 43 A7 (4211)
57 35 A8 (4212)
56 37 B (4197) A10 (4214) 56 (4219)
56 38 X (4205)
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5.3. The antigenic nature and immuno-reactivity of the C. difficile SLPs.
Western blots were carried out using four different antisera. Each antiserum was
raised against a different C. difficile isolate from the laboratory culture collection
(mprl 604, 683, 1128, 2520). Each antiserum was tested for reactivity against the
SLPs from the isolate to which the antiserum was raised and to the SLPs of six other
isolates. The results from the Western blots are shown in Figures 5.2-5.5. and are
discussed below.
Figure 5.2(a) shows the Coomassie stained SDS-PAGE of the SLPs from isolate 683
and six other C. difficile isolates (ribotype 26, serotype A5, A4, A2, K, and D).
Figure 5.2(b) shows the Western blot result when the SLPs were tested for their
reactivity with antiserum against isolate 683. As anticipated a strong reaction to both
of the SLPs extracted from isolate 683 was observed. A cross-reaction to both of the
SLPs from isolate 4217 corresponding to ribotype 26 which has an identical SLP
profile to that of isolate 683. Cross-reaction to the heavier SLP from the other
isolates tested using antiserum to 683 was observed, suggesting antigenic
similarities.
Figure 5.3(a) shows the SLP profile of C. difficile isolate 604 and six other C.
difficile isolates (mprl 1123, 2520, 683 and serotypes A8, A9, A3). Figure 5.3(b)
shows the Western blot result when the SLPs shown in figure 5.3(a) were tested for a
reaction with the antiserum raised to C. difficile isolate 604. Cross-reaction of
varying intensity to both SLPs from isolates 1123, A8, A9 and A3 was observed.
Again cross-reaction with the heavier protein from most isolates tested with
antiserum 604 was observed.
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Antisera raised to both 2520 and 1128 was tested with the SLPs from six isolates
(serotypes C, G, K, I, F, A9). Figure 5.4(a) shows the SLP profile of 1128 and the six
other isolates listed above. Figure 5.4(b) shows the resulting Western blot using
antiserum to 1128. The antiserum raised against 1128 cross-reacted with both the
SLPs from the isolate representing serotype F. There was also a relatively strong
cross-reaction observed between the heavier SLP from each of the six isolates tested.
The antiserum raised against 2520 (NCTC 11223) cross-reacted with the SLPs from
the isolates representing serotype C and K. A strong cross-reaction with the heavy
SLP was observed for all of the other six isolates. The protein profile of 2520 and the
six isolates tested against antiserum raised to 2520 are shown in figure 5.5(a) and the
Western blot result is shown in figure 5.5(b)
The third minor protein of molecular mass 70 kDa which is common to all isolates
cross-reacted with all antisera tested, this is shown in Figures 5.2-5.5. It appears to be
an antigen common to most if not all strains.
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This investigation demonstrated that the treatment of whole washed C. difficile cells
with 5m guanidine hydrochloride extracts two major cell surface proteins which are
thought to be the SLPs. A study by Kawata et al (1984), showed that treatment of the
outer cell wall extracts with urea or guanidine hydrochloride produced almost
identical protein profiles on SDS-PAGE. More recently, Cerquetti et al (2000),
demonstrated that complex preparation of cell walls was not required for the
extraction of SLPs from C. difficile, and that treatment ofwhole cells with urea led to
the extraction of SLPs. We therefore conclude that the two major proteins extracted
from C. difficile treatment with guanidine hydrochloride are the SLPs.
This study revealed a high degree of variation in the molecular mass of the two SLPs
among C. difficile isolates of different serotype and ribotype. Other investigators
have described similar variation of these proteins (Takeoka et al, 1991; Cerquetti et
al, 2000). This variation is not unique to C. difficile, Campylobacterfetus can express
SLPs of different molecular mass (Nitta et al, 1997) and Lactobacillus acidophilus
can also express different SLPs (Boot et al, 1995). It is generally thought that this
variation may be a means of avoiding recognition by the immune system.
Further analysis of the SLPs of C. difficile using Western blotting revealed that there
was significant cross-reaction of antiserum with the heavier SLPs from different C.
difficile isolates, suggesting some degree of antigenic similarity. However, there was
very little evidence of cross-reaction of antiserum with the lighter SLP from isolates
of different serotype or ribotype, suggesting that this lighter protein is antigenically
distinct between strains. These data agree with that of Cerquetti et al (2000), and
more recently Calabi et al (2001), which states that no antigenic relationship was
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observed among SLPs of lower molecular masses and that there was cross-reactivity
among the SLPs of high molecular mass from different strains. Calabi et al (2001),
also showed that there was significant homology of the amino acid sequence of the
heavier SLPs among different strains. However, there was much less homology
among the lighter of the two SLPs among different strains.
Western blotting also indicates that the lighter SLP may be more immunogenic than
the heavier protein due to the consistently stronger reaction of antiserum with the
lighter SLP which is observed in the Western blots. This interpretation is taken with
caution, as Western blotting is not quantitative.
The role if any, of the SLPs in virulence has yet to be determined as is the
importance of any possible immune response to these proteins. However, the
findings from the study described and those of other workers indicate that the SLPs
are immunogenic and that there may be an immune response to these proteins in
human disease. Pantosti et al (1989), showed that IgG from patients with antibiotic
associated diarrhoea recognised the lighter molecular mass SLPs. However, it is the
mucosal antibody response in the gut which is important in such infections and this
has not been demonstrated It could be postulated that an IgA response to the SLPs
in the gut may offer protection from colonisation or infection with C. difficile. The
variation described, particularly of the lighter SLP may provide a means of
avoidance of the immune system as previous infection or colonisation with C.
difficile would not offer protection from re-infection with a different strain with
distinct SLPs.
The data discussed indicate that further investigation of the SLPs of C. difficile is
required to determine their role in virulence. However, this variation is also a
121
phenotypic characteristic which has the potential to be exploited as the basis of a
phenotypic typing method. The SDS-PAGE protein profiles of the C. difficile SLPs
are extremely simple, they are reproducible and can be easily interpreted.
Application of this SLP variation in C. difficile as the basis of a typing method will
be discussed in Chapter six.
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CHAPTER SIX
Assessment of the novel phenotypic S-typing method for C. difficile
and the epidemiology of C. difficile S-types in patients and their
environment.
AIMS
1. To determine the number of different C. difficile S-types that could be identified
from the patients and their environment in wards 5 and 6, RVH.
2. To compare S-typing of C. difficile with PCR ribotyping.
3. To investigate the epidemiology of C. difficile S types from patients and their
environment in wards 5 and 6, RVH.
RESULTS
6.1. S-typing of C. difficile isolates by analysis of the S-layer protein
profiles
The high degree of variation of the molecular masses of the SLPs amongst C.
difficile isolates of different serotypes and ribotypes has been described in Chapter 5,
and as demonstrated, the two SLPs produce a very simple pattern on SDS-PAGE.
This variation and the simple protein patterns produced were exploited as the basis
for the development of a phenotypic typing method for C. difficile. As described in
Chapter 5, the SLPs can be extracted by treatment with guanidine hydrochloride and
visualised on SDS-PAGE. Each isolate of C. difficile can be designated a four-digit
S-type (strain) number based on the molecular weights of the two SLPs and the S-
type number can be detennined using Phoretix™ software to calculate the molecular
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masses of the two SLPs. The C. difficile isolates collected from the patients and the
environment ofwards 5 and 6, RVH were subjected to the S-typing method and each
isolate was subsequently given an S-type number.
6.1.1. S-typing of C. difficile isolates from patients in wards 5 and 6,
RVH
A total of 206 isolates from 100 patients in RVH were subjected to S-typing and each
isolate was designated an S-type number. A total of eight distinct S-types were
identified within the collection of isolates from patients in wards 5 and 6 RVH.
In addition to the SDS-PAGE analysis of the S-layer protein profiles, the C. difficile
isolates were tested for their ability to produce C. difficile toxin(s) by the use of the
Techlab™ ELISA test kit for toxins A and/or B. This revealed that within S-type
5236, some isolates produced toxin(s) and other isolates did not. This allowed further
differentiation within S-type 5236, and a total of nine different S/toxin-types were
identified. The S-layer protein profiles from representative isolates of each of the
eight S-types identified are shown in figure 6.1. Details of the S-type, the toxigenic
potential and the frequency of isolation are summarised in table 6.1.
Toxigenic S-type 5236 was isolated from 78% patients and accounted for 150 of the
206 isolates from patients in RVH. It was evident from the data that toxin producing
S-type, 5236 was the endemic strain of C. difficile colonising the patients in wards 5
and 6, RVH. The other S- types were isolated in comparatively small numbers and
were associated with very small numbers of patients.
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Table 6.1. The frequency of isolation and the toxigenic potential of each
of the S-types isolated.
S-TYPE TOXIGENICITY NUMBER (%) OF
ISOLATES
NUMBER AND "/o1 OF
PATIENTS
5236 toxigenic 150 (73) 78
5236 non-toxigenic 8(4) 4
5242 toxigenic 27 (13) 16
5739 toxigenic 1(0.5) 1
5438 toxigenic 5(2) 5
5140 toxigenic 5(2) 3
5144 non-toxigenic 6(3) 6
5043 toxigenic 1(0.5) 1
UT2 toxigenic 3(1.5) 1
Total 206
1
As there were 100 patients in the study, the number and percentage of patients are
equivalent. The total percentage is more than 100, as 14 patients were colonised with
more than one C. difficile S-type.
UT : this toxigenic strain did not produce two distinct S-proteins on SDS-PAGE, thus
an S-type number was not designated.
6.1.2. S-typing of isolates from the environment of wards 5 and 6, RVH
Isolates collected from the environment of wards 5 and 6 were also subjected to S-
typing. Isolates were collected from a total of 185 areas within wards 5 and 6, and
203 isolates from 168 of these areas were subjected to S-typing. Toxin tests were not
performed on all of the environmental isolates, thus S-type 5236 could not be
differentiated into toxin producing and non-toxin producing strains. A small selection
of isolates representing all three S-types were tested for toxin production and all
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tested positive. As the non-toxin producing S-type 5236 occurred in small numbers
in the patient population, it is likely that this would be the only discrepancy and
would not affect the overall results to a significant extent.
Only three of the eight S-types (5236, 5242 and 5438) that were isolated from
patients were also isolated from the environment, no other S-types were identified.
The frequency of isolation of each of these three S-types is shown in table 6.2.
Table 6.2. The S-types isolated and their frequency of isolation from the
environment of wards 5 and 6, RVH.




The data relating to S-types isolated from the environment correlate well with the S-
types isolated from the patients in wards 5 and 6, RVH. Toxigenic S-type 5236 was
the most frequently isolated strain from patients and correspondingly it was the most
frequently isolated strain from the environment of these patients. The other minor S-
types were not isolated from the environment, this is likely to reflect their low
numbers or absence from the areas of the environment which were sampled.
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6.1.3. Temporal association between environmental contamination and
patient colonisation with three different S-types of C. difficile
Figure 6.2 shows the level of isolation of C. difficile S-type 5236 from patients and
the environment ofwards 5 and 6, RVH over a 15-month period. The levels of
isolation of S-type 5236 from the environment and from patients show similar trends.
Figure 6.3 shows the levels of isolation of S-type 5242 from the patients and the
environment of ward 5 and 6, RVH, again the trends for both patients and their
environment are similar.
Figure 6.2. The level of isolation of S-type 5236 from the patients and
the environment of wards 5 and 6, RVH.
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Figure 6.3. The level of isolation of S-type 5242 from the patients and





* No isolates were collected between 29/04/00 and 17/06/00 due to the illness of
the research nurse.
It is of interest that the S-type 5438 was first isolated from the environment on
20/03/00 and followed the initial isolation of this S-type from a patient on 09/03/00.
The data in figures 6.2 and 6.3 suggest that environmental contamination may be
associated with patient colonisation.
6.2. Comparison of S-typing with PCR ribotyping of C. difficile
Eleven C. difficile isolates collected from the study of patients in RVH were typed by
Dr Jon Brazier, ARU, PHLS, Cardiff, Wales. The eleven isolates represented seven
different S/toxin-types and when typed at ARU, seven different PCR ribotypes were
identified. The PCR-ribotype patterns produced by these isolates were used as
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"standards" to facilitate the typing of other isolates collected during the study in
RVH. The S-types of the eleven representative isolates and the results from the PCR
ribotyping carried out at ARU, Cardiff are shown in table 6.3.
Table 6.3. The S-types and PCR ribotypes of eleven C. difficile isolates.





5236 T (3) type 1 (3)
5236 NT (2) type 9(1)
type 10 (1)
5144 NT (1) type 10 (1)
5242 T (1) type 14 (1)
5043 T(1) type 26 (1)
5438 T (1) type 12 (1)
UT /T(2) type 5 (2)
For the purposes of comparing PCR ribotyping and S-typing, a further 37 C. difficile
isolates which represented eight different S/toxin-types were typed by the PCR
ribotyping method. Isolates were chosen to represent the entire study period. The
results are shown in table 6.4 and include the results from the eleven isolates typed
by Dr Jon Brazier, ARU, Cardiff.
The investigation identified ten PCR ribotypes within the group of eight S/toxin-
types tested. A representative of each of the ten PCR ribotypes is shown in figure
6.4.
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Table 6.4. The PCR ribotypes and S-protein types of the 48 C. difficile




5336/T (17) 17 type 01
5242/T (12) 8 type 14
4 type 106
5438/T (3) 2 type 12
1 type 14
5043/T type 26
5144/NT (3) 3 type 10
5336/NT (5) 3 type 09
2 type 10
5140/T (5) 4 type 02
1 ribotype 137
UT/T (2) 2 type 05
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Figure 6.4. Summary of the 10 PCR ribotypes identified from a selection
of C. difficile isolates collected from patients in RVH.
The isolate number and the S-type are given on the figure.
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There were two ribotypes identified within four of the S-types (5242, 5140, 5236/NT
and 5438) and within ribotypes 10 and 14, there was more than one S-type. The data
indicates that PCR ribotyping offers more discrimination than S-typing, but that
within at least ribotypes 10 and 14 there is more than one phenotype. The results also
show that the toxigenic S-type 5236 correlates to PCR ribotype 1 for all isolates




6.3.1. Assessment of S-typing and comparison to PCR ribotyping.
Historically, the typing methods used for C. difficile were based on the phenotypic
features of the organism. Techniques such as bacteriophage and bacteriocin methods
(Sell et al, 1983), serotyping (Delmee et al, 1985), radio-PAGE (Tabaqchali et al,
1984b) and immunochemical fingerprinting methods (Poxton et al, 1984) have all
been used to type C. difficile. Phenotypic methods have been recently replaced by
more sophisticated genotypic techniques. Several genotypic methods have been
developed, such as AP-PCR (McMillin & Muldrow, 1992) and PFGE which is
highly discriminatory, but is complex and labour intensive (van Dijck et al, 1996). In
addition, problems have been reported with DNA and typeability by PFGE (Kato et
al, 1994). Hyett et al (1997), found that many of the untypeable isolates belonged to
PCR ribotype 1 and suffered from DNA degradation. PCR ribotyping was initially
used by Gurtler (1993), and the method was adapted and improved by Cartwright et
al (1995) and O'Neill et al (1996). PCR ribotyping has proved to be the best of the
genotypic methods, and is currently the typing method of choice in the ARU,
Cardiff, and therefore it was considered the most useful method for this comparative
study.
The novel S-typing method assessed in this study showed a good level of
discrimination, a total of eight S-types were easily identified and visualised on SDS-
PAGE. These eight types were further discriminated to nine types by testing isolates
for their ability to produce toxin(s). As both non-toxigenic and toxigenic strains
occurred within one S-type toxin testing would be required to complement S-typing.
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The techniques involved were simple and the protein profiles were very easy to
interpret. The SLPs have been shown to be stable within any one isolate and the
results are highly reproducible (Sharp and Poxton, 1985). Some difficulties did occur
when S-types with very similar, however different protein profiles. Current gel
analysis software packages, such as Phoretix™ can be used to assist in molecular
weight calculation and differentiation ofvery similar S-types.
Comparison of S-typing with PCR ribotyping determined that PCR ribotyping
offered slightly more discrimination, in total ten PCR ribotypes were identified
compared to only nine S/toxin-types. The findings from this investigation showed
that there was more than one ribotype within a phenotype and vice versa. It was not
surprising that PCR ribotyping could further differentiate S-types, it is however of
interest that different phenotypes could occur within a genotype. As it is the
phenotypic characteristics of an organism which interact with the host to cause, or
exacerbate the pathological effects of the disease, the use of phenotypic typing
methods for epidemiological purposes should not be under-rated.
There was excellent correlation between the endemic toxigenic S-type 5236 and PCR
ribotype 1, the results indicate that PCR ribotype 1 was responsible for the
colonisation of 78% of the C. difficile culture positive patients in this study. This is
not surprising and correlates well to the data from the PHLS for England and Wales
which describes PCR ribotype 1 as the endemic strain in 57% hospitals in England
and Wales (Brazier et al, 1997b).
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6.3.2. The epidemiology of C. difficile S-types from patients and their
environment.
S-typing and toxin testing of isolates from patients and the environment of wards 5
and 6, RVH identified a total of nine distinct S/toxin-types from the 206 patient and
203 environmental isolates tested during the 17-month study period. As discussed the
endemic strain, toxigenic S-type 5236 which corresponded to PCR ribotype 1
colonised three-quarters of all the patients from whom C. difficile was isolated. The
eight other S/toxin -types colonised a comparatively small number of patients. These
findings were similar to those from a study carried out by Fawley and Wilcox (2001).
Their study investigated the patients and the environment of two elderly general
medicine wards over a 22-month period. Typing by RAPD and ribospacer
polymerase chain reaction (RS-PCR) identified eight distinct genotypes from 201 C.
difficile isolates from patients and their environment. Their study identified four
different genotypes from the patients investigated, and one of these genotypes,
corresponded to PCR ribotype 1 and accounted for 92% of all the patient isolates
(Fawley and Wilcox, 2001).
The toxigenic S-type 5236 which was endemic in patients in RVH also accounted for
the majority of the RVH environmental isolates. Two of the other eight S/toxin-types
that were isolated from patients were also isolated from the environment, suggesting
a possible association between the S-types isolated from patients and their
environment.
Other studies have made associations between the contamination of the environment
with specific strains and colonisation of patients with the same strains. Cohen (2000),
showed that the AP-PCR types identified from patients in a geriatric and general
medicine unit correlated closely with the types identified from the environment of
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these patients. Also, Delmee et al (1988), identified a relationship between the
colonisation of neonates with particular serogroups ofC. difficile, clusters of carriage
with a particular serogroup and contamination of the patient environment with the
same serogroups. However, a study in an oncology ward identified 18 different AP-
PCR types from patients and a further nine different AP-PCR types from the
environment. There was no correlation between the types isolated from the
environmental and the types isolated from patients in the oncology unit. This
suggested that in this endemic situation, cross-contamination from the ward
environment may not have been the source of colonisation, but that C. difficile
infections were the result of an endogenous source (Cohen et al, 1997).
Further analysis of the levels of isolation of individual S-types from the environment
and patients in RVH indicated an association between the levels of certain C. difficile
S-types isolated from patients and the levels of these S-types isolated from the
environment. There was evidence of peaks of environmental contamination with S-
types 5236 and 5242, corresponding with peaks in the levels of 5236 and 5242
isolated from patients. The data showed that peaks of contamination in the
environment with a particular strain may occur just before or just after a rise in the
number of patients colonised with the same strain. Interestingly, S-type 5438 was
isolated from two patients in ward 5 and then several months later from three patients
in ward 6. All the patients colonised with this strain were housed in different bays
suggesting that contamination of the environment may not have been directly
responsible if cross-infection occurred with this strain. In the study by Fawley and
Wilcox (2001), they reported that a particular genotype was not isolated from the
environment until the sixth patient in a cluster of cases became symptomatic. This
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data from both RVH and Fawley and Wilcox (2001), suggests that an increase in the
number of colonised patients can lead to an increase in the levels of environmental
contamination with the colonising strain. Fawley and Wilcox (2001), also suggested
that initial cross-infection from patient to patient or from staff to patient may occur
before heavy environmental contamination occurs and causes further cross-
contamination. This may perhaps explain the transfer of S-type 5438 between
patients in different bays within ward 5. Flowever, other sources such as commodes
and equipment which is shared between bays within wards may be the common
source of infection.
Due to the endemic nature S-type 5236 in both the environment and the patients, it
was not possible to determine if environmental contamination or patient to patient
and staff to patient spread was the main source of cross-infection in wards 5 and 6,
RVH. Fawley and Wilcox (2001), encountered similar difficulties in determining the
source of infection. They identified six different genotypes from the environment.
However, only two of these were also isolated from patients and the endemic
genotype corresponding to PCR ribotype 1 accounted for 92% of the environmental
C. difficile isolates.
In summary, S-typing is a simple typing method which appears to offer good
discrimination and reproducible results. From the isolates tested in this study S-
typing showed good correlation with PCR ribotyping, although typing of a diverse
range of isolates would be required to determine the real correlation with PCR
ribotyping. S-typing demonstrated the endemic nature of one S- type amongst a total
of nine different types isolated from patients and the environment of wards 5 and 6,
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RVH. This endemic S-type corresponded to PCR ribotype 1 which is the endemic
strain in the rest of the UK.
This study and others have demonstrated substantial evidence for environmental
contamination with C. difficile, the C. difficile types which are isolated from the
environment reflect those types which colonised C. difficile culture positive patients.
Much epidemiological evidence for the role of environmental contamination in the
transfer of infection has been demonstrated, however the relative importance of
environmental contamination, patient to patient and staff to patient cross-
contamination have to be determined. This stresses the paramount importance of
good hand washing procedures by all health workers and the need for good ward




Colonisation with different S-types of C. difficile and the development
and severity of diarrhoea.
AIMS
1. To determine if colonisation with different S-types of C. difficile had any effect
on the development of, and the duration and severity of patient symptoms.
2. To determine if colonisation with more than one S-type of C. difficile was
associated with the level of symptomatic colonisation and/or the duration and
number of episodes of diarrhoea.
Each C. difficile isolate collected from patients in ward 5 and 6, RVH was designated
an S-type number as described in Chapter 6. One isolate from each of the 206
positive stool specimens was typed. More than one specimen was collected from
most patients and more than one S-type was isolated from some patients. The data
relating to patient symptoms; the duration of diarrhoea and the number of episodes of
diarrhoea was investigated to determine if there was any association between S-type
and the development of symptoms and the severity of the disease.
RESULTS
7.1. Symptoms in patients colonised with different C. difficile S-types
Of the 100 patients from whom C. difficile was cultured, 46% were symptomatic,
that is they had at least one episode of diarrhoea within the period of two weeks prior
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to, and/or two weeks after a culture positive stool specimen was identified. Some of
the patients may have been previously asymptomatically colonised.
Of the 100 patients from whom C. difficile was detected by culture, 86 patients were
colonised by one S-type only and the remaining 14 patients had more than one S-
type of C. difficile isolated from several consecutive faecal specimens.
7.1.1. Diarrhoea in patients colonised with different C. difficile S-types
Each of the nine C. difficile S/toxin-types isolated from patients in RVH and the
number of symptomatic patients who were colonised with each of these S-types are
shown in table 7.1. Toxigenic S-type 5236 was clearly the most frequently isolated
S-type, it was isolated from a total of 78% of C. difficile culture positive patients
investigated during the study, and it was associated with symptomatic colonisation in
just over 51% of these patients. Of the patients colonised with the second most
frequently isolated S-type, 5242, 38% were symptomatically colonised. However, as
a number of patients were colonised by more than one S-type, it would be misleading
to take the data in Table 7.1, at face value, as colonisation with more than one S-type
may affect the likelihood of a patient developing symptoms. In addition, the number
of patients colonised with each of the S-types, apart from toxigenic type 5236 was
very small and thus the data could not be reliably statistically analysed to determine
the significance in the levels of symptomatic colonisation by different S-types of C.
difficile.
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Table 7.1. The number of symptomatic and asymptomatic patients who
are colonised with each of the C. difficile S-types isolated from patients
in wards 5 and 6, RVH.
NUMBER (%) OF PATIENTS
S-TYPE SYMPTOMATIC ASYMPTOMATIC TOTAL*
5236 T 40 (51) 38 (49) 78
5236 NT 2 (50) 2 (50) 4
5242 T 7 (44) 9 (56) 16
5739 T 0 (0) 1 (100) 1
5438 T 2 (40) 3 (60) 5
5140 T 1 (33) 2 (67) 3
5144 NT 4 (67) 2 (33) 6
5043 T 1 (100) 0 (0) 1
UT/T 1 (100) 0 (0) 1
*The total number of patients is more than 100% because more than one S-type was
isolated from some patients.
T= toxin producing; NT=non-toxin producing
UT=untypeable
It is generally thought that non-toxigenic strains of C. difficile do not cause
symptoms in colonised patients. It is interesting therefore to note that of the ten
patients who were colonised with only non-toxigenic S-types, six patients had
diarrhoea. The reason for their symptoms is unconfirmed, and may not be related to
C. difficile.
Of the 26 patients who met the criteria for CDAD, 24/26 were colonised with
toxigenic S-type 5236, and four of the patients were colonised with two S-types
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including toxigenic S-type 5236. One of the remaining two patients was colonised
with 5242 and the other patient with both 5438 and 5140. This implicates toxigenic
S-type 5236 in 92% of cases of CDAD and it is likely to be the sole cause in 85% of
CDAD cases.
7.2. Symptoms in patients colonised with only one S-type of C. difficile
7.2.1. Diarrhoea in patients colonised with only one S-type of C. difficile
A total of 86 patients were colonised by one S-type only, the colonising S-type and
the number of symptomatic patients are shown in table 7.2.
Forty-six percent of patients who were colonised with toxigenic S-type 5236 only
had diarrhoea compared to only 24% of patients colonised by any one of the other S-
types. The level of symptomatic colonisation was compared for patients colonised
with toxigenic S-type 5236 only and for patients colonised with any one of the other
S-types identified in the study.
The data was analysed by the Chi2 test and the statistical analysis showed that the
higher level of symptomatic colonisation in those patients colonised with S-type
5236 compared to those who were colonised with any one of the other S-types was
insignificant (Mann Whitney U test, p=0.06). However, this is a borderline
insignificant result, and hence colonisation with toxigenic S-type 5236 may be
associated with an increased level of symptomatic colonisation when compared to
the other S-types. Further investigation is required to determine the significance, if
any of this result.
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5236 T 30 (46) 35 (54) 65
( 5242 T 3 (27) 8 (73) 11
5739 T 0 (0) 3 (100) 3
5941 T
1
0 (0) 1 (100) 1
\
5144 T 2 (50) 2 (50) 4
5140 T 0 (0) 2 (100) 2
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7.2.2. The number of episodes and the duration of diarrhoea in patients
colonised with only one S-type of C. difficile
The number of episodes and duration of diarrhoea were compared in patients
colonised with toxigenic S-type 5236 only, and in patients colonised by any one of
the other S-types of C. difficile. The range and mean duration of symptoms and
number of episodes of diarrhoea in these two patient groups is given in table 7.3.
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Table 7.3. The duration of symptoms and the number of episodes of
diarrhoea in patients colonised with toxigenic S-type 5236 and in
patients colonised with any one of the other S-types.
DURATION IN DAYS OF EPISODES OF DIARRHOEA
S-TYPE SYMPTOMS
(NUMBER OF PATIENTS) RANGE MEAN RANGE MEAN
5236 1-49 8 1-12 3
(n=30)
"Other" 1-7 3 1-4 2
(n=5)
Statistical analysis using the Mann Whitney U test determined that there was no
significant difference in the number ofepisodes of diarrhoea (p=0.59), or the
duration of symptoms (p=0.09) in patients colonised with toxigenic S-type 5236
compared to those patients colonised with any one of the other S-types.
7.3. Symptoms in patients colonised with more than one S-type of C.
difficile
7.3.1. Diarrhoea in patients colonised with more than one S-type of C.
difficile
S-typing of C. difficile isolates determined that a total of 14 patients were colonised
with more than one S-type ofC. difficile, 13 of these patients were colonised with
two S-types and one patient was colonised with three S-types of C. difficile. The
symptomatic status of the patients colonised by more than one S-type is shown in
Table 7.4.
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T= toxin producing; NT=non-toxin producing
UT=untypeable
Of those patients colonised by more than one S-type, 79%( 11/14) were symptomatic
compared to only 41% (35/86) of those patients who were colonised by only one S-
type. When the level of symptomatic colonisation was compared between the two
patient groups using the Chi2 test, the result (pF= 0.01) indicated that colonisation
with more than one C. difficile S-type(s) is significantly associated with symptomatic
colonisation with C. difficile.
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7.3.2. The number of episodes and the duration of diarrhoea in patients
colonised more than one S-type of C. difficile
The number of episodes and the duration of diarrhoea were compared in
symptomatic patients colonised with one S-type only and in those patients colonised
with more than one S-type of C. difficile. The mean and range of the duration of
symptoms and number of episodes of diarrhoea is shown in Table 7.5.
Table 7.5. The duration and the number of episodes of diarrhoea in
patients colonised with only one S-type and in those patients colonised
with more than one S-type of C. difficile.
DURATION OF SYMPTOMS NUMBER OF EPISODES
IN DAYS
S-TYPES RANGE MEAN RANGE MEAN
(n= number of patients)
One S-type only 1-49 7 1-12 3
(n=35)
More than one S-type 1-10 5 1-8 3
(n=10)
Statistical analysis of the data summarised in table 7.5, using the Mann Whitney U
test determined that there was no significant difference in the duration of symptoms
(p=0.58), or the number of episodes of diarrhoea (p= 0.58) in those patients who
were colonised with only one type of C. difficile and those patients who were
colonised with more than one S-type of C. difficile.
In conclusion, toxigenic S-type 5236 was isolated from 78% of culture positive
patients in wards 5 and 6, RYH. It was associated with 92% of cases ofCDAD. This
study did not provide any evidence that a particular S-type may be associated with
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symptomatic colonisation, or an increase in the severity of symptoms. Colonisation
with more than one S-type is associated with symptoms when compared to
colonisation with only one S-type, but is not significantly associated with the number
ofepisodes of diarrhoea or the duration of symptoms.
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7.4. DISCUSSION
The aims of this investigation were to determine which S-types were associated with
asymptomatic colonisation, which were associated with infection and disease and if
the infecting S-type ofC. difficile affected the severity of the symptoms produced.
The effect of colonisation with more than one S-type was also investigated. It was
hypothesised that the SLPs might be circumstantially related to the virulence of a
particular S-type and therefore the SLPs might be related to the severity of
symptoms.
From the study of C. difficile isolates collected from patients in RVH it was not
possible to draw any conclusions with respect to which S-types were associated with
symptomatic or asymptomatic colonisation and which S-types produced the most
severe symptoms. This was due to the endemic nature of toxigenic S-type 5236
which accounted for 78% ofall C. difficile isolates collected from patients in RVH.
All of the other S-types were isolated in small numbers and therefore reliable
statistical analysis to compare the levels of symptomatic colonisation and severity of
symptoms in patients colonised with different S-types was not possible.
Studies have implicated that there is variation in the virulence potential amongst
different strains of C. difficile. Several epidemiological studies have shown that
certain serotypes of C. difficile are associated with AAD (serotypes A, C and D).
Others are associated with adult asymptomatic carriage (serotype F) and some
serotypes with infant colonisation such as serotypes B and F (Delmee et al, 1985 and
Delmeeetal, 1988).
Data from the International Typing Study on C. difficile has implicated certain types,
such as serotype C and G with hospital outbreaks. Serotype G correlates to PCR
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ribotype 1, which has caused most outbreaks in the UK and is the most common type
referred to the ARU for England and Wales (Brazier et al, 1997b). As discussed in
Chapter 6 toxigenic 5236 correlates to PCR ribotype 1, thus the data from this study
correlates well with the findings from the rest of the UK.
In RVH, the endemic S-type 5236, was associated with a symptomatic colonisation
rate of 51%, and 92% of patients on the unit who developed CDAD were colonised
with S-type 5236. The reason that toxigenic 5236 S-type (PCR ribotypel) has
become the most commonly isolated type and the most common cause of C. difficile
associated infection in the UK is not known.
The strain appears to successfully colonise large numbers of geriatric patients
asymptomatically, but also causes a considerable proportion of CDAD. Factors
influencing the endemic nature of this strain type in the UK, could be that it
sporulates very effectively, or that it associates efficiently with the gut mucosa.
Numerous studies have investigated aspects of the variation of virulence expressed
between strains of C. difficile. As the two major toxins A and B cause the principal
pathology of the disease, the potential for toxin production is the most likely
indicator of virulence. Wren et al (1987), demonstrated variation in the amount of
toxin-produced between strains of C. difficile and showed an association between
symptoms of antibiotic associated diarrhoea and the ability of a particular strain of C.
difficile to produce toxins. However, more recently a study investigated the effect of
different strains of C. difficile in the hamster model and demonstrated no variation in
the ability to colonise and cause death between standard (toxin A + B producers)
toxigenic strains of C. difficile. However, the colonisation and mortality rate reported
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for the toxin A negative, toxin B positive strains of C. difficile was significantly less
that those toxin A and B producers (Sambol et al, 2001).
These studies indicate that the ability of different strains to produce toxin(s) is an
important virulence determinant for C. difficile disease. However, it is likely that
other virulence factors are involved in disease and that they are important in
determining the overall virulence potential of C. difficile strains. Until recently it was
generally accepted that non-toxigenie strains of C. difficile did not cause disease.
However, numerous toxin variant strains of C. difficile have recently been identified
(Rupnik et al, 1998). All of these variant strains posses toxin genes, however
deletions in one or both the genes renders them non-functional, thus toxins may not
be produced. Some of these toxin variant strains, including non-toxin producing
variant stains have been shown to produce an actin-specific ADP-ribosylating
transferase (binary toxin) (Stubbs et al,2000). This binary toxin is similar to the C.
perfringens iota toxin and the C. Botulinum C2 toxin and may be an additional
virulence factor in some C. difficile strains (Perelle et al, 1997). This may be an
important factor for those symptomatic patients who are colonised by non-toxigenic
variant strains of C. difficile.
From the study described in Chapter 6.2, which compared S-typing with PCR
ribotying, the non-toxigenic strains identified from patients in RVH, are likely to be
PCR ribotypes 9,10 and 26. These strains are non-toxigenic, but are not variant
toxinotypes, that is, they do not possess the pathogenicity locus which encodes the
genes for toxins A and B (Stubbs et al, 2000). To date it has not been determined if
such non-toxigenic strains have the ability to produce the binary toxin.
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Other potential virulence factors include capsules, hydrolytic enzymes, adhesive
factors and the putative SLPs. Seddon et al (1990), related the production of
hydrolytic enzymes such as hyaluronidase and collagenase to the relative virulence
of certain strains of C. difficile. These enzymes are likely to compromise the gut
integrity, thus contributing to the pathology of disease and potentially revealing
receptors for toxins and further adhesion of the organism. Capsules are well
documented as anti-phagocytic factors and have been reported on certain C. difficile
strains, although Davies and Borriello, (1990) reported the presence of capsules in
vitro, but they could not determine any association with virulence.
It has been suggested that the SLPs may be involved in the virulence of C. difficile.
They may have a role in the association and adhesion of C. difficile with the gut wall,
or alternatively they may play a role in the evasion of the host immune system. As
there is a high degree of variation in the SLP profile from strain to strain, it could be
postulated that the S-layers produced by certain strains may be more effective
adhesion factors or evaders of the host immune system, thus affecting the general
virulence of a particular strain.
The study of isolates from patients in RVH demonstrated that different S-types can
be isolated from the same patient over time. From the data collected it was not
possible to determine if the patients from whom more than one S-type was isolated
were colonised concurrently by more than one S-type, or if they were colonised by
different S-types at different times. However, consecutive culture results from
individual patients indicate that different S-types were often isolated alternatively,
this suggests that most of these patients did harbour more than one S-type of C.
difficile and that they were likely to be colonised with more than one S-type at the
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same time. Likewise, as only one isolate from each culture positive stool specimen
was S-typed, it is not possible to definitively state that any patient was colonised by
one S-type only. Sharp and Poxton (1985), demonstrated that patients could carry
more than one S-type ofC. difficile at the same time and it has also been reported
that relapses are often caused by a different strain, which may be of endogenous
source, again suggesting colonisation with more than one S-type.
Our study indicated that patients colonised by more than one S-type of C. difficile
were significantly more likely to develop symptoms than if they were only colonised
by a single S-type, however their symptoms did not last longer, nor did they have
more episodes of diarrhoea.
In conclusion, toxigenic S-type 5236 might be associated with a greater level of
symptomatic colonisation than the other S-types identified in the study and it was
associated with the majority ofCDAD on wards 5 and 6, RVH. Colonisation with
more than one S-type was significantly associated with symptomatic colonisation but
was not associated with the severity of diarrhoea.
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CONCLUSIONS
C. difficile is a well established nosocomial pathogen, responsible for a significant
number cases of antibiotic-associated diarrhoea. The disease is predominately
associated with elderly patients who have undergone antibiotic treatment.
The study described in this thesis emphasises the high level of colonisation with C.
difficile in geriatric patients. C. difficile was isolated from 30% of all patients
sampled in wards 5 and 6, RVH; 27% of patients in ward 5 and 34% of patients in
ward 6 tested positive for the organism by culture and/or toxin detection methods. It
was interesting to note that ward 5 had a larger patient turnover, and housed up to six
"respite" patients at any one time. The isolation rate at any one time varied between
0 and 67% of patients sampled during the study. Other studies have also shown the
level of CDAD and colonisation with C. difficile to vary over time (Bender et al,
1986; Gerding et al, 1986). Considerable variation in the levels of colonisation and
infection has been observed between different wards and hospitals, and may reflect
different patient populations, antibiotic policies and infection control policies.
From the patients investigated, 4% from ward 5 and 11% from ward 6 fulfilled the
criteria for the diagnosis ofCDAD. The findings from patients investigated in RVH
correlate with other studies (McFarland et al, 1989; Gerding et al, 1986;Bender et al,
1986).
However, attention is drawn to the bias on sample collection from patients in RVH.
Not all of the admissions to wards 5 and 6 were sampled, and it is likely that
specimens were easier to collect from the most debilitated patients and those patients
with diarrhoea. Patients with diarrhoea are more likely to harbour C. difficile and this
study may have overestimated the incidence of C. difficile in the geriatric unit.
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Environmental contamination with C. difficile is well documented, however the role
ofenvironmental contamination in the epidemiology ofC. difficile colonisation and
infection is not well defined. Various studies have made an association between the
level of environmental contamination, asymptomatic colonisation and CDAD
(McFarland et al, 1989; Fekety et al, 1981). C. difficile was isolated from 7% and
20% of environmental samples from wards 5 and 6 respectively, and this is likely to
reflect the higher rate of symptomatic colonisation in ward 6, which may lead to
increased contamination of the environment. Contamination of side-rooms was
associated with the presence of colonised patients. Floors, toilet areas and sluice
rooms were the most frequently contaminated areas, reflecting the frequency with
which these areas are exposed to contamination with faecal material.
Evidence for environmental contamination by both colonised and infected patients is
convincing, however the role of the environment as a reservoir in the transmission of
the organism is not clear. It is apparent from the findings from RVH and from other
studies that good cleaning practices, infection control and antibiotic polices need to
be implemented and observed by all staff to reduce both patient colonisation and
environmental contamination. Research into the development of effective sporicides
against C. difficile is essential for efficient decontamination of the hospital
environment.
The association of CDAD with increasing age and antibiotic use is well detennined.
A large number of other risk factors related to underlying disease, medication and
medical procedures have been implicated in the disease. Different studies have
produced conflicting studies, and the most influential risk factors have been difficult
to determine. As well as influencing factors related to medication and medical
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procedures, other influences such as environmental contamination and the effects of
the immune status may be of paramount influence, but they are difficult to
investigate; thus much of the evidence surrounding these factors is circumstantial.
In this investigation it was hypothesised that C. difficile disease occurs as a two-step
disease process. The proposed two-step model (Starr et al, 1997), suggests that
patients undergo the transition from a C. difficile culture negative state to an
asymptomatic C. difficile culture positive state, with no detectable toxin in the faeces.
The patient may remain in this asymptomatic state, or the patient may undergo the
transition from C. difficile culture positive to C. difficile culture and toxin positive.
The aim of this study was to determine which of the risk factors investigated
significantly influenced both the overall disease process, and each of the two-steps in
the proposed model. It was anticipated that the study would provide useful
information regarding the risk factors which allow colonisation with C. difficile, and
the factors that allow or enhance toxin production in high levels in the gut.
The data from the study of patients in RVH indicates that different risk factors
significantly influence each of the two steps in the model. The model showed that
any antibiotic use, but especially the third generation cephalosporin, ceftriaxone
significantly influenced the first step, and other cephalosporins and amoxycillin
influenced the second step. This raises questions regarding the mechanisms by which
the C. difficile colonises and subsequently proliferates and produces large amounts of
toxin in the gut.
Further studies are required to determine the most significant factors in each step.
Such information may be useful in the development of control strategies to prevent
outbreaks of infection. Investigation of the effects of significant risk factors such as
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antibiotics on the organism in vitro and in vivo may help to elucidate the mechanisms
of pathogenesis, which are not fully understood.
Clinical isolates collected from patients in RVH were typed using a novel phenotypic
typing method. This S-typing method exploited the high degree of variation in the
molecular masses of the two S-layer proteins from C. difficile. Investigation of the S-
layer proteins from C. difficile revealed that there was considerable variation in the
molecular masses of the two S-layer proteins from different serotypes and ribotypes
of C. difficile. The proteins were visualised on SDS-PAGE and the patterns were
extremely simple and easy to interpret. Calculation of the molecular masses was
perfonned on Phoretix1M software, and showed that in the isolates tested, the protein
of heavier molecular weight mass varied between 50-57 kilo Daltons (kDa) and the
smaller protein from 35-48 kDa. Each of the clinical isolates was designated a four-
digit S-type number based on the molecular masses of the two S-layer proteins.
S-typing of 206 clinical isolates from 100 patients revealed eight different S-types,
one of which was further differentiated into two types by testing for the potential to
produce toxin(s) in vitro. When the novel S-typing method was compared to PCR
ribotyping, ten different PCR ribotypes were determined. PCR ribotyping offered
better discrimination, but the two methods correlated well. It is important to note that
different S-layer phenotypes occurred within a genotype, and vice versa, as the ideal
genotypic typing method should reflect the phenotypic similarities and variations of
the organism, as well as offering good discrimination and reproducibility.
S-type 5236/T was isolated from 78% of patients, and was the endemic strain in
wards 5 and 6, RVH. This S-type correlates with PCR ribotype 1 which is the
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endemic strain in England and Wales (Brazier, 1998). S-type 5236/T was also the
most frequently isolated type from the environment.
This study sought to determine if particular S-types were associated with
asymptomatic colonisation and if others were associated with disease. Due to the
high frequency of endemic S-type 5236/T and the small numbers of other S-types, it
was not possible to compare symptoms between patients with different S-types.
Patients colonised with more than one strain of C. difficile were also investigated to
determine if they suffered from more episodes or a longer duration of disease. The
statistical analysis found that colonisation with more than one S-type was significant
in the development of symptoms, however not on severity of diarrhoea.
The location of the S-layer proteins on the bacterial cell surface make them ideal
candidates for host-pathogen interactions and it is highly probable that they do play a
role in virulence by influencing adherence, association with the mucosa or avoidance
of the immune system. As well as the high degree of variation in the molecular mass
of the S-layer proteins, this study showed the S-layer proteins to be immunogenic in
rabbits. Western blotting showed that the heavier protein exhibited antigenic
similarities between strains, whereas the lighter protein was more antigenically
distinct between strains.
Further studies on C. difficile should aim to determine the risk factors which most
influence colonisation and disease, the mechanisms by which antibiotics and other
risk factors may exhibit their effects by possible up-regulation of toxins, and other
virulence factors should be investigated. Potential virulence factors including the S-
layer proteins, flagella and capsules should be examined to determine their role if
any, in the pathogenesis ofC. difficile.
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Culture Media and Buffers
Media Formulations
All culture media were autoclaved at 121°C for 15 min before the addition of
selective agents, blood and/or egg yolk emulsion.
Cycloserine-Cefoxitin, Egg-Yolk Agar (CCEY) for the isolation of C.
difficile (adapted from Brazier, 1993)
Fastidious anaerobe agar (Lab M, Bury, England) 23 g
Cholic acid sodium salt (Sigma Chemicals, USA) 0.5 g
Cefoxitin (Sigma Chemicals) 8 jag/ml
Cycloserine (Sigma Chemicals) 250 pg/ml
Egg-yolk emulsion (Oxoid, Basingstoke, Hampshire) 20 ml
Lysed horse blood (Oxoid) 5 ml
Distilled water 500 ml
Cooked meat broth (CMB) Medium
(Collee and Marr, 1996)
Add 4 ml AIM to 0.5 cm3 cooked meat particles (see below for preparation) and
autoclave at 121°C/15 min.
Preparation of Cooked Meat particles
All fatty material was removed from 500 g fresh sheep hearts. The meat was then
minced and added to 500 ml of distilled water containing 1.5 ml of 1 M NaOH
solution and simmered for 20 min. The liquid was then drained off and dried at 60°C
and particles were stored at -20°C until required.
180
Appendix 1
Anaerobic investigation medium (AIM)
(Brown et al, 1996)
Proteose peptone (Oxoid) 20 g
Yeast Extract (Oxoid) 5 g
Trypticase (BBL, Becton Dickinson, USA) 5 g
NaCl 5 g
Cysteine HC1 750 mg
Na2C03 400 mg
Haemin (250pg/l) & Menadione (100pg/l) solution 20 ml
Distilled Water 1000 ml
Fastidious anaerobe broth supplemented with a modified C. difficile
supplement
Fastidious anaerobe broth (Lab M) 23 g
Cholic acid sodium salt (Sigma) 0.5 g
Modified C. difficile supplement (Oxoid, SR173E) 1 vial*
Distilled water 500 ml
*1 vial of supplement contains 250 mg cysteine hydrochloride, 6 mg Norfloxacin and
16 mg Moxalactam.
Brain heart infusion/proteose peptone medium (BHI/PP)-C. difficile
toxin production medium (Brettle et al, 1982)
Brain heart infusion broth (Oxoid) 37g
Proteose Peptone (Oxoid) lOg
Distilled water 1000 ml
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Proteose peptone yeast (PPY) medium
(Deacon et ai, 1978- adapted by Poxton et al, 1984)
Proteose peptone (Oxoid) 20g
Yeast extract (Difco Laboratories, USA) lOg
NaCl
Cysteine HC1 750 mg
Na2C03 400 mg
Haemin (250pg/l) & Menadione (100jug/l) solution 20 ml
BUFFERS.
Phosphate buffered saline (PBS).
Dulbecco A tablets (Oxoid BR14), one tablet added to 100 ml of distilled water.
POLYACRYLAMIDE GEL ELECTROPHORESIS BUFFERS
(Laemmli, 1970)
Double strength separating gel buffer [0.75 M Tris/HCI, pH 8.8, 0.2%
sodium lauryl (dodecyl) sulphate (SDS)].
Tris (hydroxymethyl) methylamine 91 g
SDS 2 g
Pyrogen free water 1000 ml
Double strength stacking Buffer (0.25M Tris/HCI, pH 6.8, 0.2% SDS).
Tris (hydroxymethyl) methylamine 15 g
SDS 1 g
Pyrogen free water 500 ml
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SDS-PAGE Electrode Buffer (0.025M Tris, 0.192M glycine, 0.1% SDS, pH
8.3)
Tris (hydroxymethyl) methylamine 6 g
Glycine (chromatographically homogeneous) 29 g
SDS 2g
Pyrogen-free water 2000 ml
Double Strength sample buffer (0.125M Tris/HCl, pH 6.8, 4% SDS, 20%
glycerol, 2% 2-mercaptoethanol, 0.002% bromophenol blue)
Tris (hydroxymethyl) methylamine 1.5 g
SDS 4 g
Glycerol (20% v/v) 25 g
2-mercaptoethanol 2 ml
Bromophenol blue 4 ml
(0.05% aqueous solution)
Pyrogen free water 100 ml
IMMUNOBLOTTING BUFFERS
Western blotting electrode buffer (0.025M Tris, 0.192M glycine, 20%
methanol, pH 8.3)
Tris (hydroxymethyl) methylamine 6 g
Glycine 29 g
Methanol 400 ml
Distilled water 1600 ml
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Tris buffered saline (TBS) [0.02M Tris/HCI, 0.5M NaCI, pH 7.5]
Tris (hydroxymethyl) methylamine 4.8 g
Sodium chloride 58.5 g
Distilled water 2000 ml
Tween Tris buffered saline (0.02M Tris/HCI, 0.5M NaCI, pH 7.5)
Tris (hydroxymethyl) methylamine 4.5 g
Sodium chloride 58.5 g
Tween 200 5 ml
Distilled water 2000 ml
Blocking Solution
(3% gelatin in TBS)
Gelatin (Bio-Rad USA, EIA grade) 22.5 g
TBS 750 ml
Antibody buffer
(1% gelatin in TBS)
Gelatin (Bio-Rad) 15 g
TBS 1500 ml









Solutions A and B were freshly prepared and mixed just prior to use.
Coomassie Blue Stain
(Hancock and Poxton, 1988)
SDS-PAGE protein gels were stained overnight in Coomassie blue solution
1, de-staining was carried out using each of solutions 2-5 for one 1 h.
Staining solution 1
Coomassie brilliant blue R-250 1000 mg
Propan-2-ol 500 ml
Acetic Acid 200 ml
Distilled water 1300 ml
Staining solution 2
Coomassie brilliant blue R-250 100 mg
Propan-2-ol 200 ml
Acetic Acid 200 ml
Distilled water 1600 ml
Staining solution 3
Coomassie brilliant blue R-250 48 mg
Acetic Acid 200 ml





Acetic Acid 200 ml
Distilled water 1000 ml
Staining solution 5
Acetic Acid 200 ml
Distilled water 1800 ml
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APPENDIX 2
A list of the strains supplied by Dr, J Brazier, ARU (mprl 4196-4219) and
the clinical isolates collected from patients in wards 5 and 6, The Royal
Victoria hospital, Edinburgh.
(The patient number, the S-type and the ability of isolates to produce toxin
are listed)
Mprl isolates




























Isolate number Patient number S-type In vitro toxin A and/or B
production
203a 52 5236 Yes
205a 59 5242 Yes
210a 52 5236 Yes
216a 89 5242 Yes
218a 49 UT Yes
222a 18 5236 No
223a 81 5236 Yes
224a 76 5236 Yes
226a 86 5236 Yes
239a 59 5242 Yes
244a 49 UT Yes
246a 101 5236 Yes
247a 18 5236 Yes
253a 76 5236 Yes
257a 61 5236 Yes
261a 81 5236 No
265a 79 5236 Yes
269a 81 5236 No
271a 79 5236 Yes
274a 47 5236 Yes
277a 49 UT Yes
280a 76 5236 Yes
281a 101 5236 Yes
289a 59 5242 Yes
310a 84 5236 Yes
316a 103 5236 Yes
322a 84 5236 Yes
332c 137 5236 No
334b 64 5236 Yes
335a 18 5236 Yes
336b 84 5236 Yes
338a 93 5236 Yes
346a 61 5236 Yes
348a 76 5236 Yes
357a 138 5236 Yes
359a 151 5043 Yes
360 93 5236 Yes
362a 76 5236 Yes
363a 81 5236 No
364a 84 5236 Yes
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Isolate number Patient number S-type In vitro toxin A and/or B
production
366a 144 5236 Yes
370a 68 5236 Yes
371 a 82 5236 Yes
375a 143 5236 Yes
381a 93 5236 Yes
386a 76 5236 Yes
391a 84 5236 Yes
392a 82 5236 Yes
394b 103 5236 Yes
399a 172 5236 Yes
401a 76 5236 Yes
402 170 5236 Yes
408b 57 5236 Yes
414a 170 5236 Yes
419a 144 5236 Yes
426 201 5242 Yes
428 147 5236 Yes
431b 137 5236 Yes
432b 57 5242 Yes
433a 49 5236 Yes
439a 76 5236 Yes
440a 49 5236 Yes
444a 119 5236 Yes
445a 84 5236 Yes
447a 163 5236 Yes
461a 144 5236 Yes
467a 103 5236 Yes
473a 201 5242 Yes
480a 144 5236 Yes
483a 182 5236 Yes
484 205 5236 Yes
485 76 5236 Yes
487 93 5236 Yes
495a 76 5236 Yes
501a 93 5236 Yes
511a 201 5242 Yes
518a 170 5236 Yes
520a 233 5236 Yes
524a 151 5236 Yes
528a 250 5236 Yes
530a 93 5236 Yes
532a 449 5242 Yes
541a 240 5941 Yes
545a 93 5236 Yes
551a 233 5236 Yes




































































































































































































































































































































































































































































































































































































































































Isolate number Patient number S-type In vitro toxin A and/or B
production
988a 610 5242 Yes
990a 627 5236 Yes
992d 469 5438 Yes
996a 596 5242 Yes
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The number of patients exposed to each of the possible risk factors
investigated by logistic regression modelling.
Risk Factor C. difficile status
Cdc- Cdc+ Cdt+
n=272 n=66 n=34
Gender 90 29 11
Neoplasia 29 6 1
Colonic disease 33 6 1
Leukaemia 2 2 0
Laxative use 134 25 11
NG/PEG use 2 2 2
Steroid use 18 3 4
Antacid use 65 19 13
Community admission 154 26 13
Hospital admission 100 40 20
Nursing home admission 18 0 1
Any antibiotic use 112 37 27
Amoxycillin 10 2 7
Co-amoxiclav (augmentin) 67 20 1
Other penicillins 12 5 16
Ceftriaxone 2 5 4
"Other" cephalosporins 3 2 6
Macrolide 15 10 5
Quinolones 26 7 6
Other parenteral (IV/IM) 25 4 3
antibiotics
Trimethoprim 12 3 6
Cephalosporins 5 7 6
Cdc- = C. difficile culture and toxin negative
Cdc+ = C. difficile culture positive (toxin negative)
Cdt+ = C. difficile culture and toxin positive.
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Abstract
Surface layers (S-layers) form regular crystalline structures on the outermost surface ofmany bacteria. Clostridium difficile possesses such
an S-layer consisting of two protein subunits. Treatment of whole cells of C. difficile with 5 M guanidine hydrochloride revealed two major
proteins of different molecular masses characteristic of the S-layer on SDS-PAGE. In this study 25 isolates were investigated. A high degree
of variability in the molecular mass of the two S-layer proteins was evident. Molecular masses ranged from 48 to 56 kDa for the heavier
protein and from 37 to 45 kDa for the lighter protein. A further protein component of 70 kDa was detectable in all isolates. No cross-
reaction was seen between the two major proteins from isolates that produced different S-layer patterns, and most S-layer proteins from
isolates with the same or similar banding patterns did not cross-react. The S-layer proteins, when detected by a combination of Coomassie
blue staining and immunoblotting, are a useful marker for phenotyping. © 2001 Federation of European Microbiological Societies.
Published by Elsevier Science B.V. All rights reserved.
Keywords: Surface layer protein; Surface layer; Phenotyping; Guanidine hydrochloride; Clostridium difficile
1. Introduction
Clostridium difficile is the most common aetiological
agent of antibiotic-associated diarrhoea and pseudomem¬
branous colitis. There are a number of virulence factors
associated with the organism including two main toxins
that are responsible for the major pathology of the disease
[!]•
C. difficile expresses two major cell surface proteins,
known as S-layer proteins. This crystalline cell surface
layer was first described by Kawata et al. in 1984 [2],
who reported that it was composed of two proteins with
different molecular masses. Sharp and Poxton [3] later
showed that these proteins varied between strains both
in molecular mass and immunogenic reactivity. S-Layers
have been reported on many bacteria including numerous
pathogens and it is assumed that they could have a role in
virulence [4], These protein components cover the entire
cell surface as a regular array, and are therefore ideal
candidates for bacteria-host interactions. S-Layer proteins
* Corresponding author. Tel./Fax: +44 (131) 650 3128.
E-mail address: i.r.poxton@ed.ac.uk (I.R. Poxton).
have been described as virulence factors for several human
pathogens, including Wolinella recta [5] and Bacillus cereus
[6]. The S-layer of C. difficile may contribute to the viru¬
lence of the organism by promoting adherence and colo¬
nisation, or by evasion of the immune system.
The aims of this study were to investigate the variability
of the S-layer proteins between different strains of C. dif¬
ficile, to determine the relative immunoreactivity of the
S-layer proteins and to assess the expression of S-layer
proteins as a useful phenotypic marker for epidemiological
studies.
Preliminary work on which this paper is based was pre¬
sented at the meeting of the Anaerobe Society of the
Americas in Buenos Aires 1998 [7],
2. Materials and methods
2.1. Bacteria! isolates
Twenty-five isolates of C. difficile were examined. Each
of the isolates had been designated a 'Delmee' serotype or
a 'Cardiff" ribotype and were kindly donated by Dr Jon
Brazier, Anaerobe Reference Unit, Cardiff. A reference
strain, NCTC11223 (mprl 2520), was also included. These
are shown in Table 1.
0928-8244/01 /$20.00 © 2001 Federation of European Microbiological Societies. Published by Elsevier Science B.V. All rights reserved.
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Table 1
The 25 strains used in the study, showing their laboratory number and
the serotype or ribotype for each strain



























2.2. Extraction of S-layer proteins from whole bacterial
cells
Overnight cultures of C. difficile were grown in pro-
tease-peptone yeast extract medium [8], pH 7.1, supple¬
mented with sodium carbonate 0.04% w/v and cysteine
hydrochloride 0.075% w/v [9], The cultures were incubated
anaerobically with 10% C02 overnight at 37°C.
Bacteria were harvested at 6000 Xg for 15 min and
washed twice in 4 ml of phosphate buffered saline. The
extracted cells were resuspended in 0.3 ml of 5 M guani-
dine hydrochloride and shaken for 2 h at room temper¬
ature. The extracted bacteria were removed by centrifuga-
tion twice for 2 min at 16 000Xg and discarded. The
guanidine hydrochloride was removed from the protein
extract by dialysis against 6.25 mM Tris-HCl buffer, pH
6.8 using a Spectra/Por® Microdialyzer with a membrane
of 10 000 MWCO and the dialysed extract was stored at
—20°C.
2.3. SDS-PAGE and immunoblotting
The protein extract (1 mg ml~') was mixed with an
equal amount of double strength SDS-PAGE buffer [10]
and heated in a 100°C boiling bath for 3 min. Extracts
were analysed on 10% separating gels, with 4% stacking
gels using the buffer system of Laemmli [10]. An initial
voltage of 60 V was used to pull the proteins through
the stacking gel. The voltage was increased to 150 V and
run for approx. 4 h until the dye front had moved through
the separating gel. The separated proteins were stained
with Coomassie blue [11] or transferred to a nitrocellulose
membrane for immunoblotting.
Briefly, the Tris-glycine transfer method of Towbin et
al. [12] as described in detail by Hancock and Poxton [11]
was followed. The separated guanidine hydrochloride ex¬
tracts were transferred to a nitrocellulose membrane
(0.2 pm pore size, Schleicher&Schuell) in Tris, glycine,
methanol buffer, pH 8.3 at 40 mA for 18 h at 4°C.
After transfer and washing the nitrocellulose was
blocked with 3% (w/v) gelatin in Tris buffered saline
(TBS, pH 7.5) for 45 min. The nitrocellulose membrane
was incubated with C. difficile rabbit antiserum, raised to
whole UV-killed cells (see Section 2.4), diluted 1/200 in
gelatin 1% (w/v) in TBS. This was incubated at room
temperature for 3 h. After washing twice for 10 min in
Tween TBS (TTBS) the membrane was incubated in anti-
rabbit IgG-horseradish peroxidase (HRP) diluted 1/2000
at room temperature for 1 h. After two further washes in
TTBS, the nitrocellulose membrane was washed three
times in distilled water. The nitrocellulose was placed
into HRP developer and the colour developed within
5-30 min. The development was stopped by several washes
in distilled water.
2.4. Rabbit antisera
Antisera were raised in rabbits to five different strains of
C. difficile (mprl strains 683, 1123, 1128, 604 and NCTC
11223) using whole UV-killed C. difficile cells as described
previously for Bacteroicles spp. [13,14],
2.5. Calculation of molecular masses
Molecular masses of the S-layer proteins were calcu¬
lated by computerised analysis of protein patterns using
Phoretix® gel analysis 1-D software. Novex, Mark 12®
molecular mass standards were used as calibrations for
the calculation of molecular masses.
3. Results
3.1. SDS-PAGE profile of guanidine hydrochloride protein
extracts
Whole C. difficile cells treated with 5 M guanidine hy¬
drochloride were shown to produce two major and one
minor protein bands on SDS-PAGE. Fig. 1 shows the
patterns produced by 15 different isolates. The two major
protein bands are characteristic of the S-layer proteins
described by Kawata et al. [2], There is a high degree of
variation in the S-layer protein profiles between the iso¬
lates. The larger of the two proteins varies in molecular
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66 kDa
55 kDa 53 kDa (Heavy band)
<- 42 kDa (Light band)
Fig. 1. SDS PAGF. of S-layer proteins of C. difficile isolates. Lane 1: molecular mass markers. Other lanes are as indicated on the gel.
mass from 48 to 56 kDa and the smaller from 37 to 45
kDa. A third, minor band is visible in some of the extracts
on the Coomassie blue stained gel. It has a molecular mass
of 70 kDa and appears to be conserved throughout these
isolates.
3.2. Calculation of the molecular masses of the S-layer
proteins
Each of the isolates used in this study was designated a
four-digit 'type number' based on the molecular masses of
the two S-layer proteins; e.g. 5336, where 53 is the molec¬
ular mass of the heavier band and 36 of the lighter band,
in kDa.
The isolates were grouped on the basis of the 'type
number', and this is shown in Table 2. A total of 12 groups
were assigned to the 24 isolates investigated.
3.3. The antigenic nature and cross-reactivity of the
C. difficile S-layer proteins
Multiple immunoblots using each of the five antisera
showed very little cross-reaction between the S-layer pro¬
teins of the different strains even when the protein profiles
were identical to the pattern produced by the strain to
which the antiserum was raised. The protein of molecular
mass 70 kDa, corresponding to the band of that mass on
the Coomassie stain, appears in all isolates and cross-re¬
acted with all antisera tested. It appears to be an antigen
common to all strains. All of the results are not shown,
but results of two of the antisera tested with representative
isolates are shown in Fig. 2.
Seven isolates (serotypes C, G, K., 1, F, A9 and
NCTC11223) with very similar S-layer protein profiles be¬
longed to type '5336'; the Coomassie blue stained gel of
six of these is shown in Fig. 2A. Immunoblotting was
performed on the S-layer proteins from these seven iso¬
lates employing two different antisera: one raised against
NCTC11223 and the other raised against MPRL 1128, a
strain that cross-reacts with serotype F. The antiserum
raised against NCTC11223 cross-reacted with the S-layer
proteins from isolates representing serotypes C and K only
(Fig. 2B). The antiserum raised against the serotype F
strain reacted only with the S-layer proteins from the iso¬
late representative of serotype F (Fig. 2C).
The S-layer proteins appear to display distinct antigenic
differences between isolates and the smaller of the S-layer
proteins exhibits a stronger reaction in the immunoblots.
Immunoblotting can further discriminate between isolates
with S-layer proteins of similar molecular mass.
Table 2
The 23 sero/ribotyped isolates grouped on the basis of their 'S-type
number'
S-Typc number Serotype Ribotype
48 45 A 23
50 41 A3





53 36 C, G, I. K, F, A9 and NCTC11223
53 42 H 106
55 43 A7
56 35 A8
56 37 B. X. A10 56
4. Discussion
Numerous methods exist for the typing of C. difficile.
Historically these have been phenotypic methods including
SDS-PAGE, immunoblotting [9] and serotyping [15],
More recently genotypic methods such as ribotyping
have been used for typing C. difficile [16]. However, ge¬
notypic methods do not provide any data on the presence
or pathogenic functions of virulence factors. The typing
method described in this paper, although phenotypic, of¬
fers important details of the cell surface structures which
are circumstantially related to virulence in the same way as
serotyping [17].
Treatment of whole washed C. difficile cells with guani-










profiles of the different serotypes and ribotyped strains.
Further analysis using immunoblotting can distinguish
strains with similar protein profiles as there appears to
be little antigenic cross-reactivity between strains unless
they share identical S-layer proteins. This agrees with ear¬
lier work which stated that any single strain only reacts
with homologous antiserum [13,19],
Immunoblotting suggests that the S-layer protein of
lower molecular mass may be more immunogenic than
the larger of the two proteins, although this interpretation
must be taken with caution as immunoblotting is not
quantitative. It is tempting to speculate that the S-layer
proteins have a role in virulence, but this and the signifi¬
cance of the immune response to the S-layer proteins have
yet to be determined.
Comparison of SDS-PAGE protein profiles is a tech¬
nique that has been used extensively in epidemiological
studies of C. difficile. Poxton et al. [9] used immunochem¬
ical fingerprinting of EDTA extracted proteins to investi¬
gate an outbreak of antibiotic-associated colitis and diar¬
rhoea. The method described in the present paper yields
only the proteins of interest. The resulting SDS-PAGE
protein profiles are extremely simple and are easily inter¬
preted by computer software analysis. The stability of the
surface proteins of C. difficile isolates was investigated
both in vitro and in vivo, and only minor variations
were observed [13]. In addition, our unpublished data
show a good correlation between this typing method and
PCR ribotyping. The profiles are clear and reproducible
and could complement other typing techniques in epide¬
miological studies.
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Fig. 2. PAGE and immunoblot analysis of S-layer proteins from a selec¬
tion of isolates belonging to group '5336'. The lanes are as indicated on
the gel. A: Coomassie blue stained SDS-PAGE. B: immunoblot using
antiserum raised to NCTC11223. C: immunoblot using antiserum raised
to MPRL 1128 (a serotype F strain).
dine hydrochloride extracts the two major cell surface pro¬
teins. A study by Kawata et al. [2] showed that treatment
of the outer cell wall extracts with urea or guanidine hy¬
drochloride produced almost identical protein extracts.
More recently, Cerquetti et al. [18] demonstrated that
complex preparation of cell walls was not required and
treatment of whole cells with urea led to the extraction
of S-layer proteins. We therefore conclude that these are
the S-layer proteins.
There is a high degree of variation in the S-layer protein
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UPDATE
The pathogenicity of Clostridium difficile
I. R. Poxton, J. McCoubrey and G. Blair
Department of Medical Microbiology, University of Edinburgh Medical School, Edinburgh, UK
It is now well established that the major virulence factors of C. difficile are the two toxins A and B. However,
the organism possesses an array of other putative virulence factors that may be important for localisation
within the colon, and in evasion of the immune system. It has been observed that certain types of C. difficile are
more commonly found causing disease than others, and this seems to be independent of toxin production.
Is this simply a reflection of their abundance in the hospital environment, or is it due to their virulence
determinants? This review covers our current knowledge of the modes of action of toxins A and B at the
cellular and molecular level. Many unanswered questions are posed that require answers before we can
fully understand the pathogenic mechanisms of the organism and be in a position to manage better the
spectrum of diseases it causes.
Keywords Toxin A, toxin B, antibiotic-associated colitis, Clostridium difficile, pathogenicity
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INTRODUCTION
The spectrum of disease and its pathology
Clostridium difficile is a commonly isolated organism from fecal
specimens obtained from neonates and the elderly. Often its
carriage is asymptomatic, and this is especially true in the
neonate. However, in the elderly, it is often associated with
disease symptoms that range from mild self-limiting diarrhea to
serious diarrhea, with or without pseudomembrane formation
(pseudomembranous colitis; Figure 1), and with the possibility
of life-threatening complications such as toxic megacolon,
perforation and peritonitis.
Antibiotics and the normal gastrointestinal microbiota
The proposed sequence of events that precipitate C. difficile
disease are as follows: on exposure of the gut to antibiotics, the
microbiota becomes disrupted and colonisation resistance is
compromised. The gut is then susceptible to colonisation by
+ C. difficile. The organism is acquired in most cases from an
exogenous source — either from an infected individual, from a
contaminated health care worker, or indirectly from a con¬
taminated environment. Once ingested C. difficile evades
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immune responses, multiplies in the colon and produces toxins
A and B. The characteristic pathology then results.
Virulence factors of C. difficile
C. difficile is typical of its genus: it is an anaerobic, Gram-
positive, spore-forming bacillus that produces toxins. The two
toxins A and B are commonly referred to as the enterotoxin
(toxin A) and the cytotoxin (toxin B). This terminology
originated from the observed actions of these toxins: demon¬
stration of fluid accumulation in intestinal loop models and the
cytopathic effects on tissue culture monolayers, respectively.
These investigations were done before the action at the mole¬
cular level was well understood. However, as is described below,
both toxins have a great deal in common.
Other toxins have been identified, in particular the bipartite,
ADP-ribosylating toxin, which is described in more detail in an
accompanying review [1],
The role of other virulence factors is much more speculative.
Adhesins have been proposed as being important but their
relevance in the colon, and their identity, is still not assured.
Several extracellular enzymes are produced that do have effects
in vitro, but their role in pathogenesis is not well defined.
Presumably these enzymes do have a role in the normal
physiological processes in the gastrointestinal (GI) tract and
may be crucial for the normal survival of the organism, giving it
an advantage when the normal GI microbiota have been
disturbed following antibiotic usage.
C. difficile is somewhat unusual in that it has an outer cell coat
termed the S-layer. This consists of two polypeptides that
together form a regular, crystalline array over the whole surface
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of the bacterium. The S-layer is proposed to be a virulence
factor and is discussed in more detail later.
THE TOXINS AND HOW THEY WORK
The majority of toxigenic strains produce both the A and B
toxins. In summary, their mode of action is similar: they are
endocytosed by the cell, they affect the actin cytoskeleton and
they result in cell death. They also induce the production of
tumor necrosis factor-alpha (TNFot) and proinflammatory
interleukins (ILs) which contribute to the associated inflam¬
matory response and pseudomembrane formation.
Toxin A causes necrosis, increased intestinal permeability and
inhibition of protein synthesis. Toxin A also affects phospho-
lipase A2, thereby producing prostaglandins and leukotrienes.
Toxin A damages villous tips and brush border membranes
and complete erosion of the mucosa may result. A viscous,
bloody fluid is produced in response to this tissue damage.
However, in the case of toxin B, there is no noticeable enter-
otoxic activity but it is lethal to cells in vitro. Therefore Toxin B
is thought to become effective once the gut wall has been
damaged.
The structure of toxins A and B
The two major toxins are coded on a pathogenicity locus
(Figure 2). The products of transcription and translation are
extremely large single-chain peptides with molecular masses of
308 kDa for toxin A and 270 kDa for toxin B [3], There are
three functional domains to these toxins (Figure 3). The toxins
ri—
txeR(1) toxB txe2 toxA txe3
txeR(1) and txe2 - peak transcription during stationary phase
? Positive regulators, co-ordinately produced
txe3 - peak transcription during exponential phase
?negative regulation of toxin genes
Figure 2 The pathogenicity locus of Clostridium difficile (modified from ref. 2).
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Figure 3 The structure of Clostridium difficile toxins A and B (modified from ref. 2).
are 50% identical at the amino acid level and have similar
primary structures. Hoffman et al. [4] noted that the enzyme
and cytotoxic activity of toxin B was to be found at the toxin's
N-terminus, which also holds the enzyme and cytotoxic activ¬
ity of toxin A. The middle section of both toxins includes a
transmembrane domain, which is thought to encode for the
translocation of the toxin into the cytosol, but this has yet to be
proven [5], The C-terminal of the toxin encompasses the
receptor-binding domain and is constructed of repetitive pep¬
tide elements.
Action of toxins A and B
The carboxy terminal of toxin A forms binding domains for
carbohydrate structures that occur on the surface of the epithe¬
lium. Toxin B binds to cells that are not covered by a thick
carbohydrate matrix. They then enter the cell by endocytosis
[6]. Both toxins require passage through an acidic intracellular
compartment in order to intoxicate cells. This route is not
known for toxin A, but toxin B is believed to be delivered by
lysosomes and is then released into the cytosol.
The major effect of toxins A and B is the disruption of the
actin cytoskeleton. Cells intoxicated by these proteins show a
retraction of cell processes and a rounding of the cell body. This
is due to the disassembly of filamentous F-actin and an increase
in G-actin prior to cell rounding [7]. Very few toxin molecules
are required to produce cell rounding. It has been proposed that
C. difficile toxins act enzymatically within cells, modifying
proteins that regulate actin polymerisation and fiber assembly.
These proteins are known as the Rho proteins, a subfamily of
the Ras-family of GTPases [7]. The mechanisms of action of
either toxin are summarised in Figure 4.
In the diseased state, the colonic epithelium is the major
target of C. difficile toxins. They cause disruption of the barrier
function by opening the tight junctions. This effect is not
merely caused by the breakdown of actin filaments but by
the inactivation of the Rho function to regulate tight junction
complexes. These barrier-disrupting effects of toxin A and B
increase the colonic permeability, the basis ofwatery diarrhea,
which is a typical feature of C. difficile antibiotic-associated
diarrhea (Figure 5).
Apoptosis of enterocytes
A study by Fiorentini et al. [8] provided the first experimental
evidence that cultured intestinal cells exposed to toxin B
showed all the features of apoptosis. A study by Mahida et al.
[9] showed the same effect being caused by toxin A. All cells
undergo apoptosis at some point, as this controlled cell death is
an important feature of tissue development and homeostasis,
keeping the number of functional cells in balance in the body.
Apoptosis can be identified as being different from cell necrosis
by distinct morphological alterations. These alterations come in
the form of nuclear condensation and fragmentation, cell
shrinkage and the absence of inflammation [8]. In monolayers
of cell cultures, apoptosis can be induced by inhibition of cell
adhesion and ofanchorage-dependent cell spreading. Toxin B is
capable of both inhibition of anchorage and cell spreading.
© 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 7, 421-427









N ^ udp G/c
GTP J L
1- 4 > UDP
Glc
1. Toxin binds to specific
receptor (Gal p1-4GlcNAc for A)




4. Rho and other small GTP-
binding proteins are
glucosylated
5. Glucosylated GTPases cause
collapse of actin cytoskeleton -
rounding with neurite-like
protrusions remaining
Figure 4 Simplified scheme for the action of
Clostridium difficile toxins on cells (modified
from ref. 6).
However, it was found that apoptosis was not only caused
by toxin B inhibiting cell adhesion due to actin depolymerisa-
tion but that Rho proteins themselves may play an important
role in the regulation of apoptosis under normal conditions [8].
Toxin B, therefore, can be seen as an inducer and not as the
cause of apoptosis. It is the effects of toxin B on the Rho
proteins that cause the abnormal activation of the apoptotic
system. With toxin A, it is thought that apoptosis occurs because
the epithelial cells are denied anchorage to the basement
membrane.
~oU<S>X<£-
















Monocyte' K~~ Neutrophil chemotaxis XX
Lamina propria
Immune activation
Figure 5 Actions of Clostridium difficile toxins A and B on intestinal epithelium (modified from ref. 6).
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Differences in cytotoxic potencies in toxin A and B
To cause pseudomembranous colitis, both toxins A and B are
normally required. The two toxins intoxicate cultured cell lines
by the same mechanism but when it comes to potency, toxin B
is around a 1000 times more potent than toxin A. Toxin B has at
least a 100-fold higher enzymatic activity than toxin A, and this
is believed to be the main determinant in the difference in
cytotoxic potency.
Due to the low enzymatic potency of toxin A, it has been
proposed that glucosylation of the Rho-proteins may not be the
primary in vivo effect of this toxin. Some believe neuronal
involvement may be a possible answer to cnterotoxic effects of
toxin A [10]. The suggestion is that the pathophysiological
process is triggered by a transepithelial signal to neuroimmune
cells that is triggered by the binding of toxin A to the intestinal
mucosa. The modification of Rho proteins by toxin A and B
would then play a secondary, but important, role in exacerbat¬
ing mucosal inflammation and destruction. This theory agrees
with an experiment done by Riegler et al. [11], where toxin B
was shown to be more potent than toxin A in damaging human
colonic epithelium in vitro. The mucosal strips were devoid of
enteric nerves and thus toxin B was shown to be 10 times more
effective in causing damage.
ACTIVATION OF THE IMMUNE SYSTEM
Colitis is characterised by a massive influx of neutrophils into
the colonic mucosa, and in pseudomembranous colitis there is
an acute inflammatory infiltrate with microabscesses and pseu-
domembranes rich in neutrophils [12], The movement of
neutrophils from circulating blood to the site of injury is a
crucial event during the inflammatory process. IL-1, IL-8, TNF
and leukotriene B4 are products ofresident cells and are thought
to be involved in neutrophil infiltration into the inflamed
site.
Both toxins stimulate the release of TNFtx from cultured
monocytes. Toxin B was again found to be 1000 times more
potent than toxin A in this system [12], Both toxins also activate
monocytes and macrophages in the lamina propria in vitro to
release IL-8. This causes neutrophil extravasation and tissue
infiltration by creating a chemotactic gradient that induces
neutrophil migration to the site of mucosal inflammation
[13], Using mast cell-deficient mice, Pothoulakis et al. [14]
demonstrated the importance of mast cells for neutrophil
recruitment and fluid secretion induced by toxin A in vivo.
Isolated mast cells were also shown to respond to toxin A by
releasing TNFct This activation could be inhibited with a
specific antagonist to substance P. Substance P is a peptide
found in gut tissue and in the CNS that acts as a neurotrans¬
mitter. This suggests that toxin A activates mast cells via the
release of substance P from adjacent sensory neurons [15].
This can also be seen as another point marking toxin A activity
with neuronal stimuli.
Neutrophil recruitment appears to be an essential step in the
pathogenesis of C. difficile toxin-induced intestinal injury as
biopsy specimens from patients with C. difficile colitis show
marked vascular congestion, neutrophil infiltration of the
lamina propria and inflammation. Although it was shown by
Calderon et al. [15] that toxin A was able to activate neutrophils,
mast cells and macrophages in vitro, there is still some spec¬
ulation as to how this works in vivo due to the large size of the
toxin. Toxin A can cause detachment and apoptosis of enter-
ocytes and so, in this disrupted epithelium, toxin A may diffuse
and interact with the inflammatory cells in the lamina propria.
Also, localised areas of injury and inflammation may result from
cell rounding that would cause breaches in the colonic epithe¬
lium through which tiny amounts of toxin A and B can pass.
These small amounts cannot directly activate neutrophils but
may activate tissue macrophages to produce IL-8 and other
proinflammatory cytokines. Once the inflammatory cascade is
initiated, it can result in a marked acute inflammatory cell
infiltration, further mucosal injury and focal pseudomenrbrane
formation [13].
IMMUNITY AND HOST DEFENCES
Innate mechanisms
Probably the best defence against infection by C. difficile is an
intact normal bowel microbiota - preventing establishment of
C. difficile by colonisation resistance [16], Normal gut motility
and an effective gastric acid barrier are no doubt also important
[17].
Acquired immune mechanisms
Experiments with hamsters suggest that systemic IgG to toxin A
— induced by vaccination — is protective [18], and secretory
(IgA) antibodies to toxins A and B may be protective as
demonstrated by protecting hamsters fed milk from immunised
mothers. However, this is an area still requiring a great deal of
work, especially to determine the potential for immunisation in
humans [17].
PHEN0TYPIC VARIATION
There is a degree ofphenotypic variation between strains of C.
difficile. In respect to pathogenicity, it seems that non-toxigenic
strains can be considered non-pathogenic or avirulent. How¬
ever, it is well accepted that there are degrees of virulence
between strains. The discovery of virulent strains of toxin
A-negative/toxin B-positive phenotype indicated that toxin
A was not essential for virulence. How these strains cause
© 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 7, 421-427
426 Clinical Microbiology and Infection, Volume 7 Number 8, August 2001
Figure 6 Sodium dodecyl sulfate polyacryla-
mide gel electrophoresis of S-layer proteins from
11 different strains of Clostridium difficile. The S-
layer proteins were extracted from whole bacter¬
ia with guanidine hydrochloride.
disease is not readily apparent but based on the discussion above
there is so much similarity between toxins A and B that once
there is any damage to the mucosal cell layer then either could
cause symptoms.
In common with several pathogens, C. difficile has an S-layer
covering its entire surface. We have proposed recently that this
might have a role in virulence [19], There is certainly a degree of
correlation between serotype and virulence that is independent
of toxin production: certain serotypes are more often associated
with disease. Serotype correlates well with S-type and also to
ribotype [19 and unpublished data]. Figure 6 shows an example
of the S-layer proteins extracted from different strains with
guanidine hydrochloride, and each strain belongs to a different
serotype.
UNANSWERED QUESTIONS
Despite knowing a great deal about the mode of action of the
major toxins, and understanding the epidemiology of the
pathogen, many questions remain unanswered. For some, there
are partial answers but, in the opinion of the authors, none of
the following are yet answered fully:
Why are infants not affected?
Do the toxins have any role in the healthy intestine?
Is immunity to cell surface components protective - would
whole cell vaccines be a possibility?
Why are some types much more virulent than others?
What is the molecular basis of serotype?
Why are there so many S-types?
What is the genetic basis for S-layer peptide variation?
It is generally agreed that C. difficile-associated disease is
increasing worldwide, and our last question, 'Have super
strains evolved?', remains unanswered. Is the increase purely
because the organism - as spores — becomes persistent in the
environment of the elderly patient, where it is maintained
by constantly being passaged in susceptible individuals, or
have previously harmless strains from neonates acquired viru¬
lence attributes, and are more persistent, more virulent strains
evolving?
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UPDATE
Typing of Clostridium difficile
J. S. Brazier
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Clostridium difficile is primarily recognised as a nosocomially acquired pathogen manifesting in gastrointestinal
disease subsequent to the patient receiving broad-spectrum antibiotics. Infection can be sporadic, but
outbreaks commonly occur within a ward or hospital as a result of cross-infection. Since the 1980s, the
epidemiology of C. difficile disease has been studied by the application ofmany different typing or
fingerprinting methods; these, and the lessons learned, are reviewed herein.
Keywords Clostridium difficile, typing
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PHENOTYPIC TYPING METHODS
Early methods of typing Clostridium difficile were, of necessity,
based on phenotypic properties such as antibiograms. In one of
the first documented outbreak investigations, Burdon et al. [1]
found a common resistance pattern to three antibiotics in
isolates from cases on a surgical ward that were distinct from
isolates in the rest of the hospital. However, this approach is at
best only rudimentary, and a more detailed approach was tried
by Wiist et al. [2] who combined plasmid analysis, soluble
protein polyacrylamide gel electrophoresis (PAGE), immunoe-
lectrophoresis of extracellular antigens and antibiograms to 16
isolates from related cases of C. difficile infection. Using these
methods they showed that 12 of the 16 strains were indistin¬
guishable, providing strong evidence that cross-infection had
taken place. Sell et al. [3] used a combination ofbacteriocin and
bacteriophage typingmethods, with a high percentage ofstrains
being non-typeable. Immuno-chemical fingerprinting of
EDTA-treated cell extracts of C. difficile was evaluated [4],
and Nakamura et al. [5] were the first investigators to use serum
agglutination as a typingmethod by raising three antisera against
C. difficile. This method could differentiate four distinct serovars
among 79 isolates from healthy carriers. Delmee's group [6]
improved this method and developed a serotyping scheme that
could recognise 19 distinct sero-groups. This method is fre¬
quently used as the standard by which other typing methods are
compared.
These early typing methods were ostensibly developed to
understand the epidemiology of C. difficile infection at a local
level. Many of these investigations found evidence that a single
type was responsible for a number of cases within their hospital,
thus confirming that C. difficile disease could be a cross-infection
problem. It soon became apparent, however, that whilst these
Corresponding author and reprint requests: J. S. Brazier, Public Health
Laboratory, University Hospital of Wales, Cardiff CF14 4XW, UK
methods were adequate for local use, there was a need for typing
schemes that could be applied to further our understanding of
the epidemiology of C. difficile disease on a wider scale. To
facilitate this, comparisons between typing schemes were per¬
formed, and Mulligan et al. [7] found good correlation between
the types recognised by plasmid profiling, serotyping, PAGE of
cell surface antigens and immunoblotting. Sodium dodecyl
sulfate (SDS)-PAGE of whole-cell proteins was applied to
79 isolates in an outbreak investigation and this method yielded
a maximum of approximately 40 bands ranging in size from 18
to 100 kilo-daltons (kDa). This investigation showed 60 of
the 79 isolates to be indistinguishable. SDS-PAGE of EDTA-
extracted cell surface antigens was compared to serogrouping by
Ogunsola et al. [8], analysing 61 isolates. This method yielded
bands ofbetween 30 and 67 kDa and split their 79 isolates into
17 groups, which generally correlated well with the results of
serogrouping, and could in fact, differentiate between some
members of the same serogroup. The whole-cell fingerprinting
method ofpyrolysis mass spectrometry (PMS) has been success¬
fully used as a means of investigating putative C. difficile out¬
breaks [9]. This method has the advantage that it can cope with a
large throughput of strains and has a high degree ofdiscrimina¬
tion. Its disadvantages, however, are the initial cost of the
equipment and its inability to assign a permanent type to a
strain.
MOLECULAR TYPING METHODS
Molecular typing methods are generally regarded as superior to
phenotypic methods in terms of the stability ofmarker expres¬
sion and providing greater levels of typeability, and a number of
molecular methods have been applied to C. difficile. Plasmid
profiling proved largely unsuccessful due to the sparse distribu¬
tion of these extra-chromosomal genetic elements within the
species. However, analysis of chromosomal DNA of C. difficile
was tried by Kuijper et al. [10] who used whole cell DNA
restriction endonuclease analysis (REA) using Hindlll in an
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